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HIV infection became a newly recognized disease in the mid 1980s. High morbidity 
and mortality associated with it prompted the urgent development of new 
therapeutic agents and combination therapies. Throughout the next 20 years the 
hopes for cure have risen and fallen, and the vaccine research has failed to reach 
the evasive target of HIV prevention. It is the development and optimization of 
antiretroviral therapy (ART) that formed the roadmap for the universal control and 
prevention of existing and new infections, respectively. As with any new therapeutic 
modality, the data guiding the dosing, efficacy and safety of antiretroviral (ARV) 
drugs for children have lagged substantially behind as compared to the information 
available for adults. An advanced PubMed search for "HIV pharmacokinetics", 
restricted to age groups of infant, child or adolescent, and all categories of original 
clinical studies (e.g. excluding reviews and other publication types) resulted in 326 
citations.1 Removing any age restriction increased the number of citations to 1404. 
While one can argue about the absolute numbers and whether classification is 
appropriate for all publications in the PubMed database, the ratio is nonetheless 
significant and not surprising, with over four times as many pharmacokinetic (PK) 
studies conducted in HIV-infected adults than in children.1  
 
Since the early 1990s administration of prophylactic ART to pregnant women to 
assure prevention of the mother-to-child transmission (MTCT) has become the most 
efficient and cost-effective way to achieve global control of pediatric HIV infection. 
In the countries with consistent access to ART and universal prevention of MTCT the 
number of pediatric HIV infections has decreased dramatically: only 4,400 children 
living with HIV infection and fewer than 500 new infections in children younger than 
15 years of age were estimated for the North American region in 2007.2 In the last 
decade much progress has been made in the universal ART coverage of women 
during pregnancy and labor in resource-limited settings. Per World Health 
Organization (WHO) report, an estimated 45% of pregnant women living with HIV 
received ARV drugs to prevent transmission of HIV to their children in 2008.3,4 
However, nearly 1,200 new infections in children continue to occur daily (with more 
than 90% of them in the developing world), leading to a stunning estimate of more 
than 2 million children younger than 15 years of age living with HIV worldwide.3,4  
 
In addition to the younger cohort of perinatally infected children, over 1 million new 
infections are estimated in adolescents aged 15 - 24 years of age.4 The 
seroprevalence of HIV among adolescent females remains high (> 50%), reflecting 
the burden of the epidemic borne by girls and young women and the potential for 
the continued MTCT.4 With an estimation of more than 3 million of children and 
adolescents living with HIV infection, the delivery of ART to the world's pediatric 
population is of crucial importance. In recent years significant progress has been 
made in scaling up the access to the ART among children and adolescents. In 2009 
355,000 children worldwide received ART, up from nearly 276,000 in 2008, and up 
from 127,300 in 2006.2,5 Given the growing number of HIV-infected children and 
adolescents with access to treatment, a better understanding of the therapeutic 
targets of ARV drugs in pediatric HIV infection is urgently needed. 
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The introduction of combination ART into pediatric care has led to a dramatic 
decrease in HIV mortality (> 80% - 90%) and morbidity among HIV-infected 
children.6,7-10 The main strategy of HIV therapy in the pediatric patient focuses on 
early initiation of ART regimen in order to achieve maximal suppression of viral 
replication, prevent disease progression, preserve immunologic function, and reduce 
the emergence of viral resistance, while allowing normal growth and development 
of the child. Since HIV infection represents an infectious inflammatory disease 
generated by a retrovirus, the pathogenesis and the general virologic and 
immunologic principles underlying the use of ART are similar for all HIV-infected 
people. However, the important etiological, physiological, psychological and social 
differences between children and adults create unique considerations for HIV-
infected pediatric patients, and require a population specific approach to ART.  
 
As mentioned above, the majority of pediatric HIV infection is acquired through 
perinatal transmission of the virus from an HIV-infected mother. Important 
differences in the clinical and virologic manifestations of perinatal HIV infection 
secondary to the occurrence of primary infection in growing, immunologically 
immature infants create unique treatment initiation criteria that are significantly 
different from those guiding the start of ART in HIV-infected older children and 
adults. Secondly, the perinatal exposure to the ART administered to mother in 
utero, intrapartum and/or postpartum may present additional challenges to the 
emergence of resistance and drug associated toxicities in this vulnerable population. 
Third, the immunologic parameters (CD4+ cell count) of HIV disease are closely 
related to the child's growth and create age specific parameters for the evaluation 
of pharmacodynamic (PD) response to ART in pediatric HIV disease. Most 
importantly, significant changes in the PK parameters of ARV drugs are caused by 
the continuing development and maturation of organ systems involved in drug 
absorption, distribution, metabolism, and elimination. Moreover, the extensive 
physiologic changes during a child's maturation do not occur with precisely 
predictable timing or magnitude, and developmental rather than chronological age 
needs to be considered.11,12 All of these factors strongly oppose the notion of "one-
size fits all" dosing for pediatric HIV-infected patients, and mandate a rational 
consideration of the optimal dose for every child.1  
 
Several pediatric HIV research networks (Pediatric AIDS Clinical Trials Group 
(PACTG)/International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT), 
Collaborative HIV Pediatric Study (CHIPS), Pediatric European Network for 
Treatment of AIDS (PENTA), the HIV Netherlands Australia Thailand Research 
Collaboration (HIVNAT), and Adolescent Medicine Trials Network (ATN)) have 
addressed issues of developmental PK/PD of ART in HIV-infected pediatric patients. 
While many of these studies have contributed to the development of the HIV 
pediatric treatment guidelines in the United States,13 Europe14 and WHO,3 
significant gaps of knowledge of ART still exist.  
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The overwhelming majority of the ARV PK studies in children have been designed to 
find the dose which provides ARV exposures (e.g. peak and trough plasma 
concentrations, and area under the concentration-time curve) similar to those 
already known to be safe and effective in adults.1 Very limited information on the 
potential differences in the PD of ART in children is available. The effect of puberty 
on ARV drug disposition has not been investigated to date. While considered useful 
in pediatric populations by the European and US guidelines, the published ARV 
therapeutic drug monitoring (TDM) experience in children, with active dose 
management in response to measured drug concentrations, is almost non-existent.1 
Little is known about the relationships between ARV PK and ART associated toxicity, 
and only a few publications have addressed the long-term consequences of pediatric 
ART exposure. Equally, a limited number of pediatric studies have addressed the 
association of pharmacogenetics (PG) of ART with toxicities and outcome, and 
questions about developmental differences in drug metabolizing and drug 
transporter gene expression remain to be answered.  
 
With changes in patients' age and maturity, ART evolves from the meticulous, 
twice-daily dosing of milliliters of liquid preparations to co-formulated tablet 
preparations. Simultaneously, pediatric adherence barriers evolve during child's 
growth from spitting and vomiting of liquid preparations in infancy to the rejection 
of ART and increased peer pressure during puberty. Although some strategies for 
adherence interventions and simplified ART regimens in pediatric HIV management 
have been proposed, many of them have not been rigorously evaluated to date. 
Moreover, developmental and psychosocial factors affecting ART adherence in 
children and adolescents from different cultural and ethnic regions of the world are 
not well described and need to be evaluated. Culturally sensitive and acceptable 
adherence interventions need to be developed.  
 
As the access to ART is increasing among the pediatric population worldwide, the 
potential role of malnutrition and concomitant infections in altering the PK of ARV 
drugs in pediatric patients needs to be recognized. The co-morbidity with certain 
infections such as tuberculosis leading to concomitant therapy with potential for 
significant drug-drug interaction with ARV drugs pose an additional challenge for the 
choice of proper ART in these settings.15 Decreased weight and delayed growth 
among children with HIV infection represent common health challenges in resource-
limited settings.16-18 The co-morbidity with gastrointestinal illnesses, hepatitis, 
malaria and tuberculosis may lead to altered absorption of ARV drugs. The loss of 
fat and lean body mass, and associated metabolic and endocrine abnormalities have 
the potential to influence the volume of distribution and the total body clearance of 
ARV drugs, particularly of lipophilic drugs, such as protease inhibitors.19-20 
Currently, the data about regional differences in children's growth are very limited, 
and accurate growth curves and sexual maturation staging of HIV-infected children 
and adolescents of various ethnic and racial backgrounds urgently need to be 
developed.  
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Finally, multi-drug ARV resistance represents a significant challenge for ART 
management in the resource-rich settings. Despite the low burden of pediatric HIV 
infection in developed countries, the most treatment-experienced children and 
adolescents presently reside in North America and Europe. From 1997 to 2001, 
among a cohort of more than 2000 U.S. HIV-infected children, the proportion 
receiving three or more sequential triple-ART regimens increased from 4 to 17%, 
while the durability of triple-therapy regimens declined from 13 months for the first 
to 7 months from the first to third regimen.6 In a European cohort of 654 perinatally 
infected children from the United Kingdom and Ireland, 52% and 12% of the 166 
patients with resistance assays had dual- or triple class resistance mutations, 
respectively.21 With the increasing availability of ART to the pediatric population in 
developing countries, the number of treatment-experienced children will continue to 
rise globally. The availability of the newer potent classes of ARV drugs in those 
regions, however, is quite remote due to their high cost and manufacturing 
restrictions. The optimization of the ARV dose needs to be evaluated to address the 
need of successful virologic suppression in children with viral resistance. 
 
As new ART studies in children and adolescents become available, the pediatric ARV 
treatment guidelines continue to evolve throughout the world with the most recent 
WHO and US pediatric guidelines updates released in the summer of 2010 and 
European guidelines updated in the fall of 2009. The goal of this thesis is to 
contribute to the ongoing work by many excellent researchers and practitioners in 
an effort to achieve universal success in the management of pediatric HIV infection. 
 
 
AIM AND OUTLINE OF THIS THESIS 
The overall aim of this thesis is to increase efficacy of ART in HIV-infected 
children and adolescents, leading to improved outcomes and decreased drug 
toxicity in pediatric HIV-infected children worldwide.  
 
Given the universal need for the optimization of antiretroviral therapy in the 
pediatric population and the limited number of pediatric studies available as 
compared to adults a series of studies were performed to evaluate the 
developmental PG/PK/PD changes, the safety and toxicity of ART in children and the 
role of adherence and dose optimization.  
 
PART I focuses on the developmental changes from infancy to adolescence and its 
impact on ARV drug disposition and efficacy. Chapter 2 reviews the history and 
current progress in pediatric pharmacological research and pediatric drug 
development. Chapter 3 focuses on the developmental changes during puberty and 
provides justification for an individualized therapeutic approach in HIV-infected 
adolescents. The current challenges in the availability, formulations and regimens of 
pediatric ART are discussed in Chapter 4.  
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PART II is dedicated to the analysis of PK and PD of several ARV drugs in children 
and adolescents.  Chapter 5 reports the data on a study conducted in collaboration 
with the University of Nijmegen, the Netherlands, on the PK of nucleoside reverse 
transcriptase inhibitor lamivudine in HIV-infected children. The development of a 
population PK model for the most widely used protease inhibitor lopinavir in 
pediatric practice is presented in Chapter 6. Most importantly, Chapter 6 addresses 
the potential impact of suboptimal therapeutic concentrations of lopinavir predicted 
by the model in treatment-experienced HIV-infected children. In continuation of the 
research on lopinavir, the effects of the drug metabolizing (CYP3A5) and drug-
transporter (MDR1 and SLCO1B1) polymorphisms on the PK/PD of 
lopinavir/ritonavir therapy in children is investigated in the research presented in 
Chapter 7.  
 
PART III consists of two studies focusing on the role of TDM in the management of 
ART of pediatric HIV infection. Chapter 8 investigates the non-invasive evaluation of 
salivary concentrations of non-nucleoside reverse transcriptase inhibitor nevirapine 
as an alternative to the plasma sampling in pediatric HIV-infected children. The role 
of TDM in optimization of pharmacotherapy of HIV infection in adolescent patients is 
further discussed in Chapter 9.  
 
The individualized approach to the management of the HIV infection in children and 
adolescents is addressed in PART IV. Chapter 10 investigates the role of the 
pharmacy refill mechanism in the adherence to ART and virologic and immunologic 
outcomes of HIV infection in adolescents. The development and application of 
biomarkers for the early identification of HIV-associated nephropathy are presented 
in Chapter 11. Finally, the general discussion in Chapter 12 focuses on the current 
gaps in the knowledge of antiretroviral therapy in pediatric patients and outlines the 
roadmap of future studies to develop an optimized approach to ART in HIV-infected 
infants, children and adolescents worldwide.  
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ABSTRACT 
The data guiding the dosing, efficacy and safety of medicines for children have 
lagged substantially as compared to the information available for adults. As a 
consequence, pediatricians faced with the prospect of confining their practice to 
medicines with adequate information have frequently resorted to prescribing 
medicines for unapproved uses (different dose, frequency, age group, route, 
indication or formulation). Although a long time in coming, the past decade, have 
witnessed a new era in drug development for children - an era that is still in its 
infancy, but which is currently showing signs of maturation. This review will give 
some of the history and current progress in pharmacological research and pediatric 
drug development. 
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HISTORY 
The history of drug therapy is replete with examples of adverse reactions to drugs 
in neonates, infants, children and adolescents. In 1937, 107 people - primarily 
children - died after taking elixir of sulphanilamide to treat streptococcal infection. 
Sulphanilamide was not very water soluble, but a chemist at Massengill Co. found 
that it dissolved well in diethylene glycol (more commonly known as antifreeze), 
which is now known to be highly toxic. In 1956, Andersen et al. at Columbia 
reported an excessive mortality rate and an increased incidence of kernicterus 
among premature babies receiving a sulfonamide antibiotic compared with those 
receiving chlortetracycline.1 Then, in 1959, Sutherland described a syndrome of 
cardiovascular collapse in three newborns receiving high doses of chloramphenicol 
for presumed infections.2 More recently, the therapeutic misadventures experienced 
by low birth weight infants exposed to a parenteral vitamin E formulation3 and the 
"gasping syndrome" by infants who received excessive amount of benzyl alcohol4 all 
serve to underscore the generally held perception that newborn infants are more 
likely to experience adverse reactions to drugs. More recently, all therapeutic issues 
surrounding the retinoic acid embryopathy and maternal antidepressant drug use 
have refocused attention on the effects of drugs on the fetus and newborn.5  
 
As a result of these experiences, pediatricians have become extremely conservative 
in their use of drug therapy. Although this conservative approach has permitted the 
fulfillment of the physician's oath to "do no harm," it also has prevented the 
adoption of newer therapeutic modalities and their adaptation to neonatal patients. 
 
A more specific approach to pediatric therapeutics that will improve the safe use of 
medicines in this population requires a thorough understanding of human 
developmental biology as well as insights regarding the dynamic ontogeny of the 
processes of drug absorption, drug distribution, drug metabolism, and drug 
excretion. In addition, there must be a rigorous appreciation of the developmental 
aspects of drug-receptor interactions, including the ontogenetic changes in receptor 
number, receptor affinity, receptor-effector coupling, and receptor modulation and 
regulation. 
 
 
OFF-LABEL PRESCRIBING 
At intervals since 1968, surveys have documented that only a minority of medicines 
receive labelling for pediatric use. Even fewer receive labelling for use by neonates 
and infants.6 In the period 1973 - 1997, the percentage of approved drugs that 
contained no labelling information for children remained fairly stable at 71 - 81%.6 
Of the 33 new molecular entities (NMEs) approved in 1997, 27 had potential for 
pediatric use, but only nine contained any pediatric labelling information.  
 
With so few medicines containing adequate labelling information to guide their use, 
off-label prescribing became an accepted practice. Off-label prescribing includes the 
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use of drugs for unapproved indications, or a different age group, dosage, 
frequency or route of administration. It also includes the administration of 
extemporaneous formulations with untested bioavailability and stability. Although 
off-label use for indications beyond the initial labelled indication is seen frequently 
in adults, there is at least basic information about pharmacokinetics and safety 
available, and efficacy information is assured for at least one indication. However, 
for children, off-label prescribing means that there is no labelling information at all. 
The widespread acceptance of this practice helps perpetuate the lack of information 
to guide practice, and the disconnection between the label and practice makes the 
package insert irrelevant for patients and pediatricians as a guide for usage.  
 
 
EXTENT OF OFF-LABEL PRESCRIBING 
Numerous surveys have documented extensive off-label drug use in hospitalized 
pediatric patients. Conroy et al.7 surveyed off-label use in general pediatric wards in 
five European countries. Sixty-seven percent of all patients received at least one 
off-label prescription. 't Jong et al.8 reported an even higher incidence of off-label 
use in a prospective 19-week survey at a general hospital in The Netherlands, at 
which 92% of children received at least one off-label prescription. Sicker and 
younger children, who are more vulnerable, are more likely to receive off-label 
medicines than less acutely ill children. In specialized children's hospitals in The 
Netherlands it was found that 66% of all prescriptions were off-label.9 On general 
medical wards 59% of prescriptions were off-label compared with 76% in neonatal 
intensive care units.9 The high likelihood of neonates receiving an off-label drug was 
confirmed in an Australian neonatal intensive care unit in which 93% of extremely 
low birth weight infants received at least one off-label medicine.10 
 
In summary, off-label use of medicines has become unfortunately a necessary and 
accepted part of pediatric medical practice. Children receive ineffective doses of 
potentially effective medicines and are harmed by medicines that might not be 
effective for their conditions. The continued off-label use of medicines impedes the 
ability to organize and learn from experience, and exposes many more children to 
risk than would be the case in a carefully controlled and monitored clinical trial. 
 
 
NEW DEVELOPMENTS  
During the past two decades, tremendous strides have been made to tailor 
therapies for the needs of children. As our knowledge of normal growth and 
development has increased, so has our recognition that developmental changes 
profoundly affect the responses to medications and produce a need for age-
dependent dose requirements.11  
 
Prior to the clinical integration of developmental pharmacology into therapeutic 
decision making, numerous approaches (e.g., Young's Rule, Clark's Rule) for 
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determining pediatric drug doses were recommended. These approaches vary with 
some using discrete age points and others using allometric principles that generally 
assume predictable, linear relationships between mass (e.g., cell mass, body 
weight) and/or body surface area between infants, children, adolescents and adults. 
However, as human growth is not a linear process and age-associated changes in 
body composition and organ function are dynamic and can be discordant during the 
first decade of life, simplified dosing approaches are not adequate for individualizing 
drug doses across the span of childhood.12 As a result, these old "dosing equations" 
have been abandoned and in most instances, replaced by simple "normalization" of 
drug dose as a function of either body weight (mg/kg) or body surface area 
(mg/m2). While such guidelines are generally adequate for the initiation of therapy, 
they may not be sufficient for age-based individualization of continued (e.g., 
chronic) treatment where dramatic developmental differences in pharmacokinetics 
and/or pharmacodynamics (i.e., the determinants of appropriate dosing regimen) 
may occur. Thus, the provision of safe and effective drug therapy for pediatric 
patients requires a fundamental understanding and integration of the role of 
development on drug disposition and action.  
 
 
ABSORPTION 
For therapeutic agents administered by extravascular routes, the process of 
absorption is reflected by the ability of a drug to overcome chemical, physical, 
mechanical and biological barriers. Developmental differences in the physiologic 
composition and function of these barriers can alter the rate and/or extent of drug 
absorption. While factors influencing drug absorption are multifactorial in nature 
(e.g., physical, chemical and biological), developmental changes in the absorptive 
surfaces (e.g., gastrointestinal tract, skin, pulmonary tree, etc.) can be 
determinants of bioavailability. 
 
The oral route is the principal means for drug administration to pediatric patients. 
Changes in intra-luminal pH can directly impact both drug stability and degree of 
ionization, thus influencing the relative amount of drug available for absorption. 
Additionally, the ability to solubilize and subsequently absorb lipophilic drugs can be 
influenced by age-dependent changes in biliary function. Immature conjugation 
and/or transport of bile salts into the intestinal lumen results in low intraduodenal 
levels despite blood levels that exceed those of adults.13,14 
 
Gastric emptying and intestinal motility are primary determinants of the rate at which 
drugs are presented to and dispersed along the mucosal surface of the small 
intestine. Unfortunately, few studies have systematically evaluated the effect of 
developmental changes in gastric emptying and intestinal motility on drug absorption 
in infants and children. Generally, the rate at which most drugs are absorbed is 
generally slower and thus, the time to achieve maximum plasma concentrations is 
prolonged in neonates and young infants relative to older infants and children.  
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Despite their incomplete characterization,15 developmental differences in the 
activity of intestinal drug metabolizing enzymes and efflux transporters have the 
potential to markedly alter drug bioavailability. Notably, data on developmental 
expression of the efflux transporter P-glycoprotein (MDR1) in humans is absent.  
 
 
DISTRIBUTION 
Age-dependent changes in body composition (Figure 1)16 alter the physiologic 
"spaces" into which a drug may distribute. Larger extracellular and total body water 
spaces in neonates and young infants, coupled with adipose stores that have a 
higher water/lipid ratio than in adults, produce lower plasma concentrations for 
drugs that distribute into these respective compartments when administered in a 
weight-based fashion. For lipophilic drugs that associate primarily with tissue, the 
influence of age on altering the apparent volume of distribution is not as readily 
apparent. 
 
Changes in the composition and amount of circulating plasma proteins (e.g., 
albumin, α1 acid-glycoprotein) can also influence the distribution of highly bound 
drugs. A reduction in the quantity of total plasma proteins (including albumin) in 
the neonate and young infant increases the free fraction of drug, thereby 
influencing the availability of the active moiety. Other factors associated with 
development and/or disease such as variability in regional blood flow, organ 
perfusion, permeability of cell membranes, changes in acid-base balance and 
cardiac output can also influence drug binding and/or distribution. 
 
Figure 1 Changes occurring in body fat and water stores along the continuum of age.16 
TBW – total body water; ECW – extracellular water.  
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DRUG METABOLISM 
Cardiovascular collapse associated with the "gray baby syndrome" in newborns 
treated with chloramphenicol is often cited as a clinically significant consequence of 
developmental deficiencies in drug metabolizing enzyme activities.17,18 Multiple 
examples exist of clinically important developmental changes in drug 
biotransformation sufficient to produce the need for age-appropriate dose regimen 
selection in neonates and young infants (e.g., methylxanthines, nafcillin, 3rd 
generation cephalosporins, captopril, morphine). As reflected by recent reviews, 
distinct patterns of isoform-specific developmental changes in drug 
biotransformation are apparent for many Phase I (primarily oxidation) and Phase II 
(conjugation) drug metabolizing enzymes.19,20 
 
 
PHASE I ENZYMES  
Development has a profound effect on the expression of Phase I enzymes such as 
the cytochromes P450 (CYPs). CYP3A7 is the predominant CYP isoform expressed in 
fetal liver where it may play a fetoprotective role by detoxifying 
dehydroepiandrosterone sulfate and potentially teratogenic retinoic acid 
derivatives.21 CYP3A7 expression peaks shortly after birth and then declines rapidly 
to levels that are undetectable in most adults.22 Distinct patterns of isoform-specific 
developmental CYP expression have been observed postnatally. Within hours of 
birth, CYP2E1 activity surges23 followed closely by the onset of CYP2D6 
expression.24 CYP3A4 and CYP2C (CYP2C9 and 2C19) activities appear during the 
first week of life22,25 whereas CYP1A2 is the last hepatic CYP to be acquired with 
significant expression being delayed until 1 - 3 months of life.26 
 
Insight into the ontogeny of drug metabolism also can be derived from 
pharmacokinetic studies of drugs metabolized by specific CYP isoforms. Midazolam 
plasma clearance, which primarily reflects hepatic CYP3A4/5 activity after 
intravenous administration,27 increases approximately 5-fold (1.2 to 9 ml/min/kg) 
over the first 3 months of life.28 Carbamazepine plasma clearance, also largely 
dependent upon CYP3A4,29 is greater in children relative to adults,30,31 thereby 
necessitating higher weight-adjusted (i.e., mg/kg) doses of the drug to produce 
therapeutic plasma concentrations.  
 
CYP2C9 and to a lesser extent, CYP2C19, are primarily responsible for phenytoin 
biotransformation.32 Phenytoin apparent half life is prolonged (~ 75 h) in preterm 
infants but decreases to ~ 20 h in term infants less than one week postnatal age 
and to ~ 8 h after two weeks of age.33 Saturable phenytoin metabolism does not 
appear until approximately 10 days of postnatal age, demonstrating the 
developmental acquisition of CYP2C9 activity.  
 
Caffeine and theophylline are the most common CYP1A2 substrates used in 
pediatrics. Caffeine elimination in vivo mirrors that observed in vitro with full 
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3-demethylation activity (mediated by CYP1A2) observed by approximately four 
months of age.34 Formation of CYP1A2-dependent theophylline metabolites reaches 
adult levels by approximately 4 - 5 months of postnatal age35 and in older infants 
and young children, theophylline plasma clearance generally exceeds adult values.36 
Furthermore, caffeine 3-demethylation in adolescent females appears to decline to 
adult levels at Tanner stage II relative to males where it occurs at stages IV/V,37 
thus demonstrating an apparent sex difference in the ontogeny of CYP1A2.  
 
 
PHASE II ENZYMES 
Phase II reactions generally result in pharmacological inactivation or detoxification 
by conjugating xenobiotics with small molecules such as UDP-glucuronic acid, 
glutathion, or acetyl coenzyme A. These reactions are catalyzed by a variety of 
enzymes, the activity of which appears to be associated with development. While 
the impact of ontogeny on Phase II enzymes has not been investigated to the same 
extent as for Phase I enzymes, a conceptual understanding of their known 
developmental profiles is important to understanding the acquisition of metabolic 
competence in the neonate and its potential therapeutic implications.20 
 
UDP glucuronosyltransferase (UGT) 
The mammalian UGTs are responsible for the glucuronidation of hundreds of 
hydrophobic endogenous (e.g., bilirubin, bile acids, thyroxine, and steroids) and 
exogenous (e.g., morphine, acetaminophen, and NSAIDs) xenobiotics. Additionally, 
UGTs detoxify an extensive group of potentially carcinogenic or teratogenic 
xenobiotics that enter the body as components of the diet or as air-borne 
pollutants.38 
 
The UGTs comprise a super family of enzymes that are subdivided into families 
based on sequence homology. In neonatology, serious clinical consequences of 
allelic variants in UGT isoforms are well known. Over 30 different perturbations of 
the UGT1A gene results in absent or reduced enzyme activity that can lead to lethal 
hyperbilirubinemia (Crigler-Najjar syndrome).39 Mutations of the promoter region of 
the UGT1 gene have been associated with a milder form of congenital unconjugated 
hyperbilirubinemia (Gilbert's syndrome).40 From a pharmacologic perspective, 
failure to recognize the impact of development on the glucuronidation of 
chloramphenicol and its implications for age-associated individualization of therapy 
lead to the historical catastrophe of the Grey Baby Syndrome.2 
 
Low levels of immunoreactive UGT protein are found early in gestation in liver, 
spleen, and kidney. Relatively greater reactivity has been observed in red blood 
cells as early as 32 days post-conception.41,42 Functional UGT activity, as assessed 
by bilirubin conjugation, is nearly undetectable in fetal liver with activity increasing 
immediately after birth in parallel with an increase in protein. The increase in 
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catalytic activity is not dependent upon gestational age,43-45 thereby suggesting that 
postnatal events are essential for the expression and/or activation of the UGT gene. 
 
The most complete information on the development of UGT activity as it relates to 
drug metabolism comes from studies of morphine glucuronidation by UGT2B7. 
Morphine is metabolized by UGT2B7 to morphine-6-glucuronide and morphine-3-
glucuronide.46 In vitro studies have shown that liver microsomes from fetuses aged 
15 - 27 weeks glucuronidate morphine at a rate that is only 10 - 20% of that seen 
in adult microsomes.47,48 No correlation was seen between gestational age and the 
rate of glucuronidation, again suggesting that birth related events play a role in the 
activation of this enzyme. In in vivo studies, the mean plasma clearance of 
morphine was 5-fold lower in premature infants (gestational age 24 - 37 weeks) 
when compared to children 1 to 16 years of age. Generally, morphine clearance 
reaches adult levels between 2 and 6 months, but may take as long as 30 
months.49 Since glucuronidation is the primary metabolic pathway for morphine 
metabolism, the impact of development on clearance appears to accurately reflect 
the ontogeny of UGT2B7.  
 
The impact of development on the activity of other UGT isoforms can also be 
indirectly assessed using pharmacologic substrates for this enzyme. Acetaminophen 
is metabolized by UGT1A6, and to a lesser extent by UGT1A9.50 Acetaminophen 
glucuronidation, as reflected by urinary metabolite data, appears neglible in the 
fetus, is low at birth and appears to approach full competence by 9 to 12 months of 
postnatal life.51 Zidovudine plasma clearance in neonates less than 2 weeks of age 
is only half that of infants 2 weeks and older.52 Collectively, the pharmacokinetic 
data for the aforementioned UGT substrates illustrate that the developmental profile 
for acquisition of enzyme activity is isoform and substrate specific. 
 
N-acetyltransferase (NAT) 
Recognized initially for its ability to metabolize isoniazid, N-acetyltransferase (NAT) 
was one of the first drug metabolizing enzymes shown to possess genetic 
polymorphisms that dramatically affected the pharmacokinetics of its substrate.53 
Genetic variation, primarily in the NAT2 gene locus, is responsible for the division of 
the general population into rapid and slow acetylators. Subsequently, several 
studies have shown an association between polymorphisms at both the NAT1 and 
NAT2 loci and susceptibility to disease or drug reactions.54-56  
 
Relatively sparse information on the ontogeny of human NAT1 and NAT2 is 
available. NAT1 mRNA has been identified in fetal, newborn, and adult skeletal 
muscle with relatively greater immunostaining in fetal tissue.57 Using caffeine as a 
probe for NAT activity, a discordant relationship between genotype and phenotype 
in infants has been observed. Little difference in NAT activity is observed between 
premature infants and those 1 - 19 months of age.58 In subsequent studies, the 
cumulative frequency of fast acetylators was shown to increase with age, reaching a 
plateau at around 4 years.59,60 Thus, there are a relatively higher proportion of 
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phenotypically slow acetylators in children less than 2 years. A maturational process 
appears to occur, independent of genotype, that is not complete until about 4 years 
of age. This maturational process may reflect developmentally regulated expression 
of the NAT gene, or may arise secondarily from the maturation of pharmacokinetic 
parameters other than metabolism (i.e., absorption, distribution, elimination).61 
 
Altered NAT expression and activity with age may have important clinical 
implications for drug dosing and toxicity and possibly, in the initiation and 
progression of certain disease processes. A higher incidence of adverse effects from 
co-trimoxazole has been demonstrated in children with a slow acetylator 
genotype.56 A significantly greater portion of children with immunoglobulin 
E-mediated food allergies are homozygous slow acetylators when compared to 
normal children. In these studies, no homozygous fast acetylators were observed in 
the group of individuals with severe food allergies.55 Collectively, our best evidence 
would indicate that all infants, particularly neonates, are essentially slow acetylators 
and would be subject to the consequences of decreased drug metabolism and 
increased disease susceptibilities inherent to this phenotype. 
 
In contrast to the cytochromes P450, what is currently known concerning the 
developmental pattern for the acquisition of phase II enzyme activity is far less 
precise. As illustrated in Table 1, the presence or absence of activity for many 
phase II drug metabolizing enzymes has been investigated in the fetus, neonate 
and infant. While pharmacokinetic data for many drugs that are substrates for these 
enzymes (e.g., zidovudine, acetaminophen) suggests a pattern for the acquisition of 
function during postnatal life, the apparent absence of enzyme/isoform-specific 
quantitative data precludes reliable prediction of drug clearance based upon age-
associated differences in enzyme activity at the present time.  
 
 
RENAL ELIMINATION 
Maturation of renal function is a dynamic process that begins early during fetal 
organogenesis and is complete by early childhood. The developmental increase in 
glomerular filtration rate (GFR) involves active nephrogenesis, a process that begins 
at 9 weeks and is complete by 36 weeks of gestation, followed by postnatal changes 
in renal and intrarenal blood flow.62 Following birth, the GFR is approximately 2 - 4 
ml/min/1.73 m2 in term neonates and as low as 0.6 - 0.8 ml/min/1.73 m2 in 
preterm neonates. GFR increases rapidly during the first two weeks of life followed 
by a steady rise until adult values are reached by 8 - 12 months.63,64 Similarly, 
tubular secretory pathways are immature at birth and gain adult capacity during the 
first year of life. Collectively, these changes dramatically alter the plasma clearance 
of compounds with extensive renal elimination and thus, provide a major 
determinant for age-appropriate dose regimen selection. Pharmacokinetic studies of 
drugs primarily excreted by glomerular filtration such as ceftazidime64 and 
famotidine65 have demonstrated significant correlations between plasma drug 
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clearance and normal, expected maturational changes in renal function. For 
example, tobramycin is eliminated predominantly by glomerular filtration, 
necessitating dosing intervals of 36 to 48 h in preterm and 24 h in term newborns.66 
Failure to account for the ontogeny of renal function and adjust aminoglycoside 
dosing regimens accordingly can result in exposure to potentially toxic serum 
concentrations.67 Also, concomitant medications (e.g., betamethasone, 
indomethacin) may alter the normal pattern of renal maturation in the neonate.68 
Thus, for drugs with extensive renal elimination, both maturational and treatment 
associated changes in kidney function must be considered and used to individualize 
treatment regimens in an age-appropriate fashion. 
 
 
CONCLUSIONS 
The advances in pediatric clinical pharmacology during the past decade reside with 
an enhanced understanding of the influence of growth and development on drug 
disposition and action. As this moves forward, it is essential that the ultimate goal 
be kept clearly in sight. Specifically, providing infants and children with safe and 
effective drug therapy made possible by including them in the process of 
development of medications essential to ensure their health.  
 
The goal of rational drug therapy in neonates, infants, children and adolescents 
resides with the ability to individualize it based upon known developmental 
differences which impact drug disposition and action. The clinical challenge in this is 
accounting for the variability in all of the contravening factors that influence 
pharmacokinetics (e.g., polymorphic expression of drug metabolizing enzymes and 
efflux transporters, effect of disease and/or concomitant therapy on 
enzyme/transporter activity, altered drug delivery associated with drug formulations 
that may not be suited for accurate drug dosing) and pharmacodynamics (e.g., 
polymorphic expression of cellular transporters and/or receptors) between patients 
of a given age and developmental stage. Despite the fact that most therapeutic 
drugs are polyfunctional substrates for drug metabolizing enzymes (both Phase I 
and II) and that their activity (as well as transporters and potentially, drug 
receptors) is polygenically determined, knowledge of substrate specificity for a 
given drug and the patterns of expression for activity which are associated with age 
(development) can afford the clinician with an element of prediction, be it applied to 
projecting either the dose of a drug and/or its pharmacologic consequences in the 
pediatric patient.  
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ABSTRACT 
Adolescents infected with human immunodeficiency virus (HIV) represent a 
heterogeneous group of pubertal children and young adults. Antiretroviral therapy 
(ART) in adolescents is complex and depends on multiple factors. The continued use 
of higher (weight- or surface-based) pediatric doses can result in potentially toxic 
drug exposure, whereas early introduction of lower adult doses can lead to the 
development of drug resistance and virologic failure. The physiological and 
psychosocial changes during puberty create strong grounds for an individualized 
therapeutic approach in HIV-infected adolescents. 
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Despite significant progress in the prevention of mother-to-child transmission of 
human immunodeficiency virus (HIV) infection, it was estimated that there were 2.3 
million children under the age of 15 years with HIV infection in 2006.1 Among 
those, ~ 780,000 (600,000 - 1,000,000) were estimated to be in need of 
antiretroviral therapy (ART). In the United States and other developed countries, an 
increasing number of children with perinatally acquired HIV infection are now 
surviving into adolescence and adulthood. In addition, large numbers of American 
teenagers continue to acquire HIV infection through sexual contact and intravenous 
drug use; youths between 13 and 24 years of age account for 15% of the 40,000 
new HIV cases per year.2 Based on the strengthening global response to the 
problem of HIV/AIDS in recent years, the number of adolescents receiving ART 
worldwide is rapidly increasing.3 Given the growing number of HIV-infected youth 
with access to ART, a better understanding of the disposition of antiretroviral (ARV) 
drugs during puberty is urgently needed. The selection of ART dosages for patients 
in the pubertal stages of maximal growth is left to the provider's discretion, and 
individual differences in the progression to sexual maturation are often not provided 
for. The recently published report by the Committee on Pediatric AIDS, dealing with 
increasing access to ARV drugs for pediatric patients, identifies the lack of 
appropriate dosing of ARV drugs in adolescents as one of the barriers to providing 
ART to HIV-infected children and youth globally.3 The report underlines that, even 
with the availability of appropriate ART, the pharmacokinetic (PK) data may be 
insufficient to appropriately guide the dosing in adolescent patients, who may need 
higher than "maximum adult dose" to ensure adequate drug exposure.3,4 
Consequently, adolescents are identified as a separate study cohort when 
investigating the PK and pharmacodynamics (PD) of ARV agents in children, and the 
need for phase II and III studies in this cohort is underscored.  
 
Several pediatric HIV research networks (Pediatric AIDS Clinical Trials Group 
(PACTG)/International Maternal Pediatric Adolescent AIDS Clinical Trials, 
Collaborative HIV Pediatric Study, Pediatric European Network for Treatment of 
AIDS, the HIV Netherlands Australia Thailand Research Collaboration, and 
Adolescent Medicine Trials Network) have addressed issues of developmental PK/PD 
of ART in HIV-infected pediatric patients. However, very few studies have 
investigated the PK/PD of ARV agents in adolescents and young adults. The PK of 
abacavir were reported from the PACTG protocols P1018 and P1052;5,6 lamivudine 
and zidovudine data (including data on phosphorylation to the intracellular 
triphosphate metabolites) were collected in PACTG studies P1012 and P1052;7 
lopinavir/ritonavir and saquinavir were studied in PACTG protocol P1038;8 and 
atazanavir was studied in PACTG protocol 1020A and in Adolescent Medicine Trials 
Network studies along with tenofovir.5,9 The PACTG protocol P1038 and the author's 
study in children with experience of ARV suggested that the use of high doses of 
lopinavir/ritonavir might be required for salvage HIV therapy in adolescent 
patients.8,10 The Adolescent Medicine Trials Network study by Kiser et al. evaluated 
the PK of the combined administration of atazanavir/ritonavir and tenofovir in 
young adults with HIV infection.9 A higher level of tenofovir exposure was expected 
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on the basis of data from healthy volunteers, but this was not seen in HIV-infected 
subjects, most likely because of a faster tenofovir clearance, as apparent in the 
higher creatinine clearances observed in this age group.9 None of the available 
studies in adolescents has investigated the effects of pubertal changes on the 
required dosage in ART, and information on failed ART or increased drug resistance 
in HIV-infected adolescents is very limited. No studies have addressed the 
important issue of the long-term effects of ART exposure during puberty. Such 
possible effects include ART-associated hyperlipidemia and a risk of developing 
cardiovascular disease. Finally, adolescent patients are frequently exposed to 
antidepressants, hormonal contraceptives, anabolic steroids, alcohol, and illicit 
drugs. No studies are available to date on the effects of psychotropic drugs, 
substance abuse, and exogenous sex hormones on ART drug disposition and 
efficacy in adolescence, although there is an abundance of pharmacological data 
pertaining to the adult population.  
 
HIV-infected adolescents represent a heterogeneous group of pubertal children and 
young adults at different stages of psychosocial development, with vertically and 
horizontally transmitted HIV infection, varying demographic and socioeconomic 
statuses, and diverse histories of sexual and substance abuse. The choice of ART 
regimen must balance many of these factors in addition to the selection of the 
correct dosage of ARV drugs. Clinicians are faced with the dilemma of choosing a 
dosing regimen that falls somewhere between pediatric (weight- and surface- 
based) and adult (fixed-dose) guidelines. The World Health Organization guidelines 
and the US guidelines for ART in adolescent patients include adolescents within both 
categories: "pediatric" (infants and children) and "adults and adolescents." The 
World Health Organization defines the "adolescent" cohort as children aged between 
10 and 19 years; the US guidelines use 12 years of age as the cutoff for transition 
to adolescence.5,11 (Table 1) The appropriate dosing of ARV medications in 
adolescents is complex and depends on multiple factors, including developmental 
changes throughout puberty. Although current pediatric HIV treatment guidelines 
for older children recommend considering Tanner stages of puberty when 
prescribing ART, they do not provide data justifying those recommendations. For 
children in early puberty (Tanner stages I and II), the US guidelines recommended 
using pediatric schedules, whereas for adolescents in their growth spurt (Tanner 
stages III and IV), both adult and pediatric dosing schedules are recommended.5 
The World Health Organization pediatric guidelines extend pediatric dosing to 
Tanner stage III and recommend adult dosing in adolescents in Tanner stages IV 
and V.11 Both guidelines recommend considering issues such as toxicity, adherence, 
and virologic and immunologic parameters when determining the timing of 
transition from pediatric to adult doses. The continued use of higher (weight- or 
surface-based) pediatric doses during adolescence can result in increased and 
potentially toxic drug exposure, whereas early introduction of lower adult doses can 
lead to suboptimal therapeutic exposure and development of drug resistance and 
subsequent virologic failure.  
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Few studies have addressed the effect of HIV infection and ART on puberty, and 
these were conducted in adolescents with perinatally acquired HIV infection in the 
era of limited therapeutic choices.12,13 The study by De Martino et al. reported a 
delay in the onset of puberty in Caucasian HIV-infected children independent of 
clinical or immunological status.12 A much larger prospective cohort study from the 
United States, carried out by the PACTG 219 Study Team among children of diverse 
ethnic and racial backgrounds, reported a direct association between 
immunosuppression and a delayed onset of puberty.13 This study, however, 
simplified the classification of Tanner stages and did not record orchidometric data. 
This omission could lead to a potential misclassification of the Tanner stage. 
Recently, a much smaller longitudinal study of 10 HIV-infected children, involving a 
thorough puberty evaluation including serial quantitations of plasma growth 
hormones (GHs), gonadotropins, and sex steroids, has demonstrated that children 
with a good control of HIV infection showed growth and pubertal development 
within the physiological percentile for their age.14 Further studies are necessary to 
understand the impact of perinatally and behaviorally acquired HIV infection and 
ART on the onset and progression of puberty. 
 
Puberty is characterized by an increase in growth velocity, changes in body 
composition, and the appearance of striking somatic changes. The changes in body 
composition vary between the sexes, with a significant increase in lean body mass 
in boys and an accumulation of fat in girls.15,16 Girls are generally a year or two 
more advanced in pubertal maturation than boys, and the African-American race 
has been associated with an earlier onset of menarche.16,17 Peak height velocity in 
girls occurs before menarche (which in turn takes place ~ 2 - 2.5 years after the 
first signs of breast development), whereas significant changes in genital 
development usually precede peak height velocity in boys.18 In each gender, it 
takes about 4.5 years (3 - 6 years) from the first appearance of secondary sex 
characteristics to adult body configuration. Significant hormonal changes occur 
during adrenarche just prior to the appearance of secondary sexual characteristics, 
and gonadotropins, sex steroids, and GHs show different secretory patterns during 
different pubertal stages in boys and girls. The increase in circulating GH and 
insulinlike GH (IGF-1) levels is seen in girls at Tanner stage II (Breast II), whereas 
in boys it is usually delayed until stages II to III (Genital II–III).19 In boys, rapidly 
rising testosterone levels cause an increase in GH/IGF-1 secretion and growth 
velocity. In girls, mean plasma levels of estradiol have been shown to rise steadily 
throughout puberty, with wide individual fluctuations depending on the time relative 
to menarche and the ovulatory cycle.19 A careful history and thorough physical 
examination by an experienced provider is required for accurately evaluating the 
onset and progress of puberty.  
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: 
90
 -
 1
50
 m
g/
m
2 /
do
se
 t
w
ic
e 
da
ily
 (
av
er
ag
e 
do
se
 1
20
 m
g/
m
2 )
 o
r 
in
 t
re
at
m
en
t-
na
ïv
e 
pa
tie
nt
s 
3 
- 
21
 y
ea
rs
 o
f a
ge
 2
40
 m
g/
m
2 /
do
se
 o
nc
e 
da
ily
. 
A
do
le
sc
en
t/
ad
ul
ts
: 
or
al
 s
ol
ut
io
n 
—
 b
od
y 
w
ei
gh
t 
>
 6
0 
kg
 —
 2
00
 m
g/
do
se
 
tw
ic
e 
da
ily
 o
r 
25
0 
m
g/
do
se
, 
if 
co
-a
dm
in
is
te
re
d 
w
ith
 T
D
F.
 B
od
y 
w
ei
gh
t 
<
 6
0 
kg
 —
 1
25
 m
g/
do
se
 t
w
ic
e 
da
ily
. 
Th
e 
to
ta
l d
ai
ly
 d
os
e 
m
ay
 b
e 
ad
m
in
is
te
re
d 
on
ce
 d
ai
ly
, 
tw
ic
e 
da
ily
 d
os
in
g 
is
 p
re
fe
rr
ed
. 
 
Em
tr
ic
ita
bi
ne
 
(F
TC
, E
m
tr
iv
aT
M
) 
N
o 
do
si
ng
 g
ui
de
lin
es
 fo
r 
ch
ild
re
n.
  
A
du
lts
 —
 2
00
 m
g/
do
se
 o
nc
e 
da
ily
. 
Pe
di
at
ric
: 
or
al
 s
ol
ut
io
n 
—
 6
 m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 2
40
 m
g)
 o
nc
e 
da
ily
. 
C
ap
su
le
s 
(b
od
y 
w
ei
gh
t 
>
 3
3 
kg
) 
—
 2
00
 m
g/
do
se
 o
nc
e 
da
ily
. 
A
do
le
sc
en
t 
>
 1
8 
ye
ar
s/
ad
ul
ts
: 
or
al
 s
ol
ut
io
n 
—
 2
40
 m
g/
do
se
 o
nc
e 
da
ily
, 
ca
ps
ul
es
 —
 2
00
 m
g/
do
se
 o
nc
e 
da
ily
. 
 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
  
• 
Tr
uv
ad
a®
 (
20
0 
m
g 
FT
C
/3
00
 m
g 
TD
F)
 —
 1
 t
ab
le
t/
do
se
 o
nc
e 
da
ily
. 
 
• 
A
tr
ip
la
TM
 (
20
0 
m
g 
FT
C
/3
00
 m
g 
TD
F/
60
0 
m
g 
EF
V
) 
—
 1
 t
ab
le
t/
do
se
 
on
ce
 d
ai
ly
. 
La
m
iv
ud
in
e 
(3
TC
, 
Ep
iv
ir®
,  
Ep
iv
ir 
H
BV
) 
B
od
y 
w
ei
gh
t 
<
 5
0 
kg
 —
 4
 m
g/
kg
/d
os
e 
tw
ic
e 
a 
da
y 
to
 a
 m
ax
im
um
 o
f 
15
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
B
od
y 
w
ei
gh
t 
>
 5
0 
kg
 —
 1
50
 m
g/
do
se
 t
w
ic
e 
da
ily
. 
A
du
lts
 —
 1
50
 m
g/
do
se
 t
w
ic
e 
da
ily
 o
r 
30
0 
m
g/
do
se
 o
nc
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T:
  
• 
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
 —
 1
 t
ab
le
t/
do
se
 t
w
ic
e 
da
ily
. 
• 
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
/3
00
 m
g 
A
B
C
 —
 1
 t
ab
le
t/
do
se
 t
w
ic
e 
da
ily
. 
• 
30
 m
g 
d4
T/
15
0 
m
g 
3T
C
/2
00
 m
g 
N
V
P 
—
 1
 t
ab
le
t/
do
se
 t
w
ic
e 
da
ily
. 
Pe
di
at
ric
: 
4 
m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 1
50
 m
g)
 t
w
ic
e 
da
ily
. 
Ad
ol
es
ce
nt
 ≥
 1
6 
ye
ar
s/
ad
ul
ts
: 
bo
dy
 w
ei
gh
t 
>
 5
0 
kg
 —
 1
50
 m
g/
do
se
 
tw
ic
e 
da
ily
 o
r 
30
0 
m
g/
do
se
 o
nc
e 
da
ily
. 
B
od
y 
w
ei
gh
t 
<
 5
0 
kg
 —
 4
 
m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 1
50
 m
g)
 t
w
ic
e 
da
ily
. 
C
om
bi
na
tio
n 
AR
T 
(a
do
le
sc
en
ts
 >
 1
2 
ye
ar
s/
ad
ul
ts
: 
 
• 
C
om
bi
vi
r®
 (
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
) 
—
 1
 t
ab
le
t/
do
se
 t
w
ic
e 
da
ily
. 
 
• 
Tr
iz
iv
ir®
 (
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
/3
00
 m
g 
A
B
C
) 
—
 1
 t
ab
le
t/
do
se
 
tw
ic
e 
da
ily
.  
• 
Ep
zi
co
m
®
 (
30
0 
m
g 
3T
C
/6
00
 m
g 
A
B
C
) 
—
 1
 t
ab
le
t/
do
se
 o
nc
e 
da
ily
. 
S
ta
vu
di
ne
 
(d
4T
, Z
er
it®
) 
B
od
y 
w
ei
gh
t 
<
 3
0 
kg
 —
 1
 m
g/
kg
/d
os
e 
tw
ic
e 
da
ily
. 
B
od
y 
w
ei
gh
t 
>
 3
0 
kg
 —
 3
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
B
od
y 
w
ei
gh
t 
>
 6
0 
kg
 —
 4
0 
m
g/
do
se
 t
w
ic
e 
da
ily
 (
us
in
g 
30
 m
g 
do
si
ng
 
Pe
di
at
ric
: 
bo
dy
 w
ei
gh
t 
<
 3
0 
kg
 —
 1
 m
g/
kg
/d
os
e 
tw
ic
e 
da
ily
. 
Ad
ol
es
ce
nt
 (
bo
dy
 w
ei
gh
t 
≥
 3
0 
kg
)/
ad
ul
ts
: 
bo
dy
 w
ei
gh
t 
30
 -
 <
 6
0 
kg
 —
 
30
 m
g/
do
se
 t
w
ic
e 
a 
da
y.
  
  
le
ad
s 
to
 d
el
ay
 o
r 
re
du
ct
io
n 
of
 t
ox
ic
ity
, 
al
th
ou
gh
 li
m
ite
d 
da
ta
 o
n 
ef
fic
ac
y 
is
 a
va
ila
bl
e)
. 
A
du
lts
 —
 b
od
y 
w
ei
gh
t 
>
 6
0 
kg
 —
 4
0 
m
g/
do
se
 t
w
ic
e 
da
ily
, 
bo
dy
 
w
ei
gh
t 
<
 6
0 
kg
 —
 3
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T:
 
• 
1 
m
g/
kg
/d
os
e 
d4
T 
pl
us
 4
 m
g/
kg
/d
os
e 
3T
C
 (
or
al
 s
ol
ut
io
n)
 t
w
ic
e 
da
ily
 o
r 
30
 m
g 
d4
T/
15
0 
m
g 
3T
C
 (
1 
ta
bl
et
/d
os
e)
 t
w
ic
e 
da
ily
. 
• 
30
 m
g 
d4
T/
15
0 
m
g 
3T
C
/2
00
 m
g 
N
V
P 
—
 1
 t
ab
le
t/
do
se
 t
w
ic
e 
da
ily
. 
B
od
y 
w
ei
gh
t 
≥
 6
0 
kg
 —
 4
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
Te
no
fo
vi
r 
(T
D
F,
 V
ire
ad
®
) 
 
N
o 
do
si
ng
 g
ui
de
lin
es
 fo
r 
ch
ild
re
n.
 
A
du
lts
 —
 3
00
 m
g/
do
se
 o
nc
e 
da
ily
. 
Pe
di
at
ric
: 
in
ve
st
ig
at
io
na
l d
os
e 
—
 2
10
 m
g/
m
2 /
do
se
 (
m
ax
im
al
 d
os
e,
 3
00
 
m
g)
 o
nc
e 
da
ily
. 
A
do
le
sc
en
t 
>
 1
8 
ye
ar
s/
ad
ul
ts
: 
30
0 
m
g/
do
se
 o
nc
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
  
• 
Tr
uv
ad
a®
 (
20
0 
m
g 
FT
C
/3
00
 m
g 
TD
F)
 —
 1
 t
ab
le
t/
do
se
 o
nc
e 
da
ily
. 
 
• 
A
tr
ip
la
TM
 (
20
0 
m
g 
FT
C
/3
00
 m
g 
TD
F/
60
0 
m
g 
EF
V
) 
—
 1
 t
ab
le
t/
do
se
 
on
ce
 d
ai
ly
. 
Zi
do
vu
di
ne
  
(Z
D
V,
 A
ZT
, 
R
et
ro
vi
r®
) 
C
hi
ld
re
n 
—
 1
80
 -
 2
40
 m
g/
m
2 /
do
se
 (
m
ax
im
al
 d
os
e,
 3
00
 m
g)
 t
w
ic
e 
da
ily
. 
A
du
lts
 —
 2
50
 -
  3
00
 m
g/
do
se
 t
w
ic
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T:
  
• 
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
 —
 1
 t
ab
le
t/
do
se
 t
w
ic
e 
da
ily
. 
• 
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
/3
00
 m
g 
A
B
C
 (
ta
bl
et
) 
—
 1
 t
ab
le
t/
do
se
 
tw
ic
e 
da
ily
. 
Pe
di
at
ric
: 
16
0 
m
g/
m
2 /
do
se
 e
ve
ry
 8
 h
ou
rs
 (
th
re
e 
tim
es
 d
ai
ly
) 
or
 1
80
 -
 
24
0 
m
g/
m
2 /
do
se
 t
w
ic
e 
da
ily
. 
Ad
ol
es
ce
nt
 ≥
 1
2 
ye
ar
s/
ad
ul
ts
: 
20
0 
m
g/
do
se
 t
hr
ee
 t
im
es
 d
ai
ly
 o
r 
30
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
C
om
bi
na
tio
n 
AR
T 
(a
do
le
sc
en
t/
ad
ul
ts
):
  
• 
C
om
bi
vi
r®
 (
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
) 
—
 1
 t
ab
le
t/
do
se
 o
nc
e 
da
ily
. 
 
• 
Tr
iz
iv
ir®
 (
30
0 
m
g 
A
Z
T/
15
0 
m
g 
3T
C
/3
00
 m
g 
A
B
C
) 
—
 1
 t
ab
le
t/
do
se
 
on
ce
 d
ai
ly
. 
Ef
av
ire
nz
 
(E
FV
, 
D
M
P-
26
6E
FV
, 
S
us
tiv
aT
M
) 
B
od
y 
w
ei
gh
t 
<
 4
0 
kg
 —
 1
9.
5 
m
g/
kg
/d
os
e 
(s
yr
up
) 
or
 1
5 
m
g/
kg
/d
os
e 
(c
ap
su
le
/t
ab
le
t)
 o
nc
e 
da
ily
. 
B
od
y 
w
ei
gh
t 
>
 4
0 
kg
 —
 6
00
 m
g/
do
se
 o
nc
e 
da
ily
. 
A
du
lts
 —
 6
00
 m
g/
do
se
 o
nc
e 
da
ily
. 
Pe
di
at
ric
: 
bo
dy
 w
ei
gh
t 
<
 4
0 
kg
 (
20
 -
 <
 2
5 
kg
 —
 3
00
 m
g;
 2
5 
- 
<
 3
2.
5 
kg
 
—
 3
50
 m
g;
 3
2.
5 
- 
<
 4
0 
kg
 —
 4
00
 m
g)
 p
er
 d
os
e 
on
ce
 d
ai
ly
. 
Ad
ol
es
ce
nt
 (
bo
dy
 w
ei
gh
t 
≥
 4
0 
kg
)/
ad
ul
ts
: 
60
0 
m
g/
do
se
 o
nc
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
 
• 
A
tr
ip
la
TM
 (
20
0 
m
g 
FT
C
/3
00
 m
g 
TD
F/
60
0 
m
g 
EF
V
) 
—
 1
 t
ab
le
t/
do
se
 
on
ce
 d
ai
ly
. 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 c
er
ta
in
 P
Is
 r
eq
ui
re
s 
fo
llo
w
in
g 
do
se
 a
dj
us
tm
en
ts
 
—
 3
00
 m
g 
A
TV
 p
lu
s 
10
0 
m
g 
R
TV
 w
ith
 6
00
 m
g 
EF
V
, 
al
l o
nc
e 
da
ily
; 
1,
00
0 
m
g 
ID
V
 3
 t
im
es
 d
ai
ly
 p
lu
s 
60
0 
m
g 
EF
V
 o
nc
e 
da
ily
; 
70
0 
m
g 
f-
A
M
P 
pl
us
 1
00
 m
g 
R
TV
 o
nc
e 
da
ily
 o
r 
1,
40
0 
m
g 
f-
A
PV
 p
lu
s 
30
0 
m
g 
R
TV
 
w
ith
 6
00
 m
g 
EF
V
, 
al
l o
nc
e 
da
ily
. 
 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
VC
 r
eq
ui
re
s 
60
0 
m
g 
M
V
C
 t
w
ic
e 
da
ily
 w
ith
 6
00
 
m
g 
EF
V 
on
ce
 d
ai
ly
. 
C
om
bi
na
tio
n 
AR
T 
(a
do
le
sc
en
ts
 >
12
 y
ea
rs
/a
du
lts
):
 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 L
PV
/R
TV
 r
eq
ui
re
s 
60
0 
m
g 
LP
V
/1
50
 m
g 
R
TV
 (
3 
20
0/
50
 m
g 
ta
bl
et
s)
 t
w
ic
e 
da
ily
 w
ith
 6
00
 m
g 
EF
V
 o
nc
e 
da
ily
. 
 
  
D
ru
g
 
W
H
O
 G
u
id
el
in
es
 
U
S
 G
u
id
el
in
es
 
Et
ra
vi
ri
ne
 
(E
TR
, 
ET
V
, 
In
te
le
nc
eT
M
, 
TM
C
12
5)
 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 c
hi
ld
re
n.
 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 a
du
lts
. 
Pe
di
at
ri
c:
 n
ot
 a
pp
ro
ve
d 
fo
r 
us
e 
in
 c
hi
ld
re
n.
 
A
do
le
sc
en
t/
ad
ul
ts
: 
ad
ul
t 
do
se
 f
or
 A
R
V
-e
xp
er
ie
nc
ed
 p
at
ie
nt
s 
20
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
N
ev
ir
ap
in
e 
(N
V
P,
 V
ir
am
un
e®
) 
C
hi
ld
re
n:
 1
60
 -
 2
00
 m
g/
m
2 /
do
se
 (
m
ax
im
al
 d
os
e,
 2
00
 m
g)
 t
w
ic
e 
da
ily
. 
S
ca
le
 u
p 
th
e 
do
si
ng
 s
ch
ed
ul
e 
at
 in
iti
at
io
n 
st
ar
ti
ng
 a
t 
16
0 
m
g/
m
2 /
do
se
 o
nc
e 
da
ily
 f
or
 t
he
 f
ir
st
 1
4 
da
ys
, 
an
d 
m
ov
in
g 
up
 t
o 
fu
ll 
do
se
 if
 n
o 
ra
sh
 o
r 
un
to
w
ar
d 
ef
fe
ct
s 
af
te
r 
14
 d
ay
s.
 
A
du
lts
 —
 2
00
 m
g/
do
se
 o
nc
e 
da
ily
 f
or
 1
4 
da
ys
, 
fo
llo
w
ed
 b
y 
20
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T:
 
• 
30
 m
g 
d4
T/
15
0 
m
g 
3T
C
/2
00
 m
g 
N
V
P 
—
 1
 t
ab
le
t/
do
se
 t
w
ic
e 
da
ily
. 
 
Pe
di
at
ri
c:
 1
50
 -
 2
00
 m
g/
m
2 /
do
se
 (
m
ax
im
al
 d
os
e,
 2
00
 m
g)
 t
w
ic
e 
da
ily
. 
S
ca
le
 u
p 
th
e 
do
si
ng
 s
ch
ed
ul
e 
at
 in
iti
at
io
n 
st
ar
tin
g 
at
 1
50
 m
g/
m
2 /
do
se
 
on
ce
 d
ai
ly
 f
or
 t
he
 f
ir
st
 1
4 
da
ys
, 
an
d 
m
ov
in
g 
up
 t
o 
fu
ll 
do
se
 if
 n
o 
ra
sh
 
or
 u
nt
ow
ar
d 
ef
fe
ct
s 
af
te
r 
14
 d
ay
s.
 
A
do
le
sc
en
t/
ad
ul
ts
: 
20
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
 
C
om
bi
na
tio
n 
A
R
T 
(a
do
le
sc
en
ts
 >
 1
2 
ye
ar
s/
ad
ul
ts
):
  
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 L
PV
/R
TV
 r
eq
ui
re
s 
do
se
 a
dj
us
tm
en
t 
fo
r 
LP
V
/R
TV
. 
 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
V
C
 r
eq
ui
re
s 
15
0 
m
g 
M
V
C
 d
os
e 
w
ith
 2
00
 
m
g 
N
V
P,
 a
ll 
tw
ic
e 
da
ily
. 
A
ta
za
na
vi
r 
(A
TV
, 
R
ey
at
az
TM
) 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 c
hi
ld
re
n.
 
A
du
lts
 —
 3
00
 m
g 
A
TV
 p
lu
s 
10
0 
m
g 
R
TV
 o
nc
e 
da
ily
. 
Pe
di
at
ri
c:
 N
ot
 a
pp
ro
ve
d 
fo
r 
us
e 
in
 c
hi
ld
re
n.
 C
ur
re
nt
ly
 u
nd
er
 t
he
 s
tu
dy
 
in
 P
A
C
TG
/I
M
PA
A
C
T 
10
20
 A
. 
A
do
le
sc
en
t 
≥
 1
6 
- 
21
 y
ea
rs
/a
du
lt
s:
 in
 t
re
at
m
en
t-
na
ïv
e 
pa
ti
en
ts
 —
 4
00
 
m
g 
da
ily
 (
th
is
 d
os
e 
m
ay
 b
e 
in
ad
eq
ua
te
).
 I
n 
tr
ea
tm
en
t-
ex
pe
ri
en
ce
d 
pa
tie
nt
s 
—
 3
00
 m
g 
pl
us
 1
00
 m
g 
R
TV
 o
nc
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T(
ad
ul
ts
):
 
• 
O
nl
y 
R
TV
-b
oo
st
ed
 A
TV
 (
30
0 
m
g 
A
TV
 p
lu
s 
10
0 
m
g 
R
TV
) 
sh
ou
ld
 b
e 
us
ed
 in
 c
om
bi
na
tio
n 
w
ith
 T
D
F,
 L
PV
/R
TV
. 
 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
V
C
 r
eq
ui
re
s 
15
0 
m
g 
M
V
C
 d
os
e 
tw
ic
e 
da
ily
 
w
ith
 3
00
 m
g 
A
TV
 p
lu
s 
10
0 
m
g 
R
TV
. 
D
ar
un
av
ir
 
(D
R
V
, 
TM
C
11
4,
 
Pr
ez
is
ta
®
) 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 c
hi
ld
re
n.
 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 a
du
lts
. 
Pe
di
at
ri
c:
 N
ot
 a
pp
ro
ve
d 
fo
r 
us
e 
in
 c
hi
ld
re
n 
<
 1
8 
ye
ar
s.
 C
ur
re
nt
ly
 
un
de
r 
th
e 
D
EL
PH
I 
(T
M
C
 1
14
-C
2T
2)
 s
tu
dy
. 
A
do
le
sc
en
t 
≥
 1
8 
ye
ar
s/
ad
ul
ts
: 
60
0 
m
g/
do
se
 D
R
V
 p
lu
s 
10
0 
m
g 
R
TV
 
tw
ic
e 
da
ily
. 
D
R
V
 s
ho
ul
d 
no
t 
be
 u
se
d 
w
ith
ou
t 
R
TV
. 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
V
C
 r
eq
ui
re
s 
15
0 
m
g 
M
V
C
 d
os
e 
w
ith
 D
R
V
 
60
0 
m
g 
pl
us
 1
00
 m
g 
R
TV
, 
al
l t
w
ic
e 
da
ily
. 
Fo
sa
m
pr
en
av
ir
 
(f
-A
M
P,
 L
ex
iv
aT
M
) 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 c
hi
ld
re
n.
 
A
du
lts
 —
 7
00
 m
g 
f-
A
M
P 
pl
us
 1
00
 m
g 
R
TV
 t
w
ic
e 
da
ily
. 
Pe
di
at
ri
c 
>
 6
 a
nd
 <
 1
8 
ye
ar
s:
 in
 t
re
at
m
en
t-
na
ïv
e 
pa
tie
nt
s 
—
 3
0 
m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 1
,4
00
 m
g,
 c
an
 b
e 
us
ed
 in
 p
at
ie
nt
s 
w
it
h 
bo
dy
 w
ei
gh
t 
≥
 4
7 
kg
) 
tw
ic
e 
da
ily
 w
ith
ou
t 
R
TV
 o
r 
18
 m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 7
00
 m
g,
 c
an
 b
e 
us
ed
 in
 p
at
ie
nt
s 
w
ith
 b
od
y 
w
ei
gh
t 
≥
 3
9 
kg
) 
pl
us
 R
TV
 3
 m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 1
00
 m
g)
 t
w
ic
e 
da
ily
 
  
(c
an
 b
e 
us
ed
 in
 p
at
ie
nt
s 
w
ith
 b
od
y 
w
ei
gh
t 
≥
 3
3 
kg
).
 I
n 
tr
ea
tm
en
t-
ex
pe
ri
en
ce
d 
pa
tie
nt
s 
—
 1
8 
m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 7
00
 m
g,
 c
an
 
be
 u
se
d 
in
 p
at
ie
nt
s 
w
ith
 b
od
y 
w
ei
gh
t 
≥
 3
9 
kg
) 
pl
us
 R
TV
 3
 m
g/
kg
/d
os
e 
(m
ax
im
al
 d
os
e,
 1
00
 m
g,
 c
an
 b
e 
us
ed
 in
 p
at
ie
nt
s 
w
ith
 b
od
y 
w
ei
gh
t 
≥
 3
3 
kg
) 
tw
ic
e 
da
ily
. 
A
du
lts
d :
 in
 t
re
at
m
en
t-
na
ïv
e 
pa
ti
en
ts
 —
 1
,4
00
 m
g/
do
se
 t
w
ic
e 
da
ily
 
w
ith
ou
t 
R
TV
 o
r 
70
0 
m
g 
pl
us
 1
00
 m
g 
R
TV
 b
ot
h 
tw
ic
e 
da
ily
 o
r 
1,
40
0 
m
g 
pl
us
 2
00
 m
g 
R
TV
 o
r 
10
0 
m
g 
R
TV
 b
ot
h 
gi
ve
n 
on
ce
 d
ai
ly
. 
In
 t
re
at
m
en
t-
ex
pe
ri
en
ce
d 
pa
tie
nt
s 
—
 7
00
 m
g 
pl
us
 1
00
 m
g 
R
TV
 t
w
ic
e 
da
ily
. 
O
nl
y 
bo
os
te
d 
f-
A
M
P 
w
ith
 R
TV
 s
ho
ul
d 
be
 u
se
d 
in
 t
re
at
m
en
t-
ex
pe
ri
en
ce
d 
pa
tie
nt
s.
 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
  
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 E
FV
 r
eq
ui
re
s 
f-
A
M
P 
do
se
 o
f 
70
0 
m
g 
pl
us
 
10
0 
m
g 
R
TV
 t
w
ic
e 
da
ily
 o
r 
1,
40
0 
m
g 
f-
A
M
P 
pl
us
 3
00
 m
g 
R
TV
 o
nc
e 
da
ily
. 
 
• 
O
nl
y 
bo
os
te
d 
f-
A
M
P 
sh
ou
ld
 b
e 
us
ed
 in
 c
om
bi
na
tio
n 
w
it
h 
EF
V
. 
 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
V
C
 r
eq
ui
re
s 
15
0 
m
g 
M
V
C
 d
os
e 
tw
ic
e 
da
ily
 
in
 c
om
bi
na
tio
n 
w
ith
 7
00
 m
g 
f-
A
M
P 
pl
us
 1
00
 m
g 
R
TV
 t
w
ic
e 
da
ily
. 
In
di
na
vi
r 
(I
D
V
, 
C
ri
xi
va
n®
) 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 c
hi
ld
re
n.
  
A
du
lts
 —
 8
00
 m
g 
ID
V
 p
lu
s 
10
0 
m
g 
R
TV
 t
w
ic
e 
da
ily
. 
Pe
di
at
ri
c:
 N
ot
 a
pp
ro
ve
d 
fo
r 
us
e 
in
 c
hi
ld
re
n.
 I
nv
es
ti
ga
tio
na
l d
os
e 
of
 
50
0 
m
g/
m
2  
of
 b
od
y 
su
rf
ac
e 
ar
ea
 e
ve
ry
 8
 h
ou
rs
 (
th
re
e 
tim
es
 d
ai
ly
) 
in
 
ch
ild
re
n 
4 
- 
15
 y
ea
rs
 o
f 
ag
e 
re
su
lte
d 
ad
eq
ua
te
 A
U
C
 a
nd
 lo
w
 p
la
sm
a 
ID
V
 t
ro
ug
h.
 
A
do
le
sc
en
t 
>
 1
8 
ye
ar
s/
ad
ul
ts
: 
80
0 
m
g/
do
se
 e
ve
ry
 8
 h
ou
rs
. 
A
du
lt 
do
se
 in
 c
om
bi
na
tio
n 
w
ith
 R
TV
 —
 8
00
 m
g 
ID
V
 p
lu
s 
10
0 
m
g 
R
TV
 t
w
ic
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T(
ad
ul
ts
):
  
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 E
FV
 r
eq
ui
re
s 
80
0 
m
g 
ID
V
 p
lu
s 
10
0 
or
 2
00
 
m
g 
R
TV
 t
w
ic
e 
da
ily
. 
 
Lo
pi
na
vi
r/
R
it
on
av
ir
 
(L
PV
/R
TV
, 
K
al
et
ra
®
, 
A
B
T 
37
8)
 
B
od
y 
w
ei
gh
t 
14
 -
 3
9.
9 
kg
 —
 1
0 
m
g 
LP
V
/k
g/
do
se
 t
w
ic
e 
da
ily
 
(e
qu
iv
al
en
t 
to
 3
00
 L
PV
 m
g/
m
2 )
. 
B
od
y 
w
ei
gh
t 
15
 -
 4
0 
kg
 —
 2
.5
 m
g 
R
TV
/k
g/
do
se
 t
w
ic
e 
da
ily
 (
eq
ui
va
le
nt
 t
o 
75
 m
g/
m
2 )
. 
M
ax
im
al
 d
os
e 
—
 4
00
 m
g 
LP
V
 p
lu
s 
10
0 
m
g 
R
TV
 t
w
ic
e 
da
ily
. 
A
du
lts
/c
om
bi
na
tio
n 
A
R
T 
—
 c
ap
su
le
s 
(1
33
.3
 m
g 
LP
V
/3
3.
3 
m
g 
R
TV
) 
3 
ca
ps
ul
es
 t
w
ic
e 
da
ily
 o
r 
4 
ca
ps
ul
es
 t
w
ic
e 
da
ily
 w
he
n 
co
-
ad
m
in
is
te
re
d 
w
ith
 E
FV
 (
60
0 
m
g 
on
ce
 d
ai
ly
) 
or
 N
V
P 
(1
50
 m
g 
tw
ic
e 
da
ily
);
 t
ab
le
ts
 (
20
0 
m
g 
LP
V
/ 
10
0 
m
g 
R
TV
) 
fo
r 
tr
ea
tm
en
t-
na
ïv
e 
pa
tie
nt
s 
—
 2
 t
ab
le
ts
 t
w
ic
e 
da
ily
, 
fo
r 
tr
ea
tm
en
t-
ex
pe
ri
en
ce
d 
pa
tie
nt
s 
—
 3
 t
ab
le
ts
 t
w
ic
e 
da
ily
 w
he
n 
co
-a
dm
in
is
te
re
d 
w
ith
 E
FV
 
(6
00
 m
g 
on
ce
 d
ai
ly
) 
or
 N
V
P 
(1
50
 m
g 
tw
ic
e 
da
ily
).
 
Pe
di
at
ri
c:
 b
od
y 
w
ei
gh
t 
>
 1
5 
- 
<
 4
0 
kg
 —
 1
0 
m
g/
kg
 L
PV
/2
.5
 m
g/
kg
 
R
TV
 t
w
ic
e 
da
ily
 w
ith
 f
oo
d.
 A
pp
ro
xi
m
at
el
y 
eq
ui
va
le
nt
 t
o 
23
0 
m
g/
m
2  
LP
V
/5
7.
5 
m
g/
m
2  
R
TV
 p
er
 d
os
e.
 B
od
y 
w
ei
gh
t 
>
 4
0 
kg
 —
 4
00
 m
g 
or
 
23
0 
m
g/
m
2  
LP
V
/5
7.
5 
m
g/
m
2  
R
TV
 p
er
 d
os
e 
(m
ax
im
al
 d
os
e,
 4
00
 m
g 
LP
V
/1
00
 m
g 
R
TV
).
 U
se
 o
f 
23
0 
m
g/
m
2  
LP
V
 d
os
e 
pr
ov
id
es
 a
de
qu
at
e 
A
U
C
 f
or
 L
PV
, 
bu
t 
m
ig
ht
 p
ro
du
ce
 lo
w
er
 t
ro
ug
h,
 h
ig
he
r 
do
se
s 
m
ay
 b
e 
co
ns
id
er
ed
. 
A
do
le
sc
en
t 
>
 1
2 
ye
ar
s:
 4
00
 m
g 
LP
V
/1
00
 m
g 
R
TV
 p
er
 d
os
e 
tw
ic
e 
da
ily
 
w
ith
 f
oo
d.
 
A
do
le
sc
en
t 
>
 1
8 
ye
ar
s/
ad
ul
ts
: 
in
 a
nt
ir
et
ro
vi
ra
l n
aï
ve
 p
at
ie
nt
s 
—
 8
00
 
m
g 
LP
V
/2
00
 m
g 
R
TV
 p
er
 d
os
e 
on
ce
 d
ai
ly
. 
 
  
 D
ru
g
 
W
H
O
 G
u
id
el
in
es
 
U
S
 G
u
id
el
in
es
 
Lo
pi
na
vi
r/
R
it
on
av
ir
 
(L
PV
/R
TV
, 
K
al
et
ra
®
, 
A
B
T 
37
8)
 
(c
on
tin
ue
d)
 
 
C
om
bi
na
tio
n 
A
R
T 
(a
do
le
sc
en
ts
 >
 1
2 
ye
ar
s/
ad
ul
ts
):
  
• 
O
nc
e 
da
ily
 d
os
e 
sh
ou
ld
 n
ot
 b
e 
us
ed
 in
 p
at
ie
nt
s 
w
ith
 c
on
co
m
ita
nt
 
th
er
ap
y 
w
ith
 E
FV
, 
N
V
P,
 f
-A
M
P 
or
 N
FV
. 
 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 N
V
P,
 E
FV
 o
r 
f-
A
M
P 
re
qu
ir
es
 in
cr
ea
se
 in
 
LP
V
/R
TV
 d
os
e 
to
 3
00
 m
g/
m
2  
LP
V
/7
5 
m
g/
m
2  
R
TV
 p
er
 d
os
e 
in
 
ch
ild
re
n 
<
 1
2 
ye
ar
s 
of
 a
ge
 a
nd
 6
00
 m
g 
LP
V
/1
50
 m
g 
R
TV
 p
er
 d
os
e 
tw
ic
e 
da
ily
 w
ith
 f
oo
d.
  
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
  
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 S
Q
V
 r
eq
ui
re
s 
1,
00
0 
m
g 
S
Q
V
 d
os
e 
w
ith
ou
t 
ad
di
tio
na
l R
TV
 t
w
ic
e 
da
ily
 w
ith
 t
w
ic
e 
da
ily
 4
00
 m
g 
LP
V
/1
00
 m
g 
R
TV
. 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
V
C
 r
eq
ui
re
s 
15
0 
m
g 
M
V
C
 d
os
e 
w
ith
 4
00
 
m
g 
LP
V
/1
00
 m
g 
R
TV
, 
al
l t
w
ic
e 
da
ily
. 
N
el
fin
av
ir
 
(N
FV
, 
V
ir
ac
ep
t®
) 
B
od
y 
w
ei
gh
t 
≥
 2
0 
kg
 —
 m
ax
im
um
 r
ec
om
m
en
de
d 
do
se
 o
f 
1,
25
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
A
du
lts
 —
 1
,2
50
 m
g/
do
se
 t
w
ic
e 
da
ily
. 
Pe
di
at
ri
c 
<
 1
3 
ye
ar
s:
 4
5 
- 
55
 m
g/
kg
/d
os
e 
tw
ic
e 
da
ily
 o
r 
25
 -
 3
5 
m
g/
kg
/d
os
e 
th
re
e 
tim
es
 d
ai
ly
. 
A
do
le
sc
en
t 
/a
du
lts
: 
1,
25
0 
m
g/
do
se
 t
w
ic
e 
da
ily
 o
r 
75
0 
m
g/
do
se
 t
hr
ee
 
tim
es
 d
ai
ly
. 
R
ito
na
vi
r 
(R
TV
, 
N
or
vi
r®
) 
C
hi
ld
re
n 
<
 1
6 
ye
ar
s 
—
 4
00
 m
g/
m
2 /
do
se
 (
m
ax
im
al
 d
os
e,
 6
00
 m
g)
 
tw
ic
e 
da
ily
. 
S
ca
le
 u
p 
th
e 
do
si
ng
 s
ch
ed
ul
e 
at
 in
iti
at
io
n 
st
ar
tin
g 
at
 
25
0 
m
g/
m
2 /
do
se
 o
f 
bo
dy
 s
ur
fa
ce
 a
re
a 
tw
ic
e 
da
ily
 w
ith
 in
cr
em
en
ts
 
by
 5
0 
m
g/
m
2 /
do
se
 e
ve
ry
 2
 -
 3
 d
ay
 in
te
rv
al
s 
to
 f
ul
l d
os
e 
as
 
to
le
ra
te
d.
 
A
s 
a 
bo
os
te
r 
fo
r 
LP
V
 f
or
 b
od
y 
w
ei
gh
t 
15
 -
 4
0 
kg
 —
 2
.5
 
m
g/
kg
/d
os
e 
tw
ic
e 
da
ily
. 
 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 a
du
lts
. 
Pe
di
at
ri
c:
 3
50
 -
 4
50
 m
g/
m
2 /
do
se
 (
m
ax
im
al
 d
os
e,
 6
00
 m
g)
 t
w
ic
e 
da
ily
. 
S
ca
le
 u
p 
th
e 
do
si
ng
 s
ch
ed
ul
e 
at
 in
iti
at
io
n 
st
ar
tin
g 
at
 2
50
 m
g/
m
2 /
do
se
 
tw
ic
e 
da
ily
 w
ith
 in
cr
em
en
ts
 b
y 
50
 m
g/
m
2  
at
 2
- 
to
 3
-d
ay
 in
te
rv
al
s 
to
 
fu
ll 
do
se
 a
s 
to
le
ra
te
d.
 
A
do
le
sc
en
t/
ad
ul
ts
: 
60
0 
m
g/
do
se
 t
w
ic
e 
da
ily
. 
S
ca
le
 u
p 
th
e 
do
si
ng
 
sc
he
du
le
 a
t 
in
iti
at
io
n 
st
ar
tin
g 
at
 3
00
 m
g/
do
se
 t
w
ic
e 
da
ily
; 
an
d 
in
 
st
ep
w
is
e 
in
cr
ea
se
 u
nt
il 
fu
ll 
do
se
 is
 r
ea
ch
ed
 o
ve
r 
5 
da
ys
 a
s 
to
le
ra
te
d.
 
C
om
bi
na
tio
n 
A
R
T(
ad
ol
es
ce
nt
s/
ad
ul
ts
):
  
• 
R
TV
 is
 u
se
d 
at
 lo
w
er
 d
os
es
 a
s 
a 
ph
ar
m
ac
ok
in
et
ic
 e
nh
an
ce
r 
to
 o
th
er
 
PI
s 
w
ith
 d
os
es
 r
an
gi
ng
 f
ro
m
 1
00
 t
o 
40
0 
m
g.
  
S
aq
ui
na
vi
r 
(S
Q
V
, 
In
vi
ra
se
®
) 
N
ot
 li
ce
ns
ed
 f
or
 u
se
 in
 c
hi
ld
re
n 
<
 1
6 
ye
ar
s 
of
 a
ge
 o
r 
le
ss
 t
ha
n 
25
 k
g.
 
N
ev
er
 s
ho
ul
d 
be
 t
ak
en
 u
nb
oo
st
ed
. 
A
du
lts
 —
 1
,0
00
 m
g 
S
Q
V
 p
lu
s 
10
0 
m
g 
R
TV
 t
w
ic
e 
da
ily
. 
Pe
di
at
ri
c:
 N
ot
 a
pp
ro
ve
d 
fo
r 
us
e 
in
 c
hi
ld
re
n.
 I
nv
es
ti
ga
tio
na
l d
os
e 
of
 5
0 
m
g/
kg
/d
os
e 
ev
er
y 
8 
ho
ur
s 
(t
hr
ee
 t
im
es
 d
ai
ly
) 
pr
ov
id
ed
 in
ad
eq
ua
te
 
A
U
C
 a
nd
 p
la
sm
a 
tr
ou
gh
. 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 R
TV
, 
LP
V
/R
TV
 a
nd
 
N
FV
 is
 b
ei
ng
 in
ve
st
ig
at
ed
. 
A
do
le
sc
en
t 
>
 1
6 
ye
ar
s/
ad
ul
ts
: 
1,
00
0 
m
g 
pl
us
 1
00
 m
g 
R
TV
 t
w
ic
e 
da
ily
. 
N
ev
er
 s
ho
ul
d 
be
 u
se
d 
un
bo
os
te
d.
 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
  
• 
C
o-
ad
m
in
is
te
re
d 
w
ith
 L
PV
/R
TV
 r
eq
ui
re
s 
1,
00
0 
m
g 
S
Q
V
 w
ith
ou
t 
ad
di
tio
na
l R
TV
 t
w
ic
e 
da
ily
 w
ith
 t
w
ic
e 
da
ily
 4
00
 m
g 
LP
V
/1
00
 m
g 
R
TV
. 
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
V
C
 r
eq
ui
re
s 
15
0 
m
g 
M
V
C
 d
os
e 
w
ith
 1
,0
00
 
  
m
g 
S
Q
V
 p
lu
s 
10
0 
m
g 
R
TV
, 
al
l t
w
ic
e 
da
ily
. 
Ti
pr
an
av
ir
 
(T
PV
, 
A
pt
iv
us
®
) 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 c
hi
ld
re
n.
 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 a
du
lts
. 
Pe
di
at
ri
c:
 N
ot
 a
pp
ro
ve
d 
fo
r 
us
e 
in
 c
hi
ld
re
n.
 C
ur
re
nt
ly
 u
nd
er
 s
tu
dy
 in
 
PA
C
TG
10
51
/B
I1
18
2.
14
. 
A
du
lt 
do
se
d :
 5
00
 m
g 
pl
us
 2
00
 m
g 
R
TV
 t
w
ic
e 
da
ily
. 
C
om
bi
na
tio
n 
A
R
T 
(a
du
lts
):
  
• 
C
o-
ad
m
in
is
tr
at
io
n 
w
ith
 M
V
C
 r
eq
ui
re
s 
30
0 
m
g 
M
V
C
 d
os
e 
w
ith
 5
00
 
m
g 
TP
V
 p
lu
s 
20
0 
m
g 
R
TV
, 
al
l t
w
ic
e 
da
ily
. 
M
ar
av
ir
oc
  
(M
V
C
, 
S
el
ze
nt
ry
®
) 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 c
hi
ld
re
n.
 
N
o 
do
si
ng
 g
ui
de
lin
es
 f
or
 a
du
lts
. 
Pe
di
at
ri
c:
 N
ot
 a
pp
ro
ve
d 
fo
r 
us
e 
in
 c
hi
ld
re
n 
<
 1
6 
ye
ar
s.
 N
o 
da
ta
 
cu
rr
en
tly
 a
va
ila
bl
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To date, little attention has been paid to the developmental processes of puberty, and 
drug PK/PD data in the adolescent population are remarkably limited.20 The concept 
of adolescent developmental pharmacology was proposed by Hein in 1987.21 Since 
then, few PK studies have been published in this field.22-24 Changes in the effects of 
ABCB1 polymorphisms on the bioavailability of oral cyclosporine have been shown to 
occur in pediatric renal transplant patients > 8 years of age as compared to younger 
children.24 The sexual maturation rate was shown to affect the net renal tubular 
secretion of digoxin.25 Tanner stage and presence of sex steroids were shown to 
affect the clearance of antipyrine.22 Puberty has also been shown to affect the activity 
of selected CYP450 isoforms. Using a caffeine breath test, Lambert et al. 
demonstrated an association between Tanner stage and age-dependent inducibility of 
the CYP1A2 pathway.23 The correlation with Tanner stage appeared to be sex-
dependent, with a decrease in clearance seen at an earlier Tanner stage in girls than 
in boys. Similar data on sex-associated differences were observed in studies on 
theophylline metabolism in adolescents.26 A recent study by Saitoh et al. on the effect 
of CYP2B6 on efavirenz PK in HIV-infected children has demonstrated that age and 
CYP2B6 G516T genotype were independently and statistically associated with 
efavirenz clearance.27 These results suggest that age-related changes in CYP2B6 
activity may need to be considered when evaluating the impact of genetic variants on 
efavirenz PK in children. Developmental changes in CYP450 activity have the 
potential to affect disposition and clearance of non-nucleoside reverse transcriptase 
inhibitors and protease inhibitors during puberty and may produce new models of 
drug-drug interactions with CYP450 substrates, inducers, and suppressors such as 
those used in concomitant ARV and antimycobacterial therapy.  
 
A high level of patient adherence to the regimen is required to achieve a successful 
outcome for ART.28 It must be recognized that HIV-infected adolescents face multiple 
challenges in fulfilling the adherence requirements because of the dynamic period of 
transition from childhood to adulthood. In addition to the well-recognized pediatric 
adherence barriers such as dependence on a caregiver for obtaining medications, 
palatability, pill burden, and interference with lifestyle, many obstacles to adherence 
emerge in adolescence, and these are related to the psychosocial changes during 
puberty. Among these are changes in lifestyle involving growing independence and 
rebellion against parental involvement, increased peer pressure and fear of 
stigmatization, increased risk-taking behavior, denial and fear of HIV infection 
(particularly in recently diagnosed youth), long history of poor adherence and 
nondisclosure issues in perinatally infected adolescents, psychiatric problems 
(depression), and alcohol and substance abuse.29,30 A comprehensive assessment of 
adherence through multiple methods (such as self-report, pill count, pharmacy refills, 
and therapeutic drug monitoring) should be incorporated into the ART of every 
adolescent HIV patient. Although strategies to promote long-term adherence to ART 
have not been rigorously evaluated in adolescents to date, preliminary data suggest 
that interventions based on intensive follow-up, involvement of family and peers, use 
of reminder systems, alternative dosing schedules, and directly observed therapy 
may facilitate adherence to the dosing regimen in this vulnerable population.30 
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The developmental physiological, psychological, and social changes during puberty 
create strong grounds for an individualized therapeutic approach to HIV-infected 
adolescents. The concept of developmental rather than chronological age needs to 
be considered in adolescents. As the use of ART continues to expand among an 
aging cohort of HIV-infected children and newly infected adolescents, large 
collaborative studies are urgently needed to evaluate ARV drug exposure in 
adolescents, and accurate growth curves and sexual maturation staging of HIV-
infected children and adolescents of various ethnic and racial backgrounds need to 
be developed. Finally, better adherence interventions and simplified ART regimens 
with newer ARV agents are needed to improve the outcome of therapy in HIV-
infected adolescents.  
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ABSTRACT 
HIV-infected children represent an incredibly diverse group of patients, ranging 
from neonates to young adults. With the change in age and maturity, paediatric 
highly active antiretroviral therapy (HAART) evolves from the meticulous twice-daily 
dosing of ml of liquid preparations to a choice of once-daily dosing of a single fixed-
dose coformulated tablet. The use of simplified paediatric regimens could enhance 
the ability to achieve successful implementation of HAART in HIV-infected children. 
Pharmacokinetics and pharmacodynamic studies of antiretroviral drugs and their 
combinations need to be conducted in infants, children and adolescents to develop 
appropriate dosing in each of these specific groups. 
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It is well recognized that drug administration in children is more complex than in 
adults. A limited number of paediatric illnesses require long-term daily oral therapy, 
and HIV infection is one of these. HIV-infected children represent an incredibly 
diverse group of patients, ranging from neonates to young adults. With change in 
patient age and maturity, highly active antiretroviral therapy (HAART) evolves from 
the meticulous twice-daily dosing of ml of liquid preparations to a choice of single 
coformulated tablet administered once daily. Paediatric adherence barriers to 
HAART also evolve with growth and development, from spitting and vomiting of 
liquid preparations in infancy to the rejection of family involvement and increased 
peer pressure during puberty.  
 
Currently recommended HAART requires daily and indefinite administration of 
antiretroviral (ARV) medications. Initiation of HAART is recommended for infants 
< 12 months of age, regardless of clinical status, CD4+ T-cell percentage or HIV 
RNA viral load.1-3 In older children, the degree of immunological suppression and 
virological response, as well as the clinical course of the disease, guide the initiation 
of therapy. Administering HAART to infants and small children is particularly 
challenging, primarily because of the choice of liquid preparations, which often 
require refrigeration of large volumes. The Policy Statement by the Committee on 
Paediatric AIDS4 provides a stunning estimate of 4.3 kg of liquids (approximately 
one-half the weight of the child) for a 3-month supply of three ARV drugs for a 
10 kg infant. Getting liquids out of the container, measuring an appropriate dose 
and using different methods (spoon, bottle top or syringe) to dispense the 
medication to infants and small children are challenging tasks for the caregivers, 
many of whom are coping with their own disease. In addition, poor palatability of 
several liquid ARV drugs, particularly liquid protease inhibitors (PIs), has been cited 
as an additional barrier to adherence in infants and young children with HIV.5,6  
 
The use of simplified regimens of better tasting medications and age-appropriate 
delivery mechanisms might enhance the ability to achieve successful 
implementation of HAART in paediatric patients.4 Several studies have reported that 
caregivers and patients prefer less frequent dosing of long-term medications.7-9 
Continuous therapy with once-daily dosing of ARV drugs has been shown to improve 
adherence to HAART in adult studies without reducing drug exposure, increasing 
ARV drug-associated side effects or risking development of resistance.10,11 An 
increasing number of adult studies evaluate the pharmacokinetics (PK), safety and 
efficacy of once-daily HAART, whereas the data in paediatrics are limited to a 
handful of studies in small groups of patients. 
 
Several studies on the PK of once-daily HAART in children have been conducted 
recently. A once-daily regimen of emtricitabine/didanosine/efavirenz demonstrated 
safety and good immunological and virological efficacy over the period of 2 years in 
Pediatric AIDS Clinical Trials Group (PACTG) study P1021.12 Another study of a once-
daily efavirenz-based regimen with three nucleoside reverse transcriptase inhibitors 
(NRTIs) as a first-and second-line HAART in children older than 1 year of age 
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showed sustained CD4+ T-cell increase, irrespective of virological suppression, 
although the study had high rates of treatment discontinuation.13 High levels of 
acceptability and adherence to once-daily administration of an abacavir (ABC) and 
lamivudine (3TC) regimen in combination with non-nucleoside reverse transcriptase 
inhibitor (NNRTI) in children > 2 years of age were demonstrated by the study 
through the Paediatric European Network for Treatment of AIDS (PENTA).9 Even with 
the reduction in doses to once daily, palatability was reported to be one of the major 
barriers to adherence by over one-third of caregivers. Overall, the study showed a 
similar area under the concentration-time curve (AUC) and peak plasma 
concentrations (Cmax) in children between 2 and 13 years of age with sustained 
virological suppression.9,14 In the current issue of Antiviral Therapy, PENTA15 
continue the important work of establishing the bioequivalence of once-daily liquid 
preparations of ABC and 3TC in HIV-infected infants through PENTA trial 15. The 
investigators report bioequivalence of once-daily ABC and near bioequivalence of 
once-daily 3TC in paediatric patients between 3 and 36 months of age. The need for 
the large volume of liquids required for the once-daily dosing of the current 
preparations of ARV medications in infants and small children is underscored. 
Although the study was conducted as a single arm crossover PK study, the authors 
report promising efficacy data with sustained virological suppression at 48 weeks 
and without major safety concerns. 
 
For ARV drugs, the administration of once-daily dose carries the risk of lower trough 
plasma concentrations (Cmin) and higher Cmax than the one observed with twice-
daily dosing, requiring higher degree of drug 'forgiveness'.16 In children receiving 
once-daily ABC and 3TC in combination with NNRTI, the subtherapeutic 
concentrations of the backbone regimen can lead to the quick development of 
NNRTI resistance because of low genetic barrier. The interest in more "forgiving" 
PIs prompted a series of paediatric investigations of once-daily administration of a 
single coformulated fixed-dose combination (FDC) of lopinavir/ritonavir (LPV/r; 
Kaletra®). The study by Rosso et al.17 reported a median LPV Cmin > 1.0 mg/l in 
paediatric patients of 3 - 15 years of age, which was considered inhibitory for wild-
type virus. The high interindividual variability and low concentrations in some 
patients warrant caution and recommendation of therapeutic drug monitoring of 
once-daily LPV/r in children. The study by van der Lee et al.18 of once-daily LPV/r in 
children between 6 months and 18 years of age reported that LPV PK were 
comparable to once-daily LPV exposure in adults, although the variability in Cmin 
was much higher. The trend for younger children to have subtherapeutic Cmin was 
more pronounced than in older children, which can be explained by the larger 
variability in LPV/r metabolism and absorption. The authors suggested that the 
higher dosage of LPV/r once-daily might allow the target LPV Cmin to be achieved in 
children. A recent study by van der Flier et al.19 reported that administration of a 
new tablet formulation of LPV/r resulted in greater LPV exposure and less variability 
compared with previously studied soft-gel capsule formulations. These findings 
suggest that administration of a tablet formulation of LPV/r could result in the 
feasibility of once-daily LPV/r therapy in children.19 Finally, la Porte et al.20 recently 
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reported similar values of LPV PK (AUC, Cmax and Cmin) of once-daily LPV/r to twice-
daily LPV dosing in patients between 5 and 15 years of age, suggesting to continue 
to consider once-daily administration of this FDC PI in children. 
 
Lack of availability of appropriate paediatric drug formulations has been identified 
as major barrier in provision of efficient HAART in children and adolescents.4 
Alternative medication delivery systems, such as skin patches, are considered to be 
problematic in children because of high inter- and intrapatient variability in 
absorption and metabolism, and developmental changes in PK. Urgent need for the 
development of tablets with smaller amounts of the drugs, soluble or dispersible 
tablets, sprinkles, sachets and paediatric FDC has been underscored by the World 
Health Organization and international experts on paediatric HIV.3,4 Paediatric FDC 
are expected to improve access and adherence to HAART in children in resource-
limited settings. They can also be of use in developed countries where the 
adherence levels among children and adolescents continue to present a major 
barrier to efficient HAART. In recent years, a number of inexpensive, generic 
paediatric FDC formulations, including combinations of zidovudine (AZT), ABC, 
stavudine (d4T), 3TC and nevirapine (NVP), in a variety of different ratios and 
formulations (regular tablets, dispersible tablets and suspension for reconstitution) 
for once- or twice-daily dosing, have been developed by generic suppliers.3 
Currently, only four paediatric FDC have been approved by the US Food and Drug 
Administration through the President's Emergency Plan For AIDS Relief (PEPFAR)21: 
3TC/AZT, ABC/3TC, 3TC/d4T and 3TC/d4T/NVP. Questions about the ratio of ARV 
components and the bioequivalence of such generic formulations, particularly with 
NVP exposure, have been raised.22 It is clear that the availability of ARV FDC 
requires more randomized, controlled studies to evaluate their therapeutic potential 
in paediatric patients. PK and pharmacodynamic studies of ARV drugs and their 
combinations need to be conducted in infants, children and adolescents to develop 
appropriate dosing in each of these specific age groups.4 The World Health 
Organization has underscored the need for research on the efficacy of early PI- and 
NVP-based regimens in infancy, and further studies of PK, adherence and 
acceptability of the NRTI backbone regimen in children.3 
 
As the access to HAART continues to expand among HIV-infected children, the need 
for simplified and feasible paediatric ARV regimens grows. There is no single 
solution to the successful delivery of HAART in children, and varying approaches 
need to be undertaken, depending on the available resources and clinical and social 
situations. Medical providers caring for an HIV-infected paediatric patient need to be 
prepared to adjust the treatment plan and interventions based on the 
developmental stage of the child and the degree of family and other support 
involved. The goal of paediatric HAART is to successfully navigate the patient 
through infancy, childhood and puberty, maintaining normal physical growth and 
neurocognitive development, and restoring and/or preserving their immune function 
and quality of life. The main task is to transition HIV-infected youth to long-term 
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adult care with maximal and durable virological suppression and preserved 
therapeutic options for the future management of their disease.  
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ABSTRACT 
The recommended dose of lamivudine in children is higher when compared with 
adults: 4 mg/kg vs ~ 2 mg/kg (150 mg) and administered twice a day. Limited data 
are available to demonstrate that this increased dose results in adequate exposure 
to lamivudine in children with human immunodeficiency virus (HIV) infection. Data 
were selected from children who were using lamivudine for at least 2 weeks before 
a full pharmacokinetic (PK) study was conducted. Lamivudine PK parameters were 
significantly related to age. The age of 6 years appeared to be a cutoff for a change 
in PK parameters of lamivudine, with children < 6 years of age (n = 17) having a 
median area under the curve 43% lower and a median peak plasma concentration 
47% lower (both P < 0.001) than older children (n = 34). In conclusion, further 
investigation of the relationship between decreased lamivudine exposure and 
treatment outcome and long-term resistance development in younger children with 
HIV infection is warranted. 
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INTRODUCTION 
Lamivudine (3TC, Epivir®) has been licensed for the treatment of human 
immunodeficiency virus (HIV) infection in pediatric patients from 3 months to 16 
years of age at a dose of 4 mg/kg twice daily (b.i.d.) (with a maximum of 150 mg 
per dose). When compared with the adult dose of 150 mg b.i.d (approximately 4 
mg/kg/day), this higher daily dose (8 mg/kg/day) in children was based on the 
reported increase in systemic clearance of lamivudine associated with younger age. 
The Epivir® Prescribing Information states that "total exposure to lamivudine, as 
reflected by mean area under the curve (AUC) values, was comparable between 
pediatric patients receiving an 8 mg/kg/day dose and adults receiving a 4 
mg/kg/day dose."1 However, validation of this higher dose in children is limited to a 
small number of patients and data are mostly on file with the manufacturer.2 
Recently, we reported a possible age effect on lamivudine pharmacokinetics (PKs) in 
a comparative study of once- and twice-daily administration of lamivudine in 
children.3 The purpose of this study has been aimed at further investigation of the 
relationship between lamivudine PK and the age of children with HIV infection. 
 
 
METHODS 
Plasma samples from children participating in a number of PK studies at our 
institutes were available for analysis.3-7 All study protocols were approved by the 
local ethics committees. Children had to use the recommended lamivudine dose 
regimen of 4 mg/kg b.i.d. for at least 2 weeks before enrollment in this study. 
Lamivudine was administered as either oral solution (10 mg/ml) or tablets (150 mg). 
The adult dose of 150 mg b.i.d. was used as the maximum dose. Blood samples 
were taken at regular time intervals after observed drug intake with breakfast during 
8 or 12 h (6 - 10 samples). In case of sampling up to 8 h (n = 12), C12h was 
calculated using the individual elimination rate constants (β) by the equation:  
 C12h =  C8h x exp-(β x 4) 
A sampling schedule of 8 h contributed at least 90% of total AUC.  
Lamivudine plasma concentrations were determined by high performance liquid 
chromatography with UV detection as previously reported.8 The lower limit of 
quantification is 0.050 mg/l. Average accuracy ranged from 92 to 98% and 
precision ranged from 0.7 to 2.3%. PK parameters were calculated using non-
compartmental methods using WinNonlin software version 4.1.9  
 
 
RESULTS  
A total of 51 children participated in the study: 23 boys and 28 girls. Age at time of 
PK sampling ranged from 1.7 to 18 years (median: 8.4 years). AUC0–12 (r2 = 0.180; 
F = 10.757; P = 0.002), peak plasma concentration (Cmax) (r2 = 0.158; F = 9.171; 
P = 0.004), trough plasma concentration (Cmin) (r2 = 0.092; F = 4.971; P = 0.030), 
CL/F.kg (r2 = 0.354; F = 26.833; P < 0.001), and Vd/F.kg (r2 = 0.156; F  = 9.072; 
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P = 0.004) were significantly related to age, with younger children having higher 
oral clearance of lamivudine (Figure 1 and Table 1). Lamivudine half-life was not 
significantly influenced by age. By visual inspection, the age of 6 years appeared to 
be a cutoff for a change in PK parameters of lamivudine in this dataset, with 
younger children (n = 17) having a median AUC 43% lower and a median Cmax 47% 
lower (both P < 0.001) than older children (n = 34) (Table 1). In line with these 
observations, CL/F.kg and Vd/F.kg were 79 and 89% higher in children 6 years and 
younger compared with children 7 years and younger (P < 0.001 and P = 0.005, 
respectively; Figures 1 and 2). Sensitivity analyses showed that differences 
between age groups became less pronounced when other cutoff points were 
selected for age (for instance, the difference in median AUCs was 40% (P = 0.029) 
or 27% (P = 0.006) when 3 or 9 years of age were selected, respectively).  
 
Table 1 Plasma pharmacokinetic parameters of lamivudine in children aged ≤ 6 and 7 years or  
      older (median + IQR) 
Parameter Age ≤ 6 years Age 7 years or older 
Number of children 17 34 
Gender (F/M) 13/4 15/19 
Age (years) 3.8 (2.5 - 4.8) 10.1 (8.5 - 12.3) 
Weight (kg) 14.6 (13.8 - 16.7) 32.3 (27.9 - 42.4) 
Height (cm) 98 (91 - 106) 138 (128 - 146) 
Body surface area (m2) 0.63 (0.60 - 0.70) 1.12 (0.97 - 1.31) 
Lamivudine dose    
 In mg 60 (50 - 70) 150 (100 - 150) 
 In mg/kg 4.0 (3.8 - 4.1) 3.9 (3.2 - 4.2) 
 In mg/m2 97* (88 - 103) 111 (103 - 120) 
AUC0-12 (mg/l·h) 3.71* (3.44 - 6.17) 6.54 (5.21 - 8.58) 
AUC corrected for dose in mg/kg 0.97* (0.82 - 1.49) 1.74 (1.35 - 2.22) 
AUC corrected for dose in mg/m2 0.045** (0.034 - 0.061) 0.059 (0.049 - 0.072) 
Cmax (mg/l) 0.98* (0.82 - 1.43) 1.84 (1.21 - 2.28) 
Cmax corrected for dose in mg/kg 0.24* (0.20 - 0.35) 0.44 (0.34 - 0.68) 
Cmax corrected for dose in mg/m2 0.010*** (0.009 - 0.015) 0.016 (0.011 - 0.023) 
tmax (h) 2.0 (1.0 - 2.0) 1.5 (1.0 - 2.0) 
Cmin (mg/l) 0.07 (0.06 - 0.08) 0.09 (0.07 - 0.11) 
CL/F (l/h/kg) 1.03* (0.67 - 1.22) 0.57 (0.45 - 0.74) 
CL/F (l/h/m2) 22.2 (16.4 - 29.0) 17.0 (13.8 - 20.3) 
Vd/F (l/kg) 4.31**** (2.59 - 6.93) 2.29 (1.64 - 4.10) 
Vd/F (l/m2)) 93.2 (72.5 - 168.1) 67.9 (46.8 - 110.3) 
t1/2 (h) 3.27 (2.48-4.34) 3.05 (2.55 - 3.71) 
F – female; IQR – interquartile range; M – male. * P < 0.001; ** P = 0.011; *** P = 0.009;  
all comparisons to children 7 years and older; **** P = 0.005. 
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Figure 1 Association of lamivudine body weight corrected CL/F and age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Association of lamivudine body weight corrected Vd/F and age. 
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Figure 3 Association of lamivudine AUC and dose in mg/m2. 
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Lower exposure to lamivudine in younger children was not related to differences in 
lamivudine dosing in mg/kg, as the median dose in both age cohorts was 4 mg/kg 
b.i.d. (Table 1). Variability in lamivudine dose, however, was larger in children aged 
7 years and older, probably because of the use of tablets instead of oral solution. In 
contrast to the lamivudine dose based on body weight, there was a significant 
difference in median lamivudine dose in mg/m2 when comparing younger and older 
children: 97 vs 111 mg/m2 (P < 0.001). The higher dosing on body surface area 
was related to increased exposure to lamivudine (r2 = 0.288; F = 19.781; 
P < 0.001) (Figure 3). Normalization of AUC or Cmax for dose given per body weight 
or per body surface area did not markedly change the age dependency of the PK 
parameters (Table 1).  
 
The mean Cmax and AUC in children aged 7 years and older were almost similar to 
average values observed in HIV-1-infected adults:10 Cmax 1.84 vs 2.08 mg/l, AUC 
6.5 vs 8.5 mg/l·h, respectively. The reference data for adults were chosen as they 
represent the largest published dataset of adult PK parameters of lamivudine. 
Although numbers were small, there was no difference observed in mean AUC in 
children aged 7 - 12 years (n = 24) vs children aged 12 years or older (n = 10): 6.7 
vs 5.9 mg/l·h (P = 0.91) (Figure 1). Lamivudine AUC did not differ between boys 
(median value: 6.2 mg/l·h; n = 23) and girls (median value: 5.4 mg/l·h; n = 28) 
(P = 0.925).  
 
 
DISCUSSION 
Our data clearly describe the age dependency of lamivudine PKs. The Product 
Monograph of Epivir® describes this age dependency of lamivudine systemic 
clearance based on a cohort of children receiving lamivudine doses ranging from 
1 - 20 mg/kg/day.1 This includes a subset of nine children (aged 5 months to 12 
years) who received the recommended dosing of 4 mg/kg b.i.d. Thus, our dataset 
of 51 children largely increases our knowledge on lamivudine PKs in HIV-infected 
children, not only because of the higher number of children but also because we 
describe age dependency in lamivudine as apparent oral clearance (vs systemic 
clearance in the Product Monograph). The increased dose of 4 mg/kg b.i.d. provides 
comparable exposure (in terms of AUC and Cmax) in children aged 7 years and older 
compared with adults. However, for children 6 years and younger, the 
recommended dose of 4 mg/kg b.i.d. does not lead to comparable exposure, and 
this is the main finding of our study.  
 
Lower bioavailability, increased clearance and/or increased volume of distribution 
are possible explanations for the differences observed in the study. Use of oral 
solution by younger children vs use of tablets in older children can be part of the 
explanation as bioavailability of the oral solution in children may be less than that of 
the tablets. Remarkably, although both formulations have been demonstrated to be 
bioequivalent in adults (87 ± 13 vs 86 ± 16%), bioavailability in children was only 
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tested for the oral solution and appeared to be less and more variable: 66 ± 26%.1 
As we cannot exclude that there is a difference in bioavailability between the oral 
solution and the tablets in children, we strongly recommend performing 
bioequivalence studies in children with all available formulations in order to provide 
evidence-based support for dosing recommendations in children.  
 
It is easily understood that there was no possible standardized breakfast for children 
aged 1.7 to 18 years. Because lamivudine PK is not dependent on food, variability in 
breakfast is not likely to have influenced our results. Lamivudine is eliminated 
primarily by renal excretion of nonmetabolized drug. It has been previously reported 
that younger children may have increased glomerular filtration and/or tubular 
secretion capacity.11 As we have only studied lamivudine PK after oral 
administration, we cannot separate any age effect on drug bioavailability from an 
effect on renal clearance in our patients. However, it must be noted that the Epivir® 
Product Monograph describes age-dependent systemic clearance of lamivudine, 
suggesting that both bioavailability and renal clearance, independently, are 
influenced by age.  
 
Finally, it must be acknowledged that we do not have information that this lower 
exposure to lamivudine is related to reduced virological activity of lamivudine-
containing highly active antiretroviral treatment regimen in children younger than 6 
years of age. First, we have not collected data on virological response as part of our 
study, as all the enrolled subjects were receiving various regimens for different 
periods of time and were both treatment-naive and treatment-experienced. 
Furthermore, lamivudine plasma PK can only be considered as a limited marker of 
drug exposure as it is the intracellular lamivudine triphosphate metabolite that 
becomes pharmacologically active. Theoretically, increased plasma clearance of the 
lamivudine may be associated with both decreased and increased intracellular 
exposure to the lamivudine triphosphate,12 and therefore, younger children with 
increased plasma clearance of lamivudine may reach lower or higher intracellular 
concentrations of the active drug. However, this hypothesis is very hard to prove as 
adequate sampling for determination of intracellular concentrations of nucleoside 
reverse transcriptase-inhibitor triphosphates is logistically and technically difficult 
and has been conducted in limited numbers by a limited number of centers.3  
 
The only answer to the question of optimal dosing regimens of lamivudine in 
children should come from well-designed clinical studies with PK data collected from 
a sufficient number of children in each age group. Recently, Puthanakit et al.13 
presented data on 103 children, aged 2.1 - 13.8 years with a mean age of 7.7 
years, who started with lamivudine-containing highly active antiretroviral treatment 
regimens within Thailand's National Access to Antiretroviral Program. In this study, 
age was not associated with the likelihood of having a virological response at week 
72 of treatment (P = 0.92), although it must be noted that any age effect may have 
been confounded by greater use of efavirenz vs nevirapine in older subjects (and 
efavirenz may be more efficacious than nevirapine14). In our PENTA-13 study, both 
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younger and older children did equally well after switching from a twice-daily (4 
mg/kg/dose) to a once-daily (8 mg/kg/dose) regimen of lamivudine.3 Finally, no 
age effect was observed in the clinical end point study of zidovudine plus lamivudine 
vs didanosine in PACTG 300 Study15 (Glaxo-SmithKline, data on file). The data from 
these studies suggest that the reduced exposure to a lamivudine in younger 
children may not lead to a decrease in optimal efficacy of the medication. It is, 
however, unknown if the exposure to the subtherapeutic concentrations of 
lamivudine may play a role in accelerating the remote development of the 
resistance mutation for lamivudine in those children.  
 
 
CONCLUSION 
Our study demonstrates that the recommended pediatric lamivudine dose of 4 
mg/kg does not lead to similar plasma AUC and Cmax of lamivudine in children 
younger than 6 years of age when compared with older children or adults. It must 
be noted that the increased apparent clearance (corrected for body weight) of 
lamivudine in younger children has been previously reported.2,16,17 Nevertheless, 
the dosing recommendations for lamivudine in children aged 3 months to 16 years 
remain unchanged, are similar for the oral solution and the tablets despite a 
potential difference in bioavailability between these two formulations in children, 
and all age groups continue to receive the same dose of lamivudine per kilogram 
body weight. Although, there is no evidence for reduced antiviral efficacy associated 
with this age effect on lamivudine PK, the question of lower lamivudine exposure 
and the long-term associated development of lamivudine resistance remains to be 
answered.  
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ABSTRACT 
In adult protease inhibitor (PI)-experienced patients, a lopinavir (LPV) phenotypic 
inhibitory quotient (PIQ) of > 15 has been associated with a higher likelihood of 
viral suppression. The aims of this study were to develop a population 
pharmacokinetic (PK) model of LPV in children and to estimate the probability of 
achieving a PIQ of > 15. HIV-infected, PI-experienced children receiving LPV were 
intensively sampled for 12 h to measure plasma LPV. The data were fitted to 
candidate PK models (using MM-USCPACK software), and the final model was used 
to simulate 1,000 children to determine the probability of achieving an LPV PIQ of 
> 15. In 50 patients (4 to 18 years old), the median LPV plasma 12-hour-postdose 
concentration was 5.9 mg/liter (range, 0.03 to 16.2 mg/liter) lower than that 
reported in adults. After a delay, LPV was absorbed linearly into a central 
compartment whose size was dependent on the weight and age of the patient. 
Elimination was dependent on weight. The regression line of observed vs predicted 
LPV had an R2 of 0.99 and a slope of 1.0. Visual predictive checks against all 
available measured concentrations showed good predictive ability of the model. The 
probability of achieving an LPV PIQ of > 15 was > 90% for wild-type virus but 
< 10% for even moderately resistant virus. The currently recommended dose of 
LPV/ritonavir appears to be adequate for children infected with wild-type virus but is 
unlikely to provide adequate inhibitory concentrations for even moderately resistant 
human immunodeficiency virus (HIV). PI-experienced HIV-infected children will 
likely benefit from longitudinal, repeated LPV measurement in plasma to ensure 
that drug exposure is most often near the maximal end of the observed safe range.  
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INTRODUCTION 
Lopinavir/ritonavir (LPV/RTV) (Kaletra) is the first and only coformulated RTV-
boosted protease inhibitor (PI) approved for use in children. The recommended 
doses for children who weigh more than 15 kg are 10 mg/kg of body weight or 230 
mg/m2 (body surface area) twice daily, with a maximum of 400 mg per dose unless 
it is combined with drugs affecting cytochrome (CYP) P450 metabolism, which 
require LPV dose adjustment.1,2 Introduced as a salvage agent,3 LPV/RTV has 
become one of the preferred PI choices for first-line regimens in children > 6 
months of age in the countries with access to the drug.  
 
Despite evidence for good antiviral efficacy among children in a clinical trial 
setting,4-6 the standard dose may not be adequate for every child. 
Noncompartmental analysis has shown that the average LPV plasma 12-hour-
postdose concentration (Ctrough) in children given the currently recommended 
pediatric dose of LPV is 67% lower than in adults.7 Recently, Jullien et al. published 
a population pharmacokinetics (PK) model of LPV in children aged 0 to 18 years.8 
The model was based on a retrospective analysis of LPV plasma measurements in 
157 children, with a median of 3 samples (range, 1 to 14) per patient, obtained for 
monitoring purposes after self-reported LPV intake. In that model, clearance (CL) 
and volume were dependent on body weight, and there was an additional increase 
in CL in boys after the age of 12 relative to girls. The study suggested that a 
distinct possibility of LPV underdosing exists in young infants and adolescent males. 
 
PK measures of LPV exposure, such as area under the concentration-time curve 
(AUC) or Ctrough, are most relevant to clinical practice in the context of an estimated 
concentration-response relationship. Different LPV Ctrough targets have been 
proposed for PI-naïve patients (1 mg/liter)9 and for PI-experienced patients (3 to 
5.7 mg/liter).10-13 A more comprehensive target, the phenotypic inhibitory quotient 
(PIQ), incorporates viral drug susceptibility, which is measured as the concentration 
of drug required to achieve 50% in vitro inhibition of replication of the virus (IC50) 
relative to the replication of human immunodeficiency virus (HIV) in drugfree 
medium. The PIQ is the ratio of a patient's Ctrough to the IC50 of the dominant viral 
strain. For LPV, a PIQ target of 15 has been associated with more than 90% chance 
of achieving < 400 HIV copies/ml when combined with active background 
antiretroviral therapy (ART) comprising efavirenz14 or two nucleoside reverse 
transcriptase inhibitors.15 
 
We conducted a prospective study to develop a population PK model of LPV in a 
large cohort of HIV-infected children, with intense PK sampling after observed LPV 
intake. Additionally, we used Monte Carlo simulation to estimate the proportion of 
all children who would fail to achieve the LPV PIQ target of 15 when given the 
currently recommended dose of LPV.  
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MATERIALS AND METHODS 
Patients  
The participants were children with HIV type 1 infection who were receiving care at 
the large metropolitan pediatric HIV program at Children's National Medical Center, 
Washington, DC. The research protocol, parental consent, and assent documents (for 
children older than 7 years of age) were approved by the institutional review board.  
 
All subjects in this study were on uninterrupted, twice-daily doses of LPV/RTV-based 
ART for at least 4 weeks prior to study entry. Blood samples for LPV measurement 
were obtained during a 12-hour admission to the Pediatric Clinical Research Center. 
The subjects were administered their standard prescribed LPV/RTV dose under direct 
observation with a standard light snack. Plasma samples were obtained before and 
0.5, 1, 2, 4, 8, and 12 h after observed intake of LPV/RTV.  
 
Tandem mass spectrometry analysis  
For each measurement of the plasma LPV concentration, 2 ml of venous blood was 
obtained. The blood was collected in a heparin tube and separated by centrifugation 
at 4,000 rpm for 10 min. The plasma was stored at -70°C pending analysis. The 
plasma samples were incubated for 30 min at 56°C to deactivate the HIV particles. 
Heating of the samples has been proven not to produce degradation of LPV.16,17 
 
The LPV plasma concentrations were determined by a tandem-mass spectrometric 
method using the Applied Biosystems/Sciex API-2000.16,17 Within-run error was 
below 7%, and between-day error was below 10% for all analytes at the tested 
concentrations. The lower limit of quantification was 0.1 mg/liter. The laboratory at 
Children's National Medical Center that performed the LPV assays is an accredited 
member of the International Quality Control Program for Therapeutic Drug Monitoring 
in HIV infection (University Medical Center, Nijmegen, The Netherlands).18,19 
 
PK modeling and simulation 
MM-USCPACK, a parametric/nonparametric population-modeling software collection 
(available by license through the University of Southern California at 
http://www.lapk.org) was used to fit candidate PK models to the time-concentration 
data for LPV.20 The models were evaluated on the basis of maximization of the log 
likelihood, visual inspection of observed vs predicted plots, visual predictive checks, 
and parsimony.  
 
To minimize model bias from uncertainty in dose times,21-23 for each patient, the 
initial amount of LPV in the PK dosing compartment was set equal to zero under the 
reasonable assumption that the previous LPV dose approximately 12 h before had 
completed its passage through the gut. In contrast, the initial amount in the central 
PK compartment was set equal to the measured LPV trough plasma concentration 
just prior to the observed dose multiplied by the estimated volume of the central 
compartment, which was updated after each iteration. Beyond these initial conditions, 
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the only drug input to the model was the observed dose. By restricting model inputs 
to observed or measured data, this technique eliminated misspecification associated 
with variable adherence prior to the PK sampling and potentially false assumptions of 
steady state.  
 
In accordance with the allometric size scaling of PK parameters in children proposed 
by Anderson et al.,24 among others, the model was initially parameterized with the 
volume of distribution (V) proportional to weight and CL proportional to weight0.75. 
However, V and CL were strongly correlated (R = 0.76; P < 0.0001), leading to highly 
variable parameter estimates; therefore, the model was reparameterized in terms of V 
being proportional to weight and elimination (kel) being proportional to weight-0.25, 
which were independent of each other (R = 0.10; P = 0.47). By the relationship 
CL = kel · V, the net allometric power scaling on weight was the same in the CL-based 
and kel-based models. Effects of age and sex were added to the allometric model and 
retained if they improved the 2 · log likelihood by at least 4 (P < 0.05; chi-square with 
1 degree of freedom) and resulted in some qualitative improvement in either the 
observed vs predicted plots or the visual predictive check. 
 
Data for the modeling were weighted by the reciprocal of the LPV assay variance. 
This error model was obtained from the MM-USCPACK software, which fits up to a 
third-order polynomial (C0 + C1 · [drug] + C2 · [drug]2 + C3 · [drug]3) to the entire 
data set. The initial values for the polynomial coefficients were set at 0, 0.1, 0, and 
0 to reflect the standard deviation at each of the standard concentrations in the 
assay validation set. The final assay error coefficients were 0.385, 0.013, 0, and 0. 
A multiplicative scalar, gamma, on the polynomial was iteratively fitted to capture 
additional random error and approximate homoscedasticity in the residuals of 
predicted vs observed concentrations; gamma on the final run (cycle 1,290) was 
1.78.  
 
In order to compare the results of the present study with published LPV PK 
parameter values, CL and half-life (t1/2) were calculated using the following 
formulae: CL = dose/AUC and t1/2 = ln(2)/kel, where AUC is the AUC from dose time 
to infinity postdose as estimated by MM-USCPACK from model parameters, and kel 
is the LPV elimination rate constant estimated by MM-USCPACK. As a numerical 
check, CL was also calculated using the formula CL = kel · V.  
 
A visual predictive check was made to validate a model's ability to provide realistic 
predictions. Full-parameter mean and covariance data from the model, including 
weight, were passed to the simulation subroutine of the MM-USCPACK software so 
that LPV could be administered on the standard basis of body surface area (BSA). 
The BSA was calculated from weight (kg), which was also a simulated parameter, 
using the simplified formula BSA (m2) = 0.111 · weight0.65. 25 BSA calculated using 
this formula in the real population was nearly perfectly correlated (R = 0.995; 
P < 0.0001) with BSA calculated with the more familiar height- and weight-based 
Mosteller formula.26 The median dose in the study population was used for the 
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simulation, and parameters were log transformed. One thousand patients were 
simulated by Monte Carlo sampling, and LPV concentrations, which were calculated at 
the same sampling times as for the original (real) population, were compared to the 
measured, true LPV concentrations. The 25th, 50th, and 75th percentile 
concentrations of LPV from the 1,000 simulated patients were plotted vs time. 
Superimposed upon these plots were the real concentrations of each compound 
measured in the patients. The visual predictive check was acceptable if the 
distribution of the simulated population was similar to that of the real population. 
 
Using the final model, a second simulation was performed, identical to the first, 
except that the LPV dose used was the recommended dose of 230 mg/m2. This 
simulated population was used to define the increase in the LPV IC50 that would 
result in 50% of children falling below a PIQ of > 15. Furthermore, since a target 
PIQ of 15 was simply derived as the observed PIQ that was associated with 100% 
virologic response.14 a continuous model relating the PIQ to percent "clinical 
activity" of lopinavir could be made so that percent activity was equal to 
[(1 - Emin) · PIQH/PIQ                + PIQH, where PIQ is the PIQ calculated as before; Emin is  
the virologic response rate at minimal LPV PIQ (i.e., the response due to other 
drugs in the regimen); H is the "Hill constant," which determines the shape of the 
sigmoid curve when plotted on semilog paper; and PIQ50 is the PIQ that results in a 
50% loss of LPV activity, i.e., (1 - Emin)/2. Emin, H, and PIQ50 were derived from the 
data of Hsu et al. as 0.66, 1.7, and 8.7, respectively.14 
 
 
RESULTS 
Fifty-two full 12-hour PK studies were conducted with 50 PI-experienced children and 
adolescents on ART with LPV/RTV as a single PI, with 2 participants repeating the PK 
study after LPV dose adjustments made through the study protocol. The majority of 
the children were African-American (78%), the median age was 11.0 years (range, 
5.3 to 17.5 years), and equal numbers of boys and girls were enrolled. The median 
LPV dose was 275 mg/m2 (interquartile range, 246 to 287 mg/m2); 31 children were 
dosed with 200 mg LPV/50 mg RTV Kaletra capsules and the remainder with liquid 
LPV/RTV (80 mg LPV/20 mg RTV/ml). At the time of the PK studies, the new tablet 
formulation of LPV/RTV was not available.  
 
PK modeling 
From 52 study visits, there were 359 possible PK samples, 6 (1.7%) of which were 
missing and 14 (3.9%) of which were reported as below the assay's limits of 
quantification. Treating the latter simply as missing data was unlikely to significantly 
bias the results.27 The median plasma LPV post-dose Ctrough was 5.9 mg/liter (range, 
0.03 to 16.2 mg/liter); the median peak was 10.3 mg/liter (range, 0.6 to 28.8 
mg/liter), occurring a median of 3.1 h (range, 0 to 12 h) after the dose. The wide 
ranges in these values are reinforced by the variability in a plot of the individual LPV 
time-concentration curves, shown in Figure 1.  
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Figure 1 Individual observed LPV time-concentration curves for each of the 52 patient visits 
(gray lines). The median observed time-concentration curve for the entire population is super-
imposed (black line). 
 
The final model consisted of linear absorption, after a delay, into a single 
compartment. The volume was dependent on weight and inversely dependent on 
age, so that a 17-year-old adolescent would have an 80% smaller V per kilogram of 
body weight than a 4 year-old child. Elimination was inversely dependent on 
weight0.25. The net effect of the parameter dependence on age and weight implied a 
higher LPV Ctrough on average in older children. Indeed, age was moderately 
correlated with the LPV Ctrough in the study population (R = 0.21; P = 0.16) by the 
same magnitude as in the simulated population (R = 0.21; P < 0.0001), with the 
latter achieving statistical significance due to the large number of samples. Sex was 
not significantly related to any PK parameter estimate. The median and interquartile 
ranges of the individual Bayesian posterior parameter estimates, using the population 
parameter estimates as Bayesian priors, are reported in Table 1. The distributions of 
estimates for CL were similar whether calculated from the dose and AUC or kel and V, 
and the paired values were tightly correlated (R = 1.0; P < 0.0001).  
 
The quality of the fit for the model population, as measured by linear regression of 
observed vs predicted LPV concentrations, was poor for the model-based predictions 
(Figure 2A) but excellent for the Bayesian posterior predictions (Figure 2B), 
reinforcing the high degree of interindividual LPV PK variability. Plots of the 
residuals between observed and predicted concentrations with respect to either the 
Bayesian predicted concentration or time were homoscedastic and centered on zero 
(Figure 3). The visual predictive check showed that the model described the 
population well (Figure 4), despite the fact that the two Ctrough values differed by 
more than 50% in half of the children (range, 5% to 9,000%), indicating that many 
were not at steady state. Finally, the advantage of the nonparametric approach is 
obvious in Figure 5, which shows that, for example, lag time is clearly not normally 
distributed and that, although the bulk of the children had delays in absorption of 
less than 30 min, a subgroup of 15 children had delays of up to approximately 2 h. 
This can be seen by careful inspection of Figure 1 for the trajectories that peak 
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much later than the majority. The LPV/RTV formulation was significantly associated 
with absorption lag time: children dosed with LPV/RTV liquid had a twofold-shorter 
median lag time than those dosed with capsules (P = 0.005).  
 
Table 1 Estimated and calculated PK parameters in the final PK Model  
Parametera  Median (interquartile range) 
Estimated  
 tlag (h) 0.37 (0.12 - 0.86) 
 ka (h-1) 0.64 (0.21 - 1.71) 
 V (liters) = θ1 · wt/age 25.15 (14.00 - 32.88) 
 liters/kg 0.69 (0.45 - 0.98) 
  θ1 15.04 (10.30 - 17.79) 
  θ2 11.44 (3.69 - 90.66) 
 Kel (h-1) = θ3 /wt0.25 0.09 (0.07 - 0.15) 
  θ3 0.22 (0.18 - 0.37) 
 AUC0-12 (mg · h/liter) 96.09 (62.73 - 114.30) 
 AUC∞ (mg · h/liter) 190.40 (123.50 - 321.20) 
Calculated   
 CL (liters/h) = dose/AUC 1.79 (1.00 - 2.57) 
  (liters/kg0.75) 0.11 (0.07 - 0.20) 
 CL (liters/h) = kel · V 2.17 (1.39 - 3.18) 
  (liters/kg0.75) 0.14 (0.09 - 0.24) 
 t½ (h) = ln(2)/kel 7.69 (4.63 - 10.44) 
a tlag – lag time; ka – rate constant of absorption. 
 
Figure 2 Linear regression of individual observed vs predicted LPV concentrations. Predictions 
using mean model parameter values (A) and using the means of the individual Bayesian posterior 
parameter distributions (B) are shown. The solid line is the fitted regression line. The dashed line is 
the unity line, which is fully superimposed on the regression line in panel B. 
θ2 
A B 
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Figure 3 Model residual errors with respect to predicted LPV (A) and time (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Visual predictive check of concentration percentiles from model-simulated data (lines) 
superimposed on measured patient concentrations from the entire population (dots). 
 
Probability of achieving PIQ targets 
As shown in Figure 6A, for wild-type virus, > 90% of children are predicted to 
achieve an LPV IQ of > 15. However, at the Phenosense (Monogram Biosciences, 
Inc., CA) or Vircotype (Virco Labs, Inc., NJ) cutoffs between fully sensitive and 
intermediate virus (ninefold and sixfold increases in IC50, respectively), only 32% or 
48% of children are likely to achieve a PIQ of > 15. If resistance increases to 20-
fold, well within the "partially sensitive" range, which extends up to 55- and 51-fold, 
respectively, fewer than 10% of children are likely to achieve a PIQ of > 15, given 
the currently recommended LPV dose.  
 
Considering the LPV contribution to virologic effect as a continuous function of the 
PIQ, it can be seen in Figure 6B that the standard dose of LPV will maintain > 90% 
LPV activity against wild-type virus in > 75% of children. Children whose LPV dose 
is sufficient to ensure a Ctrough of 16.1 mg/liter (the 75th percentile for the 
population) will maintain at least 50% LPV effect until resistance increases to > 27 
A B 
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times that of the wild type; in contrast, children whose Ctrough is only 2.9 mg/liter 
(the 25th percentile for the population) will lose 94% of their LPV effect at this 
same level of resistance. Alternatively, children whose LPV Ctrough is at the 25th 
percentile will fall below a PIQ of 15 at a 2.8-fold increase in the IC50 compared to 
those at the 75th percentile, who will not drop below a PIQ of 15 until their viral 
IC50 is increased 15.4-fold relative to the wild type.  
 
 
Figure 5 Distribution of lag times in the population. 
 
 
DISCUSSION 
In this study, a model of LPV disposition in children and adolescents 4 through 18 
years of age was developed and validated by a visual predictive check of the 
distribution of LPV concentrations in 1,000 model-simulated patients compared with 
the distribution of LPV concentrations in the study population. In the final model, 
LPV was rapidly absorbed after an initial formulation-dependent delay, with an 
apparent V that increased nonlinearly as a function of weight over age. Overall, the 
drug CL varied according to weight0.75, in accordance with the allometric scaling 
principles in children suggested by Anderson et al.,24 among others.  
 
Because of high correlation between V and CL, the model was parameterized in 
terms of fractional elimination (kel) that declined with increasing weight. The CL-V 
correlation indicates that in the model clearance of LPV was driven primarily by the 
apparent V, which raises the possibility that LPV bioavailability may have been 
variable. Due to the lack of an intravenous formulation, the absolute bioavailability 
of LPV has not been established. Close inspection of Figure 1 reinforces the fact that 
most of the LPV PK variability is in absorption and bioavailability, since after an 
individual trajectory peaks, it generally declines consistently thereafter. In other 
words, between- individual variability is larger than within-individual variability, 
which enables the close fit shown in Figure 2B vs that in Figure 2A.  
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Figure 6 Relationship between LPV concentrations and antiviral effect. (A) Percentages of 
children who will achieve a steady-state PIQ target of at least 15 when given the standard dose of 
230 mg/m2 LPV/RTV twice daily for a given viral IC50. (B) Clinical activity of LPV plotted against 
increasingly resistant strains for the 25th, 50th, and 75th percentiles of LPV Ctrough concentrations 
in children given the standard dose. 
 
In adults given the standard dose of 400/100 mg LPV/RTV twice daily, the Kaletra 
package insert reports a steady-state LPV AUC of 92.6 mg · h/liter, a Cmax of 9.8 
mg/liter occurring 4 h after a dose, and a Ctrough of 7.1 mg/liter. For children given 
230/57.5 mg/m2 LPV/RTV twice daily, the package insert reports a steady-state LPV 
AUC of 72.6 mg · h/liter, a Cmax of 8.2 mg/liter occurring 4 h after a dose, and a 
Ctrough of 3.4 mg/liter. The children in our study received a median LPV dose of 275 
mg/m2, which is 20% higher than the recommended dose. The median LPV AUC, 
Cmax, and Ctrough were correspondingly higher than those reported for children in the 
package insert and were similar to adult values, with the exception of the Ctrough, 
which was slightly lower than that of adults. 
 
A 
B 
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With large interpatient variability in LPV PK, it is very important to estimate the 
chance of a child on ART having suboptimal LPV exposure. Other studies have 
suggested that the currently recommended dose of LPV/RTV might result in 
suboptimal exposure in HIV-infected children.1,7,28 Based on our PK model and the 
LPV pharmacodynamic models by Hsu et al. and Podzamczer et al.,14,15 we have 
shown that the majority of children are unlikely to achieve therapeutic plasma LPV 
concentrations against virus that is moderately resistant to LPV, at degrees far 
below the clinical cutoffs suggested by current phenotypic resistance testing. 
Furthermore, patients with fewer than two active background antiretroviral agents 
would have even higher IQ targets14,15 and would require correspondingly higher 
doses of LPV. It is this population of PI-experienced patients who would most likely 
derive direct benefit from measurement of plasma LPV concentrations and dose 
adjustment if necessary to avoid excessive dependence on the remaining drugs in 
the therapeutic regimen. Separate analysis in this cohort of HIV-infected children 
will compare the measured relationships of individual LPV PK and phenotypic and 
genotypic IQs to virologic responses.  
 
 
CONCLUSION  
In this study, a model of LPV disposition in pediatric patients > 4 years of age was 
developed and validated by a visual predictive check of the distribution of LPV 
concentrations in 1,000 model-simulated patients compared with the distribution of 
LPV concentrations in the study population. Based on this PK population model, the 
currently recommended dose of LPV/RTV appears to be adequate for children 
infected with wild-type virus but is unlikely to provide adequate inhibitory 
concentrations for even moderately resistant HIV. PI-experienced HIV-infected 
children would likely benefit from longitudinal, repeated LPV drug measurement in 
plasma in combination with resistance evaluation to ensure that LPV dosing is 
sufficient to maximize the contribution of LPV to virologic control.  
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ABSTRACT 
 
Objective 
CYP3A5, MDR1 (ABCB1) and OATP1 (SLCO1B1) polymorphisms have been 
associated with variability in the pharmacokinetics (PK) of protease inhibitors. The 
aim of this study was to investigate the influence of CYP3A5 A6986G, MDR1 
(C3435T and G2677T), and SLCO1B1 (T521C and A388AG) polymorphisms on the 
PK and pharmacodynamics (PD) of lopinavir/ritonavir (LPV/RTV) in HIV-infected 
children. 
 
Design and methods 
Prospective cohort study in children (4 - 18 yrs old) on stable antiretroviral therapy 
with LPV/RTV. CYP3A5, MDR1 and SLCO1B1 genotypes were determined using PCR 
amplification with allelic discrimination assays. The 12 hr plasma area under the 
concentration-time curves (AUC) and clearances (CL) of LPV and RTV were 
estimated using non-compartmental models. Analysis of covariance models with 
adjustment for age and adherence were used to assess associations between 
studied polymorphisms and AUC, CL and HIV RNA. 
 
Results 
50 children (median age 11.2 yrs) were enrolled. Allele frequencies were in Hardy-
Weinberg equilibrium: for CYP3A5 A6986G 0.42; for MDR1 C3435T 0.31 and for 
G2677T 0.20; for SLCO1B1 T521C 0.04 and for SLCO1B1 A388G 0.70. There was 
no statistically significant association between LPV or RTV AUC or CL, and CYP3A5, 
MDR1 or SLCO1B1 A388G polymorphisms. There was a significant association 
between SLCO1B1 T521C and LPV AUC (P = 0.042) and a nearly significant 
association with LPV CL (P = 0.063). Studied polymorphisms were not associated 
with virologic outcome.  
 
Conclusions 
There was no influence of the CYP3A5, MDR1 or SLCO1B1 A388AG polymorphisms 
on the PK and PD of LPV/RTV in HIV-infected children. SLCO1B1 T521C 
polymorphism was significantly associated with LPV AUC.  
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INTRODUCTION 
Lopinavir/ritonavir (LPV/RTV, Kaletra®, Abbott, Abbott Laboratories, North Chicago, 
Illinois) is a widely used protease inhibitor (PI) component of antiretroviral (ARV) 
therapy of paediatric patients due to co-formulation of LPV with RTV in liquid and 
tablet forms suitable for young patients. Limited data are available regarding the 
affect of genetic polymorphisms in drug metabolizing enzymes and drug 
transporters on the pharmacokinetics (PK) and pharmacodynamics (PD) of this 
boosted PI. 
 
LPV and RTV are both essential substrates and inhibitors of the CYP3A enzymes, 
and variations in the CYP3A5 expression have been suggested to be potentially 
responsible for the inter-individual variability in the absorption and disposition of 
several PIs.1-4 In addition to CYP3A enzymes, drug transporters may affect the 
disposition of PIs into tissues and cells.5 P-glycoprotein (P-gp) expression and 
polymorphisms in the multidrug resistant (MDR) 1 (ABCB1) gene encoding for P-gp 
have been associated with variability in drug absorption and disposition, drug 
response, and toxicity of several PIs in HIV-infected adult patients.2,6-8 Recent 
reports suggest an important role in the disposition of PIs of another major hepatic 
drug transporter: organic anion transporting polypeptide (OATP), coded by the 
SLCO genes.9,10 The trough concentrations of LPV have been reported to be 
significantly increased in patients with the SLCO1B1 521T>C polymorphism.10 
Reduced uptake of LPV by hepatocytes in carriers of SLCO1B1 T521T>C genotype 
has been suggested to be responsible for this effect, but the data on the clinical 
importance of SLCO1B1 polymorphisms in LPV PK are lacking.9 
 
While no association between the MDR1 polymorphisms and LPV or RTV plasma 
trough concentrations has been reported in adult patients with HIV infection, in 
paediatric patients the MDR1 G3435T polymorphism has been reported to affect 
plasma concentrations and virologic response to another PI, nelfinavir.11 In addition, 
recent studies of immunosuppressive therapy in children have shown that the effect 
of MDR1 polymorphisms on the PK of cyclosporine is related to age, and thus 
developmental stage.12,13 These findings suggest that developmental changes in 
MDR1 activity may need to be considered when evaluating the impact of genetic 
variants in children. To date no studies have evaluated the role of the CYP3A5, 
MDR1 and OATP1B1 expression on the PK and PD parameters of LPV or RTV in HIV-
infected children.  
 
This study was originally designed to investigate whether genetic polymorphisms in 
CYP3A5 A6986G, MDR1 (C3435T and G2677T) affect the steady-state PK and PD of 
LPV and/or RTV in HIV-infected children. Following recent reports on the 
significance of SLCO1B1 expression on the LPV PK in adults, we have also studied 
the effect of the genetic polymorphisms of SLCO1B1 (T521C and A388G) on the 
steady-state PK of LPV/RTV and evaluated the effect of these polymorphisms on the 
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virologic outcome of LPV/RTV based therapy in paediatric patients in our initial 
study cohort. 
 
 
PATIENTS AND METHODS 
Paediatric patients with HIV-1 infection (ages 4 - 18 years) receiving care at a large 
metropolitan paediatric HIV program at Children's National Medical Center (CNMC) 
and treated with ARV regimen based on Kaletra® as a single PI were eligible for 
study participation. The study protocol was reviewed and approved by the IRB at 
CNMC. Written informed consent was obtained from parents/legal guardians of 
children younger than 18 years of age. The subject's assent was obtained in 
children older than 7 years of age, unless the waiver of assent was required. Prior 
to study entry, all subjects had received uninterrupted, unchanged combination 
ARVs, which included twice daily LPV/RTV, for a minimum of 4 weeks. CYP3A5, 
MDR1 and SLCO1B1 genotypes were determined using PCR amplification followed 
by allelic discrimination assays based on the use of fluorogenic oligonucleotide 
probes (TaqMan) (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) 
and direct sequencing analysis performed on ABI Prism 3130 Genetic Analyzer 
(Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Allele frequencies 
were identified and all three SNPs were determined to be in Hardy-Weinberg 
Equilibrium (HWE) using a 1 degree of freedom chi-square test.  
 
The plasma PK samples were collected at times 0 (immediately before), 0.5, 1, 2, 4, 
8, and 12 hrs after the observed dose. LPV and RTV concentrations were 
determined by a published validated tandem-mass spectrometric method using the 
Applied Biosystems/Sciex API-2000 (Foster City, California, USA).14 Within-run 
precision (%CV) was below 7% and between-day precision was below 10% for all 
analytes at the tested concentrations. Accuracy ranged between 95% and 105%. 
Loss of assay precision (more than 15%) occurred at concentrations less than 10 
ng/mL; hence, results below this limit were censored. The ARV therapeutic drug 
monitoring (TDM) laboratory at CNMC is an accredited member of the International 
Quality Control Program for Therapeutic Drug Monitoring in HIV infection (University 
Medical Center Nijmegen, The Netherlands).  
 
Patient adherence to LPV/RTV was assessed by an interactive 3-day-recall interview 
of the caregivers and children older than 10 years of age and was calculated as the 
percentage of the number of doses taken over the number of doses prescribed. HIV 
RNA viral load (Roche Amplicor, Branchburg, NJ, USA) and self-reported adherence 
were measured every 12 weeks for 52 weeks. The lower limit of quantitation of HIV 
RNA viral load (VL) was 400 copies/ml. The virological outcome was determined as 
Study Undetectable VL (SUVL) if ever achieving VL < 400 copies/ml during the 
study duration or Ever Undetectable VL (EUVL) if ever achieving VL < 400 copies/ml 
while on ARV therapy with LPV/RTV. 
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LPV and RTV area under the time-concentration curves from 0 to 12 hours (AUC) 
were estimated by the linear trapezoidal algorithm using the R statistical package 
(version 2.9.2, R Foundation, Vienna, Austria, available at http://cran.r-
project.org/). Apparent oral clearance (CL) was estimated using the formula 
CL = F*Dose/AUC, where F is bioavailability. Since F could not be estimated without 
intravenous dosing, it was fixed at a value of 1 (note that apparent oral clearance 
will be larger than clearance after intravenous dosing if F is less than 1). 
 
Several statistical methods were used to measure the relationships between 
CYP3A5, MDR1 and SLCO1B1 polymorphisms and LPV/RTV AUC, CL and virologic 
outcome. Analysis of covariance models with adjustment for age was used to assess 
associations between polymorphisms and single parameters, multivariate analysis 
of covariance was used for associations between polymorphisms and multiple 
parameters, and logistic regression models were used to assess relationships 
between polymorphisms and virological outcome. LPV and RTV AUC and CL 
parameters were log-transformed to conform to normality and all analyses were 
performed using Stata V10 (College Station, TX, USA).  
 
 
RESULTS 
The study enrolled 50 children (24 boys, 26 girls) with a median age of 11.2 years 
(4.3 - 17.2 years). The majority of the children were African American (43), with 3 
patients of African origin, 1 Asian patient, and 3 Caucasian patients, 2 of whom 
were Hispanic. Median weight was 38.5 kg (15.4 - 90.5), median height was 139.4 
cm (108.7 - 168.3) and a median BMI was 19.0 (12.8 - 33.0). Background 
regimens consisted of 2 NRTIs in 44 (88%) patients, 3 NRTIs in 2 patients, and 1 or 
2 NRTIs plus NNRTI in 4 patients (LPV dose adjusted for NNRTI exposure). The 
median LPV/RTV dose was 275/69 mg/m2 (246/62 - 287/72 mg/m2) and the 
median LPV exposure was 2.2 yrs (0.5 - 5.2 yrs). Mean self-reported adherence 
was 88% (41 - 100%). Of the 50 participants, 27 (54%) patients achieved 
VL < 400 copies/ml at least once during the study period (SUVL) and 36 (72%) 
achieved VL < 400 copies/ml at least once on LPV/RTV therapy (EUVL).  
 
Of the 300 possible samples, 17 (5.6%) were missing or censored, and were 
equally distributed within the dosing interval. The median (range) LPV AUC and CL 
were 96.87 µg*h/l (15.29 - 228.77) and 0.09 l/h/kg (0.04 - 0.44), respectively. For 
RTV, AUC and CL were 44.73 µg*h/l (0.45 - 14.90) and 0.53 l/kg/h (0.15 - 3.74), 
respectively. As anticipated the AUC and CL of LPV had direct linear relationship 
with AUC and CL of RTV (r2 = 0.755; P < 0.0001 and r2 = 0.755; P < 0.0001, 
respectively). The CL of LPV and RTV was statistically significantly associated with 
age (P = 0.008 and P = 0.002 respectively). 
 
The allelic frequencies of the polymorphisms for CYP3A5 A6986G and MDR1 
(C3435T and G2677T) and for SLCO1B1 (T521C and A388G) were as follows: 
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CYP3A5 (A6986G) - p(A) = 0.583, p(G) = 0.417 (HWE P-value = 0.113); MDR1 
(C3435T) - p(C) = 0.688, p(T) = 0.312 (HWE P-value = 0.834); MDR1 (G2677T) - 
p(G) = 0.800, p(T) = 0.200 (HWE P-value = 0.693); SLCO1B1 (T521C) - p(T) = 
0.958, p(C) = 0.042 (HWE P-value = 0.763); SLCO1B1 (A388G) - p(G) = 0.702, 
p(A) = 0.298 (HWE P-value = 0.595) 
 
There was no statistically significant association between LPV or RTV AUC0-12 and 
CYP3A5, MDR1 C3435T and G2677T, and SLCO1B1 A388G genotypes. (Figures 1, 2, 
3 and 4) There was, however,  a significant association between SLCO1B1 T521C 
genotype and LPV AUC (P = 0.042), but no association between the same genotype 
and RTV AUC (P = 0.3453). (Figures 1 and 2) The CYP3A5, MDR1 and SLCO1B1 
polymorphisms did not significantly influence the clearance of LPV and RTV in 
children, although SLCO1B1 521T>C genotype was nearly significantly associated 
with an increase in LPV CL (P = 0.063). (Figure 3 and 4) When linear models were 
adjusted by age no statistical difference was observed. The combined PK of LPV and 
RTV (RTV AUC + LPV CL) were equally not affected by the CYP3A5, MDR1 and 
SLCO1B1 genotypes. (Table 1)  
 
CYP3A5, MDR1 and SLCO1B1 polymorphisms had no statistically significant 
association with virologic suppression (VL < 400 copies/ml) during the study period 
(SUVL) or ever achieved with LPV/RTV therapy (EUVL). (Table 2) The multiple SNP 
analysis did not reveal significant association between CYP3A5, MDR1, and 
SLCO1B1 combined genotypes and PK and PD parameters of LPV/RTV therapy. 
(Table 3)  
 
Table 1 Analysis of combined PK parameters (LPV AUC and RTV CL) in association with each SNP 
Covariates Phenotypes SNP Wald's P-value for SNP effect 
RTV AUC§ + LPV CL§§ CYP3A5 A6986G 0.6638 
RTV AUC + LPV CL MDR1 C3435T 0.9317 
RTV AUC + LPV CL MDR1 G2677T 0.9626 
RTV AUC + LPV CL OATP1B1 A388G 0.8730 
None* 
RTV AUC + LPV CL OATP1B1 T521C 0.1017 
RTV AUC + LPV CL CYP3A5 A6986G 0.6580 
RTV AUC + LPV CL MDR1 C3435T 0.7367 
RTV AUC + LPV CL MDR1 G2677T 0.9316 
RTV AUC + LPV CL OATP1B1 A388G 0.8959 
Age 
RTV AUC + LPV CL OATP1B1 T521C 0.1209 
§ AUC0-12; §§ CL0-12; * Unadjusted analysis. 
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1a              1b 
 
 
  
1c              1d 
 
 
 
1e 
 
Figure 1 Association between LPV AUC and CYP3A5, MDR1, and SLCO1B1 genotypes:  
1a) CYP3A5 A6986G; 1b) MDR1 C3435T; 1c) MDR1 G2677T; 1d) SLCO1B1 T512C;  
e) SLCO1B1 A388G.  
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2a              2b 
 
 
  
2c              2d 
 
 
 
2e 
 
Figure 2 Association between RTV AUC and CYP3A5, MDR1, and SLCO1B1 genotypes:  
2a) CYP3A5 A6986G; 2b) MDR1 C3435T; 2c) MDR1 G2677T; 2d) SLCO1B1 T512C;  
2e) SLCO1B1 A388G.  
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3a              3b 
 
 
  
3c              3d 
 
 
 
3e 
 
Figure 3 Association between LPV CL and CYP3A5, MDR1, and SLCO1B1 genotypes:  
3a) CYP3A5 A6986G; 3b) MDR1 C3435T; 3c) MDR1 G2677T; 3d) SLCO1B1 T512C;  
3e) SLCO1B1 A388G.  
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4a              4b 
 
 
  
4c              4d 
 
 
 
4e 
 
Figure 4 Association between RTV CL and CYP3A5, MDR1, and SLCO1B1 genotypes:  
4a) CYP3A5 A6986G; 4b) MDR1 C3435T; 4c) MDR1 G2677T; 4d) SLCO1B1 T512C;  
4e) SLCO1B1 A388G.  
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Table 3 Multiple SNP analysis: for each phenotype as the outcome (dependent) variable, all 5  
     polymorphisms are included in the model, with and without age as an additional      
     covariate. P-values are for the effect of each covariate 
Age effect CYP3A5 
A6986G 
effect 
MDR1 
C3435T 
effect 
MDR1 
G2677 
effect 
OATP1B1 
A388G 
effect 
OATP1B1 
T521C 
effect 
Phenotype 
P-value P-value P-value P-value P-value P-value 
LPV AUC§ 0.725 0.950 0.982 0.945 0.190 
LPV CL §§ 0.861 0.973 0.938 0.9075 0.328 
RTV AUC§ 0.705 0.935 0.908 0.750 0.716 
RTV CL §§ 0.952 0.952 0.902 0.797 0.658 
SUVL400 0.594 0.803 0.401 0.894  
EUVL400 
None* 
0.149 0.907 0.098 0.744  
LPV AUC 0.126 0.710 0.897 0.990 0.986 0.258 
LPV CL 12 0.033 0.959 0.708 0.928 0.893 0.455 
RTV AUC 0.027 0.499 0.947 0.952 0.967 0.474 
RTV CL 12 0.008 0.764 0.746 0.931 0.999 0.372 
SUVL400 0.803 0.577 0.816 0.410 0.876  
EUVL400 0.991 0.153 0.907 0.099 0.745  
§ AUC0-12; §§ CL0-12; * Unadjusted analysis. 
 
 
DISCUSSION 
The CYP3A5 6986A allelic frequency varies from approximately 50% in African 
American to 90% in Caucasian populations.15 CYP3A5 has been detected in 
measurable amounts in 10% - 30% of adult white population and in up to 60% of 
African American.16,17 The allelic frequencies in our study of predominantly African 
American children demonstrate the higher prevalence of wild-type, active enzyme 
encoding allele of the CYP3A5 gene in African American population. The allelic 
frequency of MDR1 3435C was seen in the majority of our patients in accordance 
with previously reported high frequency in the African American population.15,18 The 
incidence of MDR1 2677G allele was predominant in our study cohort and was 
higher than reported in the literature for African American adults.15,19 The allelic 
frequencies of SLCO1B1 521C polymorphisms are known to be rare in patients of 
African origin, and were very low in our study population of predominantly African 
American children (comparable with the data from Brazilian HIV-infected 
population).10,20,21 The incidence of SLCO1B1 388G allele was predominant in our 
population in accordance with published distribution in African subjects.20,21  
 
In our study neither LPV nor RTV AUC and CL were affected by the CYP3A5 A6986G 
polymorphism. These data correlate with previously published data on the lack of 
effect of CYP3A5 A6986G on LPV and RTV trough plasma concentrations in adults.22 
The study by Estrela et al. also did not find an association between another CYP3A5 
G14690A polymorphism and trough plasma concentrations of LPV/RTV and ascribed 
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the overall lack of the CYP3A5 influence on the PK of LPV/RTV to the inhibition of the 
CYPA5 activity by RTV.22 Both MDR1 C3435T and G2677T polymorphisms and their 
haplotypes also had no effect on plasma AUC and CL of LPV/RTV as previously 
reported in adult studies.23-26 The most recent adult study evaluating LPV plasma 
trough concentrations in plasma, semen and saliva of adult HIV-infected men found 
no association with MDR1 C1236T, T2677A and C3435T genotypes and haplotypes.27 
 
The reported effects of the MDR1 SNPs on the outcome of LPV/RTV based 
antiretroviral therapy have been controversial. MDR1 C3435T polymorphism has 
been associated with CD4 cell recovery in HIV-infected adult patients by Fellay et 
al.,24 but not by other studies.23,28 MDR1 C3435T polymorphism has been associated 
with HIV viral load outcome with earlier virologic failure reported in adult HIV-
infected patients with 3435CC genotype.29 These data have not been confirmed by 
Haas et al.,23 who reported that the allelic MDR1 G2677T and C3435T variants were 
not associated with difference in the rate of phase 1 viral decay. Our study found no 
association between the MDR1 polymorphisms and the virologic outcome in 
treatment-experienced HIV-infected children. 
 
Our data on the significance of SLCO1B1 T521C polymorphism on the trough 
concentrations of LPV are consistent with recently published reports from the adult 
data from Brazil and England.9,10 The study by Hartkoorn et al. has evaluated the 
effect of SLCO1A1, SLCO1B1 and SLCO1B3 on the LPV plasma concentrations in 
adult subjects (> 18 years) at 10 - 14 hours post dose (326 patients) and 2 - 6 
hours post dose (293 patients). No data on ethnic/racial background or virologic 
outcome were available. The study combined the data from a clinical database with 
in vitro research evaluating PIs as substrates to the OATP1A2, OATP1B1 and 
OATP1B3 in Xenopus laevis oocyte model. The data from the X. laevis oocyte model 
showed that the PIs saquinavir and LPV are substrates to OATP1A2, OATP1B1 and 
OATPB3, while RTV had no inhibitory effect on OATP1B1. In human samples, 
however, no association was found between SLCO1A2 and SLCO1B3 and LPV 
plasma concentrations. In contrast, the data from human samples showed a 
significant association between SLCO1B1 521T to C polymorphism with higher LPV 
plasma concentrations at both time points studied.9 Significantly higher median 
plasma LPV Cmin and C2-6 were observed in patients that were homozygous for the C 
allele at position 521 of SLCO1B1 compared with either T homozygotes or 
heterozygotes. The study by Kohlrausch et al. in Brazilian HIV-infected men showed 
similar association between SLCO1B1 521 t to C polymorphism with higher LPV Cmin 
when compared with wild-type genotype.10  
 
Similar findings of the significant effect of SLCO1B1 polymorphisms (T521C and 
A388G) on the PK of other OATP substrates such as statins have been reported and 
the SLCO1B1 polymorphism has been linked to be associated with statin-induced 
myopathy.30-33 As a result of these findings, the speculation about the association of 
SLCO1B1 polymorphism and increased risk of resistance to LPV and virologic failure 
has been made. Our study is the first to evaluate the clinical significance of the 
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SLCO1B1 polymorphisms. In our study cohort of experienced HIV-infected 
paediatric patients, the SLCO1B1 polymorphisms (A388G and T521C) had no 
statistically significant association with virologic outcome (undetectable virologic 
suppression < 400 copies/ml) during the study period or ever achieved with 
LPV/RTV based regimen. We recognize that CYP3A, MDR1 and SLCO1B1 expression 
may be affected by HIV infection and concomitant ARV therapy, and hence may be 
a confounding variable in determining drug response.34-37 The full spectrum of the 
substrates/suppressor/inducer interaction between CYP3A enzymes, P-gp, OATP 
and ARV therapy and HIV infection is complex and remains to be determined. 
 
Finally, as we reported in our population PK analysis for LPV,38 in this study we also 
found a significant association between RTV clearance and age, due to age related 
changes in apparent volume of distribution that were independent of weight. For 
both drugs, the weight-adjusted volume of distribution in l/kg on average 
diminishes with age, which is likely a reflection of the age-related reduction in 
extracellular body water as a percentage of total body weight.39  
 
This study has several limitations. First, the sample size of this paediatric cohort from 
our single center is relatively small. Second, we did not evaluate the contribution of 
the resistance to ARV drugs to the virologic outcome. Finally, the adherence in the 
study was evaluated through self-report and is subject to recall bias. 
 
 
CONCLUSIONS 
These data add to our understanding of the factors that contribute to variability in 
plasma concentrations of protease inhibitors. Our data showed the impact of the 
SLCO1B1 T521C polymorphism on LPV AUC and CL. There was no influence of the 
CYP3A5 A6986G, MDR1 (C3435T and G2677T) and SLCO1B1 A388AG 
polymorphisms on the PK of LPV and RTV in children. This is the first study to 
evaluate the clinical significance of MDR1 and SLCO1B1 polymorphisms on the 
outcome of HIV infection in paediatric patients. The virologic outcome of LPV/RTV 
based HAART was not affected by the MDR1 or SLCO1B1 polymorphisms in the 
treatment experienced HIV-infected children and adolescents. Age had a statistically 
significant effect on the clearance of LPV and RTV. The full spectrum of the 
substrates/suppressor/inducer interaction between CYP450 enzymes, P-gp, OATP 
and ARV therapy and HIV infection is complex and remains to be determined. 
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ABSTRACT 
Background 
The monitoring of nevirapine (NVP) concentrations in pediatric patients has gained 
interest since the introduction of NVP as part of the preferred first-line antiretroviral 
regimen for human immunodeficiency virus (HIV)-infected children in resource-
limited settings. Adequate trough concentrations of NVP predict successful therapy, 
whereas subtherapeutic levels are correlated with virologic failure and development 
of resistance. The aim of this study was to determine the extent of agreement 
between total and free plasma NVP concentrations and nonstimulated saliva NVP 
concentrations and to evaluate the feasibility of saliva sampling as an alternative 
tool for therapeutic drug monitoring of NVP in children.  
 
Design and methods 
The study was designed as an observational cohort analysis. NVP concentrations 
were obtained in paired plasma and saliva samples of pediatric patients receiving 
antiretroviral therapy, including NVP. NVP plasma and saliva concentrations were 
determined by a tandem-mass spectrometric method. The intraclass correlation 
coefficient and Bland-Altman analysis were used to evaluate agreement and to 
assess pattern in any discrepancies between measurements.  
 
Results 
For the random paired plasma and saliva NVP sampling, 19 African-American 
children (8 boys, 11 girls) with a median age of 8.0 years were enrolled. Two male 
subjects were recruited for the 12 hour NVP plasma and saliva pharmacokinetics 
study. The intraclass correlations between saliva and serum measurements of NVP 
concentrations indicated > 90% agreement between these two modes of 
measurement. The saliva concentrations reflected the free concentrations very 
closely but were on average 34% higher. The Bland-Altman plots indicated that the 
discrepancy between saliva and plasma measures is consistent across the range of 
average NVP concentrations. 
 
Conclusions 
Our study results strongly indicate agreement between saliva and plasma NVP 
concentrations in pediatric patients with HIV infection, on the basis of Bland-Altman 
analysis. Nonstimulated NVP saliva concentrations can be used as an alternative 
noninvasive, reliable, cost-effective method for direct measurement of adherence 
and application of therapeutic drug monitoring in NVP therapy.  
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INTRODUCTION 
Treatment of HIV infection in pediatric patients is complicated by the need for 
multiple drug therapy and lack of palatable, easy-to-use pediatric formulations with 
reliable pharmacokinetics. Nevirapine (NVP) is one of the few antiretroviral drugs 
that is well suited for infants and children, and the use of NVP in children is 
associated with excellent clinical and immunological responses.1 The administration 
of NVP is convenient, the taste of the liquid preparation is well tolerated, and the 
pill burden is low, which favors adherence to therapy. NVP-based highly active 
antiretroviral therapy (HAART) regimens are cost-effective, are available as generic 
formulations, and do not require refrigeration and for these reasons are the 
preferred first-line antiretroviral strategy for infants and children in resource-limited 
settings.2 Single-dose NVP is also a highly cost-effective strategy to reduce 
perinatal HIV-1 transmission and has become an important component of many 
programs for preventing mother-to-child transmission (PMTCT) in resource-limited 
countries.3,4  
 
Adequate levels of NVP predict successful therapy whereas subtherapeutic levels 
are correlated with virologic failure.5,6 Higher values of NVP exposure are associated 
with greater initial clearance of HIV-1 RNA from plasma and higher probability of 
achieving undetectable levels of plasma HIV1-1 RNA with more sustained 
suppression of viral replication.5 The genetic threshold for development of NVP 
resistance is low, and cross-class non-nucleoside reverse transcriptase (NNRTI) 
resistance of HIV-1 can evolve after reverse transcriptase (RT) single amino-acid 
substitutions. Low NVP concentrations (≤ 3 mg/l) are associated with a 5-fold 
increase in virologic failure.6 Patients receiving NVP as part of their HAART regimen 
are also at high risk for developing treatment-limiting toxicity. During pregnancy, 
severe NVP-induced hepatotoxicity has been associated with CD4+ counts above 
350/mm3 and with the introduction of NVP in late gestation.7 Whereas a definite 
relationship between hepatotoxicity and NVP concentrations is confounded by other 
risk factors, including pre-existing hepatic dysfunction, viral hepatitis and high 
CD4+ cell counts in several case reports indicate a causal relation between NVP 
concentrations and elevation of liver transaminase levels.8,9 Therefore, optimal use 
of NVP may require maintaining concentrations within a narrow range.  
 
NVP is metabolized by enzymes of the CYP3A and CYP2B6 families, creating a solid 
base for multiple drug-drug interactions.10,11 Many drugs used for the treatment of 
infectious complications of HIV infection and acquired immunodeficiency syndrome 
(AIDS), such as ketoconazole, fluconazole, rifampin, and rifabutin, as well as herbal 
supplements (St. John's wort) have shown significant interactions with antiretroviral 
drugs, leading to toxicity-related complications and subtherapeutic 
concentrations.12,13 For patients in developing countries, possible interactions of 
NVP with commonly used drugs or local herbal supplements are less well studied. It 
has been shown, however, that sulfadoxine-pyrimethamine, commonly used as 
prophylaxis for malaria, can lead to adverse drug reactions and overlapping toxicity 
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in pregnant women who receive daily nevirapine and/or zidovudine for the 
prevention of perinatal transmission of HIV.14 The ability to determine NVP 
concentrations in the case of drug interaction-induced toxicity or treatment failure 
may lead to appropriate NVP dose adjustment with clinical and laboratory follow-up. 
 
Because of the long half-life of NVP, a single NVP plasma concentration can be used 
for accurately estimating the area under the plasma concentration-time curve 12 
hours after dosing (AUC0-12h). The data suggest that a pharmacokinetic assessment 
with a single, nontrough, clinic sample can be used to accurately monitor NVP 
therapy and allow optimization of therapy with dose modifications.15 Samples for 
therapeutic drug monitoring (TDM) purposes may be taken without regard to time 
between intake and sampling. The minimal effective concentration (MEC) for NVP, 
based on clinical outcome data, has been reported to be 3400 ng/ml.5 Although 
obtaining a single NVP plasma concentration sample is easier than determining full 
or partial pharmacokinetic profiles with multiple sampling, noninvasive methods for 
determining NVP concentration would gain greater acceptance in pediatric and 
resource-limited settings. Previous studies have suggested that saliva assessment 
can be used as a noninvasive method for TDM of several antiretroviral drugs.16-18 
The purpose of this study was to determine the extent of agreement between total 
and free plasma NVP concentrations and nonstimulated saliva NVP concentrations in 
order to evaluate the feasibility of saliva sampling as an alternative tool for TDM of 
NVP in children.  
 
 
MATERIALS AND METHODS 
Patients 
The study represents a subgroup analysis of a pilot study of 50 subjects that was 
designed to assess the relationship between saliva and plasma levels of multi-
HAART regimens. Pediatric patients with HIV-1 infection (aged 4 to 14 years) 
receiving care at a large metropolitan pediatric HIV program in the United States 
(Special Immunology Service at Children's National Medical Center) and receiving 
HAART including NVP were eligible for study participation. The research protocol, 
parental consent, and assent documents (for children older than 7 years of age) as 
well as the confidentiality documents for the protection of personal health 
information (HIPAA) were approved by the institutional review board.  
 
Patient adherence to NVP was assessed by interviewing all caregivers as well as 
those children older than 10 years of age and able to self-report drug intake. 
Patients with reported adherence < 75 % (more than three missed drug doses 
during 1 week) were excluded. All subjects in this study had been on uninterrupted, 
unchanged, twice-daily dosed NVP-based HAART for at least 4 weeks. 
 
Blood samples for the determination of NVP concentration were collected through 
venipuncture during routine clinical visits. An extra 2 ml of blood was obtained from 
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all participants, in addition to the samples for standard of care laboratory tests. 
Nonstimulated saliva samples were collected within 10 minutes of the blood 
samples. After rinsing the mouth with water [children of all ages swished and rinsed 
twice with clean tap water (100 cc) offered in a plastic cup], participants were asked 
to spit into a small plastic cup, and 0.25 ml of saliva was transferred into a clean 
tube with a syringe. The time after the last dose and dosing regimen were recorded.  
 
In addition to single sample determinations, two patients who had been recruited 
for a separate institutional review board-approved pediatric study of 12 hour 
plasma pharmacokinetic profiles of antiretroviral agents received NVP as part of 
their HAART and consented to concurrent saliva sampling for NVP determination. 
Both subjects ingested NVP under direct observation with a light snack (apple juice 
and one cracker). Plasma and saliva samples were obtained before and 0.5, 1, 2, 4, 
8, and 12 hours after observed ingestion of NVP in these subjects.  
 
Tandem-mass spectrometry analysis  
For the determinations of total and free plasma NVP concentrations, 2 ml of venous 
blood was obtained. The blood was collected in a heparin tube and separated by 
centrifugation at 4000 rpm for 10 minutes. Plasma was stored at -70°C pending 
analysis. Saliva samples were directly frozen upon collection at -70°C pending 
analysis. They were thawed at room temperature for 20 minutes and centrifuged at 
4000 rpm for 10 minutes at the laboratory at the time of the analysis to separate 
the mucus. The plasma and saliva samples were incubated for 30 minutes at 56°C 
to deactivate infectious HIV-1 particles. The heating of the sample has been proven 
not to produce degradation of NVP during heat incubation.19,20 
 
Unbound NVP was separated with Centrifree YM-30 ultrafiltration devices (30,000 
MW cut-off; Millipore, Bedford, MA). The drug plasma and saliva concentrations 
were determined by a tandem-mass spectrometric method with use of the Applied 
Biosystems/Sciex API-2000.19,20 Within-run precision [% coefficient of variation 
(CV)] was below 7% and between-day precision (%CV) was below 10% for all 
analytes at the tested concentrations. Accuracy ranged between 95% and 105%. 
The lower limit of quantitation was at 10 ng/ml. No interference by concurrent 
medications has been reported to be associated with an assay. Cimetidine is used 
as the internal standard; therefore, cimetidine therapy was considered to be an 
exclusion criterion for participation in the study.19,20  
 
The antiretroviral TDM laboratory at Children's National Medical Center, which 
performed the NVP assays, is an accredited member of the International Quality 
Control Program for Therapeutic Drug Monitoring in HIV Infection (University 
Medical Center Nijmegen, The Netherlands).21,22 
 
Data analysis 
The analysis of the study employed two methods. The first was to use the intraclass 
correlation coefficient (ICC) to assess the level of agreement between the two 
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alternative measurements.23 In deriving the ICC using analysis of variance, we 
treated the two methods, one based on saliva and the other on serum, as fixed 
effects and treated the subjects on whom the tests were run as random effects. 
This would allow the estimates of agreement to be generalized beyond the patient 
samples from which they were derived. We considered 80% or better ICC to 
constitute excellent agreement. The second method was the use the Bland-Altman 
procedure to graphically evaluate the relationship between the average of paired 
measures and their difference to reveal patterns in any discrepancies such as any 
discrepancies increasing as the level of the measured outcome increases.24 
 
Plasma and salivary concentrations vs time data were analyzed by 
noncompartmental methods. Correlation and regression analyses were applied for 
analysis of the differences between NVP formulations. Descriptive statistics were 
used for analysis of the patient population.  
 
Table 1 Characteristics of patients who underwent random Nevirapine concentration sampling 
Characteristic Value 
Female 11 (58) 
Male 8 (42) 
Ethnicity   
 Non-Hispanic Black 19 (100) 
Age in years  
 Mean  8.5 ± 1.9 
 Median; range 8.0; 5.9 - 13.2 
CDC  clinical category    
 N 6 (32) 
 A 4 (21) 
 B 9 (47) 
DAIDS toxicity category  
 Grade I hepatic 1 (16) 
 Grade I pancreatic 6 (37) 
 Combined grade I hepatic and pancreatic 1 (5) 
CD4+ count, per mm3  
 Mean 1,268 ± 596 
 Median; range 1,066; 315 - 2,334 
Percentage of CD4+ cells/mm3  
 Mean  38 ± 8 
 Median; range 37; 15 - 49 
Viral load, copies/ml  
 Mean 13,944 ± 45,256 
 Median; range 1,000; 1,000 - 196,518 
Note: Numbers in parentheses are percentages. CDC, Centers for Disease Control and Prevention; 
DAIDS, Division of Acquired Immunodeficiency Syndrome, NIAID, NIH. 
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RESULTS 
For the random paired sampling of NVP in plasma and saliva, 19 pediatric African-
American patients (8 boys, 11 girls) with a median age of 8.0 years receiving 
antiretroviral therapy including NVP were enrolled. The majority of the participants 
had a history of moderately symptomatic HIV infection (CDC clinical category B) 
with good immunologic function and mild viremia at the time of evaluation 
(Table 1). Nine patients had mild antiretroviral or HIV-associated hepatic and 
pancreatic toxicities, and one had a combination of both (Table 1).  
 
Five subjects had evaluations on more than one occasion, several weeks apart. The 
median time from NVP intake to sample collection was 5 hours (Table 2). The mean 
NVP dose was 179 mg/m2 (SD, ± 22), every 12 hours, and 11 subjects received the 
medication as the liquid formulation. The total plasma concentrations of NVP ranged 
from 240 to 13,900 ng/ml, with a median of 9,160 ng/ml, whereas the median free 
NVP concentration was 3,690 ng/ml (range, 110 to 11,500 ng/ml). The saliva NVP 
concentrations ranged from 120 to 13,400 ng/ml (median, 5,780 ng/ml). NVP saliva 
concentrations reflected more closely the free NVP plasma concentrations but were 
on average 34% higher.  
 
Table 2 Random Nevirapine (NVP) concentration assessment 
Variable Value 
Time after NVP intake, hours  
 Mean  5.4 ± 2.8 
 Median; range 5; 2.2 - 10 
NVP dose, mg/kg/dose  
 Mean  179 ± 22 
 Median; range 187; 135 - 199 
NVP liquid 11 (58)  
NVP solid 8 (42) 
NVP total serum concentrations, ng/ml  
 Mean  
 Median; range 
8,147 ± 4,290 
9,160; 240 - 13,900 
NVP free serum concentrations, ng/ml  
 Mean   4,218 ± 2,842 
 Median; range 3,690; 110 - 11,500 
NVP saliva concentrations, ng/ml  
 Mean  5,592 ± 3,268 
 Median; range 5,780; 120 - 13,400 
Note: Numbers in parentheses are percentages. 
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In addition, two male subjects were recruited for the extended sampling for NVP 
pharmacokinetics over 12 hours (Table 3). The overall mean total and free plasma 
NVP concentrations were 5,722 ng/ml (SD, ± 4,328) and 2,818 ng/ml (SD, 
± 2,608), respectively. The mean salivary concentration was 3,885 ng/ml (SD, 
± 3,233). For the two subjects with complete profiles the total, free, and salivary 
mean AUCs were 30.6, 14.7, and 18.0 µg*hr/ml, respectively (Figures 1 and 2). 
  
The study results indicated high levels of agreement between saliva and serum 
measurements. With very few exceptions, saliva results were basically synonymous 
with serum results across the full range of data. The intraclass correlations between 
saliva and serum measurements of NVP concentrations indicated > 90% agreement 
between these two modes of measurement (Tables 4 and 5). The Bland-Altman 
plots indicated that the discrepancy between measures was consistent across the 
range of average NVP concentrations (Figures 3 and 4). The figures show the 
relationship between saliva and plasma NVP concentrations vs the average of the 
two. The plots also show 95% confidence intervals through shading as well as the 
number and percent outside of the 95% confidence interval.  
 
Overall, there was no difference in the saliva to plasma ratios between formulations. 
Although subjects taking the liquid formulation were younger, the serum albumin 
concentrations were similar between the subjects receiving each formulation, and 
sample collection occurred predominantly after drug absorption was complete for 
both formulations. For the two subjects who provided multiple samples, the average 
within-subject variability was 10%. This was lower than the 11% to 27% among 
repeated samples on separate visits.  
 
Table 3 Characteristics of patients in the 12 hour pharmacokinetics study of Nevirapine (NVP)  
      concentrations in saliva and plasma 
Characteristic Subject 44 Subject 6 
Sex Male Male 
Age, years 11.5  10.7 
Ethnicity Non-Hispanic Black Non-Hispanic Black 
CDC  clinical category   C C 
DAIDS toxicity category Normal toxicity values Grade I Pancreatic  
CD4+ cell count, per mm3 1,056 695 
CD4+ cell count, % 32 32 
Viral load, copies/ml 15,800 457 
HAART combination  3TC+NVP+LPV/rtv TNF+NVP+LPV/rtv 
NVP dose, mg/kg/dose 198 188 
CDC, Centers for Disease Control and Prevention; DAIDS, Division of Acquired Immunodeficiency 
Syndrome, NIAID, NIH; HAART, highly active antiretroviral treatment; 3TC, lamivudine; LPV/rtv, 
lopinavir/ritonavir; TNF, tenofovir. 
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Sample collection time had minimal impact on the relationship of saliva and total 
plasma NVP concentrations. The saliva/total plasma ratio was within 0.45 to 0.9 for 
all subjects, and although there was a trend toward lower ratios later in the dose 
interval, this did not reach statistical significance and was small in magnitude 
(r = 0.30, P = 0.12) (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Pharmacokinetics of nevirapine (NVP) in study subject number 6 (total, free plasma, 
and saliva concentrations). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Pharmacokinetics of nevirapine (NVP) in study subject number 44 (total, free plasma, 
and saliva concentrations). 
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Table 4 Intraclass correlation coefficients between saliva and total plasma nevirapine (NVP)  
      concentrations 
  95% Confidence interval 
Measures Intraclass correlation Lower limit Upper limit 
Single 0.913 0.830 0.957 
Average 0.955 0.907 0.978 
 
Table 5 Intraclass correlation coefficients between saliva and free plasma nevirapine (NVP)  
      concentrations 
  95% Confidence interval 
Measures Intraclass correlation Lower limit Upper limit 
Single 0.954 0.905 0.978 
Average 0.976 0.950 0.989 
 
DISCUSSION 
The use of saliva for TDM has distinct advantages for children because saliva 
sampling is painless, prevents extra blood loss, and eliminates patient and caregiver 
stress as well as the infection risk associated with venipuncture. Obtaining saliva 
instead of blood reduces the cost by eliminating the need for venipuncture and for 
the involvement of skilled nursing personnel.25 It requires fewer medical supplies 
and equipment for collection and initial processing, making it particularly suitable 
for low-resource environments. Prior studies involving children led to 
recommendations that saliva be used for TDM of certain medications, including 
phenytoin, carbamazepine, phenobarbital, and caffeine.26-28  
 
In a previous study of the NVP concentrations in stimulated saliva of adult patients 
with HIV infection, by Heeswijk et al., patients chewed for 1 minute a dental cotton 
roll impregnated with citric acid.29 The study did not estimate the final volume of 
saliva extracted through centrifugation of the cotton roll and did not specify the 
centrifugation process. Because our laboratory method required a very small saliva 
volume (0.25 ml) and was aimed at the application in pediatrics, we chose to 
evaluate nonstimulated saliva sampling. We enrolled children older than 4 years of 
age and did not encounter significant obstacles in obtaining nonstimulated saliva 
samples. Collection of samples from younger participants (the youngest was 5.9 
years of age) did take slightly longer (2 to 3 minutes, vs 1 to 2 minutes for older 
children) because these patients were less able to concentrate on the task. 
Thorough rinsing of the mouth is required prior to saliva sampling, because 
remnants of orally administered medicines may contaminate saliva specimens and 
yield spuriously high values. The similar saliva to plasma ratios between 
formulations indicate that our procedure was adequate to prevent contamination. 
Stimulation of saliva secretion with a chemical stimulus such as citric acid applied to 
the tongue facilitates sampling from younger patients and might be necessary for 
collecting samples from neonates and infants.28  
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Figure 3 Total nevirapine (NVP) plasma concentration vs saliva concentration. 
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Figure 4 Free nevirapine (NVP) plasma concentration vs saliva concentration. 
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Figure 5 Correlation between saliva/total plasma nevirapine (NVP) ratio and time after NVP dose. 
 
Since drug passage into saliva follows the general principles of movement of drugs 
across biological membranes, only the unbound fraction of the drug in plasma is 
available for diffusion into saliva. However, a pH gradient exists between plasma 
and saliva that may alter the saliva/plasma concentration ratio of many polar drugs 
through ion trapping. The use of stimulated rather than resting saliva is advocated 
by some authors, because of the benefits of larger sample volume, smaller pH 
gradient between plasma and saliva, and smaller variability in saliva/plasma 
concentration ratios.26,27 However, the acid dissociation constant (pKa) for NVP 
(2.8) is far from the physiologic pH, and thus the transfer of the drug is less 
sensitive to the plasma/saliva pH gradient. The saliva concentrations in our study 
reflected the free concentrations very closely but on average were 34% higher. 
Though we did not measure the saliva/plasma pH ratios, the pH gradient theory 
appears to be supported by the previously published data from van Heeswijk et al.29 
The study yielded similar findings in saliva-to-plasma ratio, with greater differences 
(60% higher salivary concentration over plasma) when saliva was collected with use 
of citric acid, which induced a decrease in salivary pH. Overall, the nonstimulated 
saliva to total and free plasma concentration ratios in our study show small 
variability, with a trend toward a statistically nonsignificant decrease over the dose 
interval. The 34% value indicates that the saliva measurement overestimates the 
free plasma level by an average of 34%. This difference between the saliva and 
plasma NVP concentrations does not preclude using saliva concentrations as a 
predictor of plasma concentrations, especially if a consistent regression model can 
be developed that accounts for most of the variability in plasma levels. In order to 
evaluate the utility of such a model, it will be necessary to collect data from a larger 
sample of HIV-infected children with a range of plasma values to provide a more 
complete assessment of the relationship.  
 
Our study population demonstrates a wide range of concentrations of NVP in plasma 
and saliva. Even with exclusion of the samples with total concentrations < 1000 
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ng/ml (which may have been associated with suboptimal adherence), the 
concentrations varied more than 10-fold in all 3 matrices. The high interpatient 
variability in plasma concentrations, narrow therapeutic window, strong correlation 
between drug concentration and therapeutic effect, and failure of the longterm 
outcome with inadequate target concentrations make NVP an excellent candidate 
for successful TDM. Timely dosage adjustments based on individual plasma 
concentrations can optimize the therapeutic effect of the medication and prevent 
exposure to toxic or subtherapeutic concentrations of the drug and therefore limit 
the development of resistance mutations.30 
 
Standard NVP dosage as part of HAART may have reduced virological effect due to 
poor compliance, poor absorption, increased metabolism and/or elimination, and 
drug-drug and drug-food interactions. Although the rates of adherence among 
pediatric patients are similar to those among adults with chronic diseases, 
averaging only about 50%, achieving full adherence in pediatric patients is a 
particularly difficult task. It requires not only the child's cooperation but also a 
devoted, persistent, adherent parent or caregiver. Measurement of the 
concentration of drug or its metabolite in blood and body fluids is considered one of 
the direct methods for measurement of adherence. Despite the cost and increased 
level of awareness by healthcare providers, measuring drug levels became a 
commonly used adherence assessment tool for certain drugs.17,31 Although the 
acceptance of TDM for antiretroviral drugs as the standard of care is regional, many 
publications support its role in identifying adherence problems and optimizing 
treatment in vulnerable populations such as pregnant women and children.5,30,32,33 
 
As pediatric fixed-dose combinations become available in the developing world, the 
ability to evaluate the steadystate pharmacokinetics of NVP in HIV-infected children 
of various ethnic and cultural backgrounds will become necessary. Children are at 
increased risk for subtherapeutic or toxic drug concentrations due to dependency on 
the continuous dose adjustment, palatability, and pill burden of HAART, the 
caregiver's ability to administer the medications in a proper way, and changes in 
drug pharmacokinetics during childhood development. The majority of current 
investigations involve abbreviated pharmacokinetic studies in children involving a 
minimum of 3 blood samples, requiring placement of an intravenous catheter or 3 
separate venipunctures.34 The splitting of adult-dose solid formulation 
antiretrovirals, although suboptimal, is the best currently available option for 
treatment of children in resource-limited areas of the world. Although satisfactory 
virological and immunological benefits in children receiving such formulations were 
reported from Thailand and Uganda, the use of tablets that require splitting can 
result in underdosing or overdosing of children, which can lead to increased risk of 
resistance or toxicity.34,35 
 
The implementation of PMTCT programs in developing countries has revealed the 
risk for development of high rates of resistance for different HIV subtypes after 
single-dose NVP prophylaxis in both the mother and the infected newborn.36 Recent 
Chapter 8 
 
110 
studies have yielded detectable NVP plasma concentrations after more than 2 weeks 
following single-dose exposure to NVP.37,38 The results of both of those studies 
suggest that prolonged exposure to subtherapeutic drug concentrations of NVP 
might be responsible for development of NVP resistance in women and newborns 
exposed to single-dose PMTCT prophylaxis. These data highlight the need to know 
the interpatient variability in NVP half-life in women receiving a single dose of NVP 
in order to develop interventional strategies. Recently reported high rates of 
adherence to single-dose NVP for PMTCT have created excellent grounds for 
evaluation of maternal and neonatal exposure to NVP and its variability.39 The 
application of a noninvasive method to conduct these studies would not only provide 
increased acceptance and enrollment but also would significantly reduce the risks 
associated with blood draws during pregnancy and reduce the costs associated with 
sample collection.  
 
The potential ability to apply TDM for NVP in newborns is an area of particular 
interest because of the need for different NVP dosing regimens for infants, based on 
the length of maternal history of NVP therapy and time between the last NVP intake 
and delivery. An infant's NVP exposure may vary from 1 to 2 doses postpartum.40,41 
More data are needed on the excretion of NVP in saliva in infants and neonates.  
 
The Current Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection 
in the USA mention the usefulness of direct plasma concentration monitoring only 
for assessment of adherence to therapy with protease inhibitors, on the basis of a 
study published by van Rossum in 2002.42,43 Although our study was not aimed at 
evaluating the usefulness of NVP TDM for measuring adherence and optimizing 
therapy to improve outcomes for children with HIV infection receiving NVP-based 
HAART, it offers a valuable noninvasive tool to further address these important 
questions.  
 
 
CONCLUSION 
Our study results indicate strong agreement between saliva and plasma NVP 
concentrations in pediatric patients with HIV-1 infection, on the basis of Bland-Altman 
analysis. The analysis has demonstrated that the two sampling methods are 
interchangeable and that nonstimulated saliva sampling for NVP concentrations may 
be used as a substitute for plasma sampling in clinical practice. Saliva sampling for 
NVP concentrations may be used as a noninvasive, reliable, cost-effective method for 
direct adherence measurement and application of TDM for NVP therapy. We believe 
that TDM of NVP can benefit many children and adults with HIV infection and can also 
serve as a tool in the direct measurement of adherence to NVP, particularly in 
newborns, young infants, and pregnant women, by preventing unnecessary blood 
loss, decreasing costs, and lowering the risks of infections associated with the 
venipuncture. This noninvasive measurement of NVP concentrations may prove useful 
as adapted technology for TDM of HAART in the developing world.  
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ABSTRACT 
Currently, therapeutic drug monitoring (TDM) of antiretroviral therapy (ART) is not 
performed in the United States as part of routine clinical care of an HIV-infected 
adolescent patient. TDM is recommended to rule out subtherapeutic drug 
concentrations and to differentiate among malabsorption, drug interactions, poor 
adherence, or increased drug metabolism or clearance as possible causes of 
decreased drug exposure. The use of TDM is also considered to assist in finding the 
optimal dose of a drug in patients whose virus has shown reduced susceptibility to 
that drug. The dosing of antiretroviral (ARV) drugs in adolescent patients with HIV 
infection depends on the chronologic age, weight, height, and the stage of sexual 
maturation. As a result of the limited data on the pharmacokinetics of ART during 
puberty, the transition of a dosing regimen from higher pediatric (weight and 
surface-based) to adult (fixed) range is not well defined. Developmental 
pharmacokinetic differences contribute to high variability in pediatric and adolescent 
patients and an increased frequency of suboptimal ARV exposure as compared to in 
adults. Individualized, concentration-targeted optimal dosing of ARV medications 
can be beneficial to patients for whom only limited dosing guidelines are available. 
This article describes three cases of the application of TDM in treatment-
experienced adolescent patients whose ART was optimized using ARV TDM. TDM of 
ARV drugs is useful in managing the pharmacotherapy of HIV in adolescent patients 
and is well received by the adolescent patients with HIV and their families. Among 
others, the benefits of TDM provide evidence for adherence interventions and create 
grounds for enhanced education of the adolescent patient and involved adult 
caregivers about ART. Finally, TDM in adolescents provides valuable information 
about the clinical pharmacology of ART during puberty. 
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INTRODUCTION 
Currently, therapeutic drug monitoring (TDM) of antiretroviral therapy (ART) is not 
routine in the clinical care of HIV-infected adolescents in the United States. 
Nonetheless, in the recently updated Guidelines for the Use of Antiretroviral Agents 
in Pediatric HIV Infection, TDM is considered to be useful in a pediatric patient with 
ART failure.1 TDM is recommended to rule out subtherapeutic drug concentrations 
and to differentiate among malabsorption, drug interactions, poor adherence, or 
increased drug metabolism or clearance as possible causes of decreased drug 
exposure. The use of TDM is also considered to assist in finding the optimal dose of a 
drug in a patient whose virus has shown a reduced susceptibility to that drug.2,3 
 
The dosing of antiretroviral (ARV) drugs in an adolescent patient with HIV infection 
depends on the chronologic age, weight, height, and the stage of sexual 
maturation.4 As a result of the limited data on the pharmacokinetics (PK) of ART 
during puberty, the transition of a dosing regimen from higher pediatric (weight and 
surface-based) to adult (fixed) range is not well defined. Developmental PK 
differences contribute to high variability in pediatric and adolescent patients and a 
greater frequency of suboptimal ARV exposure as compared to in adults.5-8 Although 
multiple adherence barriers represent one of the major challenges to the successful 
ART of pediatric HIV infection, the information on failed ART or increased resistance 
in the HIV-infected adolescents is very limited.9,10 Equally limited are the data on the 
short- and longterm effects of potentially toxic ARV exposures during growth and 
development in early childhood and puberty.  
 
In the absence of TDM, HIV-infected adolescents and young adults are placed at a 
significant risk of developing resistance from subtherapeutic drug exposure or 
toxicity from supratherapeutic dosing.5 This article describes three cases of the 
application of TDM in treatment-experienced HIV-infected adolescent patients whose 
therapy was ultimately optimized through the use of ARV TDM.  
 
 
PATIENTS AND METHODS 
All patients were adolescents with perinatally acquired HIV-1 infection receiving care 
at the large (greater than 300 patients) metropolitan pediatric HIV program at 
Children's National Medical Center, Washington, DC. TDM of ART has been routinely 
implemented into clinical practice within the program at Children's National Medical 
Center since 2002. In addition, in the period between 2004 and 2008, the program 
conducted a study on the optimization of ART in children and adolescents with HIV 
infection, which involved the evaluation of CYP450 and MDR1 genotypes, extensive 
(up to 12 hours) PK studies, and intense TDM follow-up.11 The research protocol, 
parental consent, and assent documents (for children older than 7 years of age) 
were approved by the Institutional Review Board. All subjects in this study were on 
uninterrupted, protease inhibitor-based ART for at least 4 weeks before study entry. 
Blood samples for ARV drug measurement were obtained during routine clinical visits 
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(for random TDM samples) and during admission to the General Clinical Research 
Center for an extensive PK study after an observed dose. The subjects were 
administered their standard prescribed dose under direct observation with a 
standard light snack. Plasma and paired saliva samples were obtained before and at 
0.5, 1, 2, 4, 8, and 12 hours after the observed intake of ARV for the 12-hour PK 
study or on the alternative schedule for a shortened PK (less than 12 hours) study. 
 
The ARV plasma and saliva concentrations of all ARV drugs except tenofovir (TFV) 
were measured in the laboratory at Children's National Medical Center, which is an 
accredited member of the of the International Quality Control Program for 
Therapeutic Drug Monitoring in HIV infection (University Medical Center Nijmegen, 
Nijmegen, The Netherlands).12,13 A published tandem-mass spectrometric method 
with an Applied Biosystems/Sciex API-2000 (Foster City, CA) was used.14-16 The 
lower limit of quantification was 10 ng/ml. TFV was measured at the University of 
Southern California using an API 3+ tandem-mass spectrometer coupled to an 
Agilent 1100 liquid chromatography system (Santa Clara, CA). Samples were 
extracted using methanol. The lower limit for TFV quantification was 10 ng/ml. For 
both assays, within-run error was below 7% and between-day error was below 10% 
for all analytes at the tested concentrations.  
 
Noncompartmental PK techniques were used to analyze individual concentration 
data. Area under the drug time-concentration curve (AUC) was calculated using the 
standard trapezoidal approximation implemented in the freely available statistical 
package "R" (Version 2.10, available at www.rproject.org). Drug clearance was 
calculated using the formula clearance = dose/AUC∞, where AUC∞ is the sum of the 
observed AUC up to the last sample time, t, and an extrapolated AUC from time t to 
infinity. The latter is calculated from the last two or three observed concentrations in 
the terminal elimination phase after drug absorption is largely complete. Adult 
reference values for all drugs included in this report are in Table 1. All plots were 
generated using R.  
 
Table 1 Reference adult PK ARV values  
Drug Dose 
(mg) 
Cmax  
(ng/ml) 
Tmax  
(hours) 
Cmin 
(ng/ml) 
AUC 
(ng*h/ml) 
CL 
(l/h) 
Reference 
Abacavir 300 3090 0.75 18 6080 51 50, 51, PI 
Tenofovir 300 326 2.3 41 3020 131* 52, 53, PI 
Efavirenz 600 4072 3 - 5 1640 58,085 10* 54, PI 
Atazanavir 400 2298 2 120 14,874 25 55, PI 
Lopinavir 400 9800 4 5500 92,600 6 PI 
Amprenavir 1200 7600 1 1480 17,700 20 PI 
Ritonavir 100 500 4 320 3580 19 56,57, PI 
* Calculated 
PK – pharmacokinetic; ARV – antiretroviral; Cmax – maximum drug concentration; Tmax – time of 
maximum concentration; Cmin – minimum drug concentration; AUC – area under the concentration-
time curve; CL – clearance; PI – package insert. Values for atazanavir are those for unboosted dose, 
i.e., without ritonavir; values for lopinavir are when given with ritonavir as a coformulation. 
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CYP2B6 genotypes were determined using polymerase chain reaction amplification 
followed by allelic discrimination assays based on the use of fluorogenic 
oligonucleotide probes (TaqMan) and direct sequencing analysis performed on ABI 
Prism 3130 Genetic Analyzer at the Department of Clinical Chemistry, Erasmus 
Medical Centrum, Rotterdam, The Netherlands.  
  
 
RESULTS 
Scenario 1: Therapeutic drug monitoring in a patient with treatment failure  
Patient A was a 13-year-old obese black girl (Tanner Stage IV) with perinatally 
acquired HIV infection, Centers for Disease Control and Prevention category B3. Her 
medical history was significant for poststreptococcal glomerular nephropathy 
(resolved), familial obesity, and mild lipodystrophy with slightly elevated cholesterol 
and triglycerides. Her mother died from AIDS, and the patient was living with her 
maternal grandmother and two siblings, both of whom were also HIV-infected. She 
has been disclosed about her HIV status since the age of 12 years. She had a 
history of multiple nucleoside reverse transcriptase and nelfinavir resistance 
mutations by the age of 11.5 years. At the age of 12 years, she was placed on a 
new regimen of atazanavir (ATV) boosted with low-dose ritonavir (RTV), nevirapine 
(NVP), abacavir (ABC) and tenofovir disoproxil fumarate (TDF). Throughout the next 
12 months, a progressive decline in CD4+ cell count and an increase in HIV RNA 
viral load were observed. 
 
Despite the immunologic and virologic evidence of treatment failure, both the 
patient and her caregiver consistently reported 100% adherence on joint and 
separate interviews. However, all random plasma ARV drug concentrations obtained 
during routine clinic visits were undetectable. The patient enrolled in our 
optimization of ART study with the CD4+ count of 18% (292 cells/mm3) and HIV 
RNA of 50,600 copies/ml.11 During the first 12-hour study visit, the patient again 
reported 100% adherence at home and was observed by staff to take all five 
medications with a glass of water after a light standardized snack. All ARVs (ABC, 
TFV, ATV, RTV, and NVP) were undetectable in the plasma and paired saliva (TFV 
not measured in saliva) predose sample and in six paired samples obtained over 12 
hours after the observed intake. Potential sample processing and laboratory errors 
were thoroughly investigated and not found. The patient denied the use of herbal 
preparations or concomitant medications except for the use of loratidine (Claritin, 
Merck & Co., Inc., Whitehouse Station, NJ) on an as-needed basis, which was not 
administered in the 24 hours before study. The findings were discussed with the 
family and the patient and it was mutually agreed to repeat the 12-hour PK study, 
which was performed 24 weeks later. During this period, the NVP therapy was 
discontinued as a result of a newly identified resistance mutation (Y181C).  
 
As previously, during the second 12-hour PK study, 100% adherence to ARV 
medications was reported by the caregiver and the patient. The concentrations of all 
ARVs were again undetectable in the plasma, whereas the saliva concentrations of 
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ABC were detectable at 1, 2, 4, and 8 hours (757, 545, 365, and 18 ng/ml, 
respectively). The study and clinical teams, including a treatment adherence 
specialist, social worker, nutritionist, and psychologist, reviewed the results and 
concluded that the evidence overwhelmingly supported either self-induced emesis 
or oral retention of the medications without swallowing. With the patient and 
caregiver's agreement, the TDM after an observed intake of the medications 
followed by 2 hours of close supervision (the patient was never left alone by the 
clinic nurse) was conducted during a routine clinic visit. The plasma concentrations 
of ABC (2105 ng/ml) and ATV (290 ng/ml) were detectable 2 hours after observed 
intake with supervision and yet RTV concentrations were still undetectable. The 
results of all PK and TDM studies were discussed with the patient and the caregiver, 
and they both denied the possibility of self-induced emesis while continuing to insist 
on 100% adherence. The family agreed, however, to a psychology evaluation and 
additional adherence interventions, which included phone call reminders, pill boxes, 
partial directly observed therapy (DOT), and financial rewards. During psychologic 
counseling, the adolescent girl admitted that she was very concerned with a 
potential ART-associated increase in her obesity and did not like swallowing the 
pills.  
 
After a further 24 weeks of counseling and adherence interventions, the positive 
feedback from the family and team assessments suggested that adherence to the 
ARV regimen had improved. Based on the low ATV/RTV concentrations at 2 hours 
postdose (references are shown in Table 1), the ATV/RTV dose had been increased 
to 600/200 mg and a third 12-hour PK study was conducted 5 weeks after ATV/RTV 
dose adjustment. (Figure 1). Although all administered ARVs were measured in 
plasma, RTV was not detected in plasma or saliva (Table 2).  
 
Table 2 The PK parameters of ARV medications in Patient A 
Drug Dose  
(mg) 
Cmax  
(ng/ml) 
Tmax  
(hours) 
AUC∞  
(ng*h/ml) 
CL  
(l/h) 
12-hour PK study with increased dose ATV/RTV 
 Abacavir 300 2590 1.2 9231 32.5 
 Tenofovir 300 257 1.2 2313 129.7 
 Atazanavir 600 2610 4.2 23,611 25.4 
 Ritonavir 200 0 - 0 - 
12-hour PK study with standard dose LPV/RTV 
 Abacavir 300 1970 1.1 8722 34.4 
 Tenofovir 300 386 1.1 2013 149.0 
 Lopinavir 400 18,100 8.2 276,959 1.4 
 Ritonavir 100 565 8.2 4190 23.9 
PK – pharmacokinetic; ARV – antiretroviral; Cmax – maximum drug concentration; Tmax – time of 
maximum concentration; AUC – area under the concentration–time curve; CL – clearance;  
RTV – ritonavir; LPV – lopinavir.  
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Figure 1 Area under the concentration–time curve of the standard dose abacavir, tenofovir, and 
high-dose atazanavir/ritonavir (600 mg/200 mg) in Patient A. 
 
 
Figure 2 Area under the concentration-time curve of the standard dose abacavir, tenofovir, and 
lopinavir/ritonavir in Patient A. 
 
As a result of persistent virologic failure and concerns for nonadherence to RTV as a 
separate pill, after the PK study, the patient was placed on a new regimen with 
ABC, TDF, and lopinavir/ritonavir (LPV/RTV; Kaletra®, Abbott, Abbott Park, IL), and 
the fourth 12-hour PK study after 10 weeks was performed (Figure 2). This PK 
study demonstrated normal PK parameters for all measured ARV medications 
including RTV (Table 2). Nonetheless, during routine clinic follow-up, the 
undetectable random LPV/RTV plasma concentrations (on two separate 
measurements), small (less than 1 log) decline in HIV RNA and continued decline in 
CD4+ cells prompted the arrangement of the full-time DOT with 30 minutes close 
Chapter 9 
 
122 
observation after the dose intake. With DOT, the patient maintained a detectable 
random plasma concentration of LPV (10,760 ng/ml) and achieved undetectable HIV 
RNA (less than 400 copies/ml) within 12 weeks.  
 
Unfortunately, after 6 months of vigorous DOT, the family grew tired of the effort 
and the ART intake again became unsupervised, which led to undetectable LPV 
plasma concentrations and recurrent treatment failure. During our recent discussion 
of adherence, the patient (now 17 years old) openly admitted that she finds 200-
mg Kaletra® tablets too difficult to swallow and was switched to 100-mg tablets. 
Further considerations are given to the return to DOT, repeat psychologic 
counseling, and new classes of ARV drugs.  
 
Scenario 2: Therapeutic drug monitoring in patients with excellent virologic 
suppression  
Patient B was a 13-year-old black boy (Tanner Stage III-IV) with perinatally 
acquired HIV, Centers for Disease Control and Prevention category B3, and history 
of excellent adherence. His medical history included lymphocytic interstitial 
pneumonitis, herpes zoster, and failure to thrive. At the age of 6 years, he was 
placed on the ART regimen with stavudine, efavirenz (EFV), and amprenavir, which 
remained unchanged for more than 7 years. Since the initiation of this regimen, he 
had maintained an undetectable HIV viral load (less than 400 copies/ml and later 
less than 48 copies/ml) and stable CD4+ cell counts greater than 500 cells/mm3 
(25% - 30%).  
 
Random TDM plasma samples obtained during routine clinic visits demonstrated 
high concentrations of EFV (21,000 ng/ml) and low concentrations of amprenavir 
(29 ng/ml) (references are shown in Table 1). The patient enrolled in the 
optimization of ART study11 and had the 12-hour PK study. Before the release of the 
results of the PK study, his medical provider increased his EFV dose from 400 mg to 
600 mg based on his weight. Subsequently, when the plasma EFV exposure was 
found to be high on the first PK study, he underwent a second confirmatory PK 
study at the higher EFV dose (Table 3). Despite the extremely high EFV exposure 
(Figure 3), at no time did the patient demonstrate any evidence of clinical or 
laboratory toxicity, including sleep patterns, energy levels, liver enzymes, amylase, 
lipase, and lipids. Nonetheless, concern for possible long-term adverse effects of 
continued high EFV exposure and a documented CYP2B6 516 TT "slow metabolizer" 
polymorphism prompted reduction of his EFV dose to 200 mg daily, 33% of the 
recommended dose for his weight. The final, abbreviated PK study on 200 mg EFV 
once daily is also shown in Figure 3, whereas the summary of PK values for all three 
doses of EFV are represented in Table 3. Subsequent random plasma concentrations 
at 9 to 11 hours after unobserved 200-mg doses at home ranged between 2790 to 
4200 ng/ml. In addition to high EFV exposure, at his first PK visit, the patient was 
found to have negligible concentrations of amprenavir (C0 = 20 ng/ml; C0.5 = 20 
ng/ml; C1 = 25 ng/ml; C2 = 42 ng/ml; C4 = 15 ng/ml; C8 = 11 ng/ml; C12 less than 
10 ng/ml). The results of the PK study prompted a change of his ART to lamivudine 
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and ABC as Epzicom® (GlaxoSmithKline, Research Triangle Park, NC), TDF, and EFV 
at doses discussed previously. The patient maintained full virologic suppression 
(HIV RNA less than 48 copies) at 52 weeks after the change in EFV dose.  
 
Patient C was a 14-year-old black boy with perinatally acquired HIV, Centers for 
Disease Control and Prevention category N-2, and a history of excellent adherence 
and virologic suppression. From 4 to 12 years of age, he was treated with 
stavudine, lamivudine, and NVP. At the age of 12 years, secondary to the request 
for once-daily dosing of ART, his regimen was switched to a fixed-dose combination 
tablet containing 600 mg EFV, 300 mg TDF, and 200 mg emtricitabine (Atripla™, 
Bristol-Meyers Squibb, Princeton, NJ). Three months after starting this new 
regimen, the patient reported headache and diarrhea, and also reported a rash, but 
all symptoms resolved within another 3 months. No toxicities on laboratory findings, 
including liver enzymes, amylase, lipase, and lipids, were detected.  
 
TDM during routine clinic visits revealed high plasma EFV concentrations ranging 
from 22,400 to 23,400 ng/ml at 10 to 11 hours after reported intake (references 
are shown in Table 1). Interestingly, high random NVP plasma concentrations (up to 
15,120 ng/ml) were also found during routine TDM in the past but were used only 
as a proof of adherence at that time. Based on these results, the CYP2B6 genotype 
was ordered and a 12-hour PK study was conducted in the clinic after unobserved 
dose intake, which was documented on the phone by the clinic nurse the night 
before the clinic visit. The EFV plasma concentrations were measured at 12, 14, 16, 
20, and 24 hours after the intake and confirmed high EFV exposure (Figure 4), 
whereas the patient genotype confirmed CYP2B6 516 TT polymorphism. Based on 
the results of the pharmacogenetic analysis and PK data, the therapy with fixed-
dose TDF/emtricitabine/EFV was discontinued and was replaced with the smaller 
dose of EFV (200 mg) in combination with TDF/emtricitabine (Epzicom®). Full 
virologic suppression (HIV RNA less than 48 copies) was maintained at 52 weeks 
after the change in EFV dose and two random concentrations measured on different 
days at 22 and 24 hours after unobserved dose intake at home were 1.8 and 1.3 
mg/l, respectively (references are shown in Table 1). 
 
Table 3 The PK parameters of three different doses of efavirenz in Patient B 
Drug Dose  
(mg) 
Cmax  
(mg/l) 
Tmax  
(h) 
AUC∞  
(mg*h/l) 
CL  
(l/h) 
Efavirenz 200 6.03 2 147 1.4 
Efavirenz 400 27.76 0.5 1875 0.2 
Efavirenz 600 27.50 0.5 1155 0.5 
Cmax – maximum drug concentration; Tmax – time of maximum concentration; AUC – area under 
the concentration-time curve; CL – clearance. 
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Figure 3 The summary of three 12-hour pharmacokinetic studies with three different doses of 
efavirenz (EFV) in Patient B. 
 
 
Figure 4 The summary of the pharmacokinetic parameters with two different doses of efavirenz 
(EFV) in Patient C. 
 
 
DISCUSSION 
TDM in HIV-infected adolescents has similar indications to adults and is primarily 
used to monitor the adherence to ART, evaluate the cause of treatment failure, and 
to manage drug–drug interactions. Depending on the availability of a TDM 
consultant and the acceptance of TDM in clinical practice, the use of ART TDM may 
extend to optimization of the ARV dose by targeting specific trough concentrations 
or ratios of trough concentration and viral susceptibility (i.e., inhibitory quotients). 
Several investigations have demonstrated the benefits of incorporating TDM into the 
Can TDM Improve Pharmacotherapy of HIV Infection in Adolescents? 
 
125 
clinical management of HIV infection.2,3 Very few studies, however, have evaluated 
the benefits of measuring ARV concentrations in HIV-infected adolescents and 
young adults.17 Our cases represent a summary of some of the diverse applications 
of TDM in the management of the pharmacotherapy of ART in adolescent patients. 
We have selected three patients, one of whom represented currently accepted 
clinical indications for the use of TDM, whereas two others would have not been 
considered for the application of TDM under current standard of care.  
 
The first scenario describes a challenging case of an adolescent patient with 
consistently reported 100% adherence despite the evidence of treatment failure. 
The high level of adherence was not only stated by the patient, but was also 
confirmed by the dedicated adult primary caregiver who also provided ART to twin 
siblings with HIV infection who are 3 years younger than Patient A. Both of these 
siblings have consistently demonstrated high levels of medical adherence, which 
has been confirmed by TDM and clinical outcome. In addition, Patient A had been 
fully aware of her HIV status since 12 years of age and had regularly participated in 
the treatment discussions. Despite the fact that some form of nonadherence had 
been long suspected by the clinical team, none of the involved home and medical 
providers foresaw her practice of withholding medications in the mouth and spitting 
them up until documented through TDM. The first and second PK studies confirmed 
the absence of the ARV drugs in plasma samples after an observed intake. The 
absence of the ARV saliva concentrations in the first study was likely related to 
prompt spitting up of the medications after intake. During the second PK study, the 
patient was detained for approximately 10 minutes by the nurse despite her urge to 
use the bathroom right after taking the medications, which could be responsible for 
the detectable concentrations of ABC in saliva. We speculate that the patient either 
swallowed the medications and induced subsequent emesis or retained the 
medications in her mouth without the staff noticing and discarded them after a 10-
minute delay. It is plausible that capsule preparations of ATV and RTV were less 
likely to start dissolving in saliva than ABC tablets, and therefore the detectable 
concentrations of ABC in saliva were found after holding the medications in the 
mouth before spitting them up (TFV was not measured in saliva).  
 
The results of the first two PK studies prompted more open, evidence-based 
discussion than previously possible with Patient A and family members involved in 
her care. An assumption of the behaviorally motivated nonadherence without the 
evidence would have had the potential to disrupt the patient and caregiver liaison 
with the medical team. Even after psychologic counseling, Patient A clearly had 
selective acceptance of ARV drugs, as demonstrated by the repeat PK study with 
increased dose of ATV/RTV. The only 12-hour PK study, which documented the 
presence of ATV, demonstrated adequate concentrations of ATV with increased dose 
(ATV/RTV = 600 mg/200 mg) and the absence of RTV in plasma samples. The PK 
parameters of ATV perfectly fit the PK of the unboosted ATV and, together with 
absent RTV in plasma, provide strong evidence for continued oral withholding of 
RTV dose by the patient despite close observation by the medical staff at the 
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General Clinical Research Center. The therapy with an unboosted ATV regimen is 
not recommended in treatment-experienced pediatric patients with pre-existing 
protease inhibitor mutations, because ATV resistance can develop through 
mutations associated with resistance to other protease inhibitors instead of through 
the ATV associated I50L mutation.1 Once placed on a fixed-dose coformulated 
boosted protease inhibitor (Kaletra®), Patient A demonstrated normal absorption 
and PK parameters for RTV.  
 
HIV-infected adolescents face multiple adherence challenges during their transition to 
adulthood: in addition to palatability issues, pill burden, and interference of ART with 
lifestyle, adolescent patients with HIV experience growing independence, increased 
peer pressure and fear of stigmatization, increased risk-taking behavior (including 
substance abuse), denial and fear of HIV infection (particularly after witnessing the 
death from HIV like in our Patient A who lost her mother to AIDS), a long history of 
poor adherence and nondisclosure issues in perinatally infected patients, and 
psychiatric problems (depression, anorexia).9,18-21 In our recent study, we have 
shown that adolescents (13 - 18 years old) were significantly less likely to reach 
undetectable HIV RNA than younger children (younger than 13 years old) (odds 
ratio = 0.38; 95% confidence interval: 0.16 - 0.89).22 For every year increase in age, 
the odds of reaching undetectable viral load (VL) decreased by 10% after controlling 
for self-reported adherence and medications refill mechanism. Although considered to 
be ready to assume the responsibility for adherence to an appropriate administration 
of their ARV medication, many adolescents lack social and financial autonomy, 
privacy, and mobility and generally will decrease their adherence to ART.23 A 
comprehensive assessment of adherence through multiple indirect methods (self-
report, caregiver report, pill count, pharmacy refills) should be incorporated into the 
management of every adolescent patient with HIV infection. Although patient and 
caregiver reports are the main adherence measurement used in the majority of 
clinical setting,20,24 TDM is the only direct measure of verifying the patient compliance 
because all other methods do not prove the actual intake of ARV drugs.  
 
Studies have shown that it is crucial to take the evolutionary nature of the 
caregiver's and the child's coping process into account when integrating adherence 
to ART into children's daily lives.25 The care team should work continuously and 
concomitantly on three factors: knowledge, capacity, and motivation. In the case of 
Patient A, TDM has allowed us to identify a cause of nonadherence in a form of a 
very complex behavioral pattern with selective acceptance of ARV medications. The 
TDM evidence created grounds for the motivation of the patient and the family and 
their cooperation with the implementation of DOT. Although the adherence 
problems in this young woman are far from being solved, the success of the 
previous TDM-based interventions allows us to continue our work with her and her 
family to explore further strategies to increase her ART adherence.  
 
According to the current TDM guidelines, the measurement of the ARV drug 
concentrations would have not been indicated in the second scenario with Patients B 
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and C as a result of the excellent virologic suppression and immunologic status with 
EFV-based ART. Doses that result in excessive plasma drug concentrations are 
unlikely to be detected unless and until clinical toxicity develops, and without TDM, 
dose-dependent vs dose-independent toxicity cannot be distinguished.5 EFV is 
extensively metabolized by CYP2B6 with partial involvement of CYP3A4 and 
CYP2A6.26-29 The CYP2B6 G to T polymorphism at position 516 has been associated 
with elevated EFV plasma concentrations and an increase in neurotoxicity in adults 
and children.30-33 Most recently, the CYP2B6 983T>C and CYP2A6 genotypes have 
also been reported to affect EFV plasma concentrations.34-36 High EFV plasma 
concentrations and successful CYP2B6 genotype-based EFV dose reduction were 
demonstrated in adults with the haplotypes CYP2B6 *6/*6 (516G>T, 785A>G) and 
*6/*26 (499C>G, 516G>T, 785A>G).37 Genotype CYP2B6-based dose reduction 
has also been proposed in several population PK models.38,39  
 
The identification of the high EFV exposure in our patients led to pharmacogenetic 
evaluation and confirmation of the "slow metabolizer" type of CYP2B6 
polymorphism. Moreover, the lack of dose proportionality in EFV AUC observed in 
Patient C indicates that at the two higher doses, the PK behavior of EFV could best 
be described as Michaelis-Menten or zero-order elimination. Michaelis-Menten PK 
occurs when clearance mechanisms become saturated and a constant amount of 
drug, rather than a constant fraction, is eliminated per unit time. The implications of 
Michaelis-Menten PK are that clearance becomes dose-dependent (Table 3) and 
small changes in dose can result in large changes in plasma concentration, as was 
observed when the dose was reduced by 50% from 400 mg to 200 mg daily, yet 
the AUC dropped by more than 90% (Table 3). Note that at all doses, the observed 
clearance was still well below the referenced adult values (Table 1). To our 
knowledge, this is the first description of Michaelis-Menten EFV PK associated with 
CYP2B6 "slow metabolizer" polymorphisms.  
 
Although the successful dose reduction of EFV has been described in adults and a 
single report in an adolescent patient, to our knowledge,40,41 this is the first report 
of successful reduction of the EFV dose in two black adolescent patients based on 
the CYP2B6 genotype in combination with PK evaluations. The CYP 2B6 516 G>T 
polymorphism is significantly higher in sub-Saharan Africans (45.5%) and blacks 
(46.7%) as compared with Hispanic (27.3%), European (21.4%), and Asian 
(17.4%) populations.42-44 In addition to the CYP2B6 516 G>T polymorphisms, the 
DNA samples for both patients were analyzed for the presence of CYP 2B6415>G, 
785A>G, 983 T>C and 1459 C>T polymorphisms. Patient C had CYP2B6 785GG 
polymorphism in addition to the CYP 516 TT genotype, suggesting the presence of 
the haplotype CYP2B6 *6/*6 (516G>T, 785A>G) associated with the "slow 
metabolizer" profile for EFV.37 Patient C had also a history of high NVP exposure 
caused by his CYP2B6 polymorphism.45 However, the plasma NVP concentrations 
were used only for the confirmation of adherence at that time. Interestingly, 
although both patients and their families recalled that children experienced 
transient sleep problems shortly after the initiation of EFV therapy, their high EFV 
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exposure did not prompt treatment discontinuation. This is consistent with recently 
published data on the lack of association between CYP2B6 genotype and EFV 
plasma concentrations and the risk of EFV discontinuations because of 
neurotoxicity.46,47 Equally, no other EFV-associated toxicities were identified in both 
patients, particularly in Patient B with more than 7 years of high EFV exposure. This 
patient was placed on the combination ART with EFV coadministered with APV 
before the wide acceptance of boosted fos-APV into pediatric practice. EFV has been 
reported to decrease the Cmax, AUC, and Cmin of unboosted APV by approximately 
40% in adults; however, this effect of EFV is compensated by the PK booster effect 
of RTV when APV is combined with RTV.48 Although the treatment with EFV in 
combination with unboosted APV is not recommended, Patient B continued his 
regimen as a result of the excellent virologic and immunologic outcome. In reality, 
his high EFV concentrations produced an APV exposure so negligible that he can be 
considered to have been treated with dual (stavudine and EFV) therapy for a 
prolonged period of time (greater than 7 years). We would like to speculate that 
such a high degree of EFV exposure allowed him to avoid development of the 
K103N, Y181C, and other multinonnucleoside reverse transcriptase resistance 
mutations on the ART regimen with a single efficient nucleoside reverse 
transcriptase backbone.  
 
In summary, our experience suggests that TDM evaluation (when available) should 
be considered in HIV-infected adolescent patients on ART independently of the 
degree of virologic suppression and immunologic outcome. We recognize that many 
of the currently identified barriers to the routine application of TDM in pediatric ART 
(prolonged time for laboratory processing, difficulties in coordinating sample 
collections at appropriate times, limited availability of certified laboratories for ARV 
drug concentrations, lack of third party reimbursement of costs) were not 
experienced at our site. The extended PK analyses were provided through grant 
funding. However, routine TDM measurements during clinic follow-up are a well-
accepted standard of care in our program and we have not encountered difficulties 
in the reimbursement process. Clearly, through the availability of a dedicated 
pediatric General Clinical Research Center and inhouse laboratory, we were able to 
repeat the studies to eliminate significant limitations of ARV TDM such as high 
intrapatient variability from single drug concentration measurement.2,49 Finally, we 
hope that similar reports and randomized controlled studies will help to eliminate 
the most significant barrier to the successful TDM of ART such as inadequate 
information on safety and effectiveness of dose adjustment strategies in children 
and adolescents.  
 
 
CONCLUSIONS 
The physiological and psychosocial changes during puberty create strong grounds 
for an individualized therapeutic approach to an HIV-infected adolescent. 
Individualized, concentration-targeted optimal dosing of ARV medications can be 
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beneficial to patients for whom there are limited dosing guidelines. TDM of ARV 
drugs is useful in managing the pharmacotherapy of HIV in adolescent patients and 
is well received by the adolescent patients with HIV and their families. Among 
others, the benefits of TDM provide evidence for adherence interventions and create 
grounds for enhanced education of the adolescent patient and involved adult 
caregivers about ART. Finally, TDM in adolescents provides valuable information 
about the clinical pharmacology of ART during puberty. 
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ABSTRACT 
Objective 
The study was aimed to evaluate the relationship between pharmacy supply, self-
reported treatment adherence and HIV viral load in HIV-infected children.  
 
Methods 
A retrospective (52 weeks) cohort study was conducted through the review of the 
existing databases. Pharmacy supply was classified as "home delivery" when the 
medications were delivered home and as "in pharmacy pick-up" when they were 
picked up at the pharmacy. Adherence was assessed through retrospective (3 days 
recall) self-report. Fisher's exact model, univariate and multivariate logistic 
regression analyses were used. 
 
Settings 
The study collected data on 140 HIV-infected children (< 18 years). Adherence, 
pharmacy supply information and HIV viral loads were obtained from clinical and 
research databases. 
 
Patients 
The data from 127 HIV-infected children (60 boys and 67 girls; mean age 9.9 
years) were collected.  
 
Main outcome measures 
Complete adherence (100%) was reported in only 24% of patients. With 40% of 
patients being rarely or never completely adherent, 64% of children achieved 
undetectable viral loads during the study period.  
 
Results 
No association between pharmacy supply and self-reported adherence was found 
(P = 0.605). Selfreported adherence (P = 0.0328) and age (P = 0.025) were the 
significant predictors of reaching undetectable viral loads. Adolescents (> 13 years) 
were significantly less likely to reach undetectable viral loads than children under 13 
years (odds ratio 0.38; 95% CI 0.16 to 0.89).  
 
Conclusion 
In our study, pharmacy supply was not associated with self-reported adherence. 
Most importantly, adherence and age were significant predictors of reaching 
undetectable viral loads. 
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INTRODUCTION 
Combination antiretroviral therapy (ART) has led to dramatic changes in the clinical 
course of HIV infection in paediatric patients.1,2 High ART adherence is required to 
achieve a complete and sustained suppression of viral replication.3-5 Poor adherence 
leads to treatment failure, the development of viral resistance with subsequent 
reduction in treatment options, increased morbidity and mortality.3-6 In adult 
patients, the mean ART adherence has been reported to be between 80% and 91%, 
and multiple adherence barriers have been identified.6,7 In paediatric HIV-infected 
patients, ART adherence has been reported to be lower (58%),8,9 due to the 
combination of patient or caregiver factors including age and maturity-related 
tolerability and parental involvement.10-13 Several population-specific ART 
adherence barriers have been established in paediatric HIV such as dependence on 
a caregiver, poor palatability (particularly of liquid preparations), large pill size and 
pill swallowing capacity relative to the child's developmental stage.9,11  
 
While some of the barriers related to the patients' ability to tolerate and receive 
ART are difficult to change, others such as pharmacy supply can be modified 
through thoughtful evaluation and interventions by the providers, pharmacies and 
insurance companies. The examination of the relationship between pharmacy 
factors and treatment adherence in adults has shown the significance of pharmacy 
supply in patient adherence.14,15 Among pharmacy-related adherence barriers 
patients reported that either the pharmacy was out of the medication or the 
medications were not refilled in a timely manner.14 As children's access to ART is 
dependent on their caregivers, the efficient mechanism of medications supply and 
positive experience of the caregiver with the pharmacy may lead to increased ART 
adherence and improved outcome in paediatric patients with HIV.16,17 To date, no 
studies have been published on the effects of pharmacy factors on treatment 
adherence and outcome in HIV-infected children and adolescents.  
 
This study was conducted to characterise the methods of obtaining antiretroviral 
medications by caregivers and to evaluate the relationship between pharmacy 
supply, self-reported ART adherence and virological outcome in children and 
adolescents with HIV.  
 
 
PATIENTS AND METHODS 
This was a retrospective (52 weeks) cohort study of 140 HIV-infected paediatric 
patients (0 - 18 years old) treated at the Special Immunology Program at the 
Children's National Medical Center, Washington DC. The Special Immunology 
Program provides care to perinatally HIV-infected children and adolescents from 
Washington DC metropolitan area including suburban areas, and is a site of multiple 
clinical studies including the National Institutes of Health and industry-sponsored 
research. Paediatric HIV-infected patients are seen in the clinic every 3 months as 
routine follow-up. Patients are given verbal and written instructions on antiretroviral 
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medications at each clinic visit. The adherence assessment, pharmacy supply 
information and HIV-RNA viral load are routinely obtained as part of standard of 
care and clinical research studies. The majority of patients (95%) are black with 
approximately equal gender distribution. More than 90% of patients receive ART 
consisting of two nucleoside reverse transcriptase inhibitors and a single protease 
inhibitor (60%) or non-nucleoside reverse transciptase inhibitor (30%).  
 
The records of self-reported adherence, HIV-RNA viral load, and pharmacy use were 
reviewed in a retrospective follow-up of 52 weeks of clinic and research records. 
Patients without ART, with incomplete pharmacy and adherence information in the 
clinical and research databases, were not included. Parents/legal guardians enrolled 
in the research studies have consented to personal health information storage in a 
database for future HIV research. The protocol and the Health Insurance Portability 
and Accountability Act/Institutional Review Board (IRB) authorisation for waiver of 
consent were reviewed and approved by the IRB at the Children's National Medical 
Center.  
 
Self-reported adherence was assessed through interactive 3 days recall 
questionnaire-based interview by the clinic staff with the caregiver and older 
children (> 10 years of age) at routine clinic visit (every 3 months). During the 
interview caregivers and older children were asked about the medications names, 
dosing schedule, time of last dose, and the number of missed doses in the 3 days 
preceding the clinic visit (yesterday, 2 days ago and 3 days ago). They were also 
asked to identify adherence difficulties such as "forgetting", "running out of 
medications", "having difficulties taking the medications", "missing medications due 
to pharmacy-related factors" and "others". Three days recall was used since the 
available data suggest that patients or caregivers cannot accurately recall missed 
doses beyond a few dates.18 The history of pharmacy use was obtained from the 
clinical database, which contained information on the pharmacies used in the 
previous 12 months (including a history of problems or switching pharmacy), 
patient satisfaction with the pharmacy and the history of missing antiretroviral 
doses due to pharmacy errors or delays. Adherence was calculated as the number 
of all antiretroviral doses taken divided by the number of doses prescribed 
x 100(%) during the 72 h preceding the visit. The patients were graded into four 
categories based on the percentage of the 100% adherence reports (complete 
adherence) during the 52 weeks of follow-up: (1) always adherent (96 - 100% of 
visits completely adherent); (2) mostly adherent (50 - 95% of visits completely 
adherent); (3) rarely adherent (25 - 49% of visits completely adherent) and (4) 
never adherent (< 25% of visits completely adherent). The pharmacy supply was 
classified as "home delivery" (HD) when the caregiver received antiretroviral 
medications at home (through mail or personal delivery) and as "in pharmacy pick-
up" (IPP), when the caregiver picked up the medications at the pharmacy. HIV-RNA 
viral load (Roche Amplicor; Roche, Molecular Systems, Inc, Branchburg, New 
Jersey, USA) was considered to be undetectable with less than 400 copies/ml (the 
lowest limit of quantitation during the study period). The demographic 
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characteristics including race, sex and age of the subjects were collected. All 
analyses were performed using SAS version 8.2.  
 
Descriptive statistics, such as means and standard deviations were calculated for 
each continuous variable, and frequency distributions were generated for each 
categorical variable as appropriate. Frequency distribution characterised the 
pharmacy supply of obtaining antiretroviral medications (IPP vs HD). Fisher's exact 
tests were used to estimate the association between pharmacy supply and self-
reported adherence. Univariate and multivariate logistic regression analyses were 
used to estimate the association between pharmacy supply, selfreported adherence, 
age and virological outcome.  
 
 
RESULTS 
Data were collected on 127 paediatric patients with perinatally acquired HIV. There 
were 60 (47%) girls and 67 (53%) boys with a mean age of 9.9 years (SD 4.3) and 
the majority (n = 117; 93%) of patients was black. The mean number of visits per 
patient was 4.5 during the 52 weeks. Seventy-seven (61%) patients were children 
under 13 years, whereas 50 (39%) were adolescents (13 - 18 years old). Eighty-
one patients (64%) have achieved an HIV-RNA viral load of less than 400 copies/ml 
during the study period.  
 
A significant proportion of the children and adolescents reported suboptimal 
adherence during the study period (table 1). The majority of caregivers of 
adolescents (n = 29; 58%) used HD, whereas among the caregivers of younger 
children 36 (47%) used IPP. The caregivers of younger children were more likely to 
use the combination (IPP plus HD) supply than the caregivers of adolescents (8% vs 
2%, respectively). Interestingly, pharmacy factors as a barrier to adherence were 
reported more often among HD (n = 8; 67%) than IPP (n = 4; 33%) patients. A 
history of missing antiretroviral doses due to the pharmacy was more frequently 
reported among the patients who used HD (n = 14; 70%) than those who used IPP 
(n = 6; 30%).  
 
There was no association between pharmacy supply (IPP vs HD) and self-reported 
adherence (Fisher's exact test P = 0.605). Examination of the multivariate logistic 
regression to determine the association between pharmacy supply, self-reported 
adherence and virological outcome revealed the overall model as significant 
(P < 0.001). Moreover, adherence (P = 0.0328) and age (P = 0.025) were the only 
significant predictors of ever reaching an undetectable viral load during the study 
period (table 2). Adolescents (13 - 18 years old) were significantly less likely to 
reach an undetectable viral load than younger children (< 13 years old) (odds ratio 
(OR) 0.38; 95% CI 0.16 to 0.89). For every year increase in age, the odds of 
reaching an undetectable viral load decreased by 10% after controlling for self-
reported adherence and refill mechanism.  
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Those patients who chose a combination of IPP and HD were four times more likely 
to become undetectable (OR 3.85; 95% CI 0.38 to 38.58) than those who used HD; 
however, due to small numbers (n = 7), this association was not statistically 
significant. For every percentage increase in adherence, the odds of reaching an 
undetectable viral load increased by 3% after controlling for age and pharmacy 
supply.  
 
Table 1 Adherence to ART and characteristics of pharmacies and pharmacy supply used to   
      obtain antiretroviral medications for HIV-infected paediatric patients 
* Percentage of patients from those who switched pharmacy (out of 12 patients). 
 ART – antiretroviral therapy; HD – home delivery; IPP – in-pharmacy pick-up. 
 
 
 N = 127 (%) 
Self-reported adherence to ART  
 Always adherent (96 - 100%) 30 (24) 
 Mostly adherent (50 - 95%) 47 (37) 
 Rarely adherent (25 - 49%) 24 (19) 
 Never adherent (< 25%) 26 (21) 
Barriers  
 None 73 (58) 
 Forgetting 14 (11) 
 Pharmacy issues 12 (9) 
 Difficulties taking the drug 9 (7) 
 Running out of medication 8 (6) 
 Other  11 (9) 
Pharmacy Use  
 General pharmacy stores 69 (54) 
 Supermarket pharmacies  17 (13) 
 Specialty pharmacy  9 (7) 
 Provider pharmacy  7 (6) 
 Other pharmacies 25 (20) 
Pharmacy supply  
 IPP 56 (44) 
 HD 64 (50) 
 Combination IPP and HD 7 (6) 
History of pharmacy use   
 History of problem with pharmacy  7 (6) 
 Switched pharmacy in past year 12 (9) 
  (Switched due to problems with pharmacy) 3 (25)* 
 Missed medication due to pharmacy 20 (16) 
 Satisfied with pharmacy 115 (91) 
Evaluating Adherence to Medication in Children and Adolescents with HIV  
 
141 
Table 2 Association between age, self-reported adherence, pharmacy supply and the odds of  
      achieving undetectable HIV-RNA viral load (< 400 copies/ml) 
Variable 
  
Unadjusted OR  
(95% CI) 
Adjusted OR* 
(95% CI) 
Age 0.92 (0.84, 1.00) 0.90 (0.81, 0.99)† 
 Children (< 13 yrs old) 1.00 1.00 
 Adolescent (13 - 18 yrs old) 0.39 (0.18, 0.83)† 0.38 (0.16, 0.89)† 
Self-reported adherence 1.02 (1.01, 1.04)† 1.03 (1.01, 1.04)† 
 Never adherent (< 25%) 1.00 1.00 
 Rarely adherent (25 - 49%) 1.15 (0.38, 3.53) 1.01 (0.30, 3.40) 
 Mostly adherent (50 - 95%) 4.46 (1.59, 12.5)† 4.80 (1.58, 14.59)† 
 Always adherent (96 - 100%) 5.23 (1.59, 17.16)† 6.39 (1.81, 22.56)† 
Pharmacy supply    
 HD 1.00 1.00 
 IPP 2.00 (0.93, 4.29) 2.37 (1.00, 5.63) 
* Adjusted for all other variables in the model. † Statistically significant. HD – home delivery;  
IPP - in-pharmacy pick-up; OR - odds ratio. 
 
 
DISCUSSION 
Whereas the overall model of association between pharmacy supply, self-reported 
adherence and virological outcome in our study was shown to be significant, self-
reported adherence and age were the only significant predictors of ever reaching an 
undetectable viral load during the 52 weeks of the study period. Previous studies 
have demonstrated the complexity of adherence assessment in children and 
adolescents with HIV.19 Direct measures of adherence, such as therapeutic drug 
monitoring, are expensive and difficult to interpret due to limited knowledge of the 
pharmacodynamics of paediatric ART. Indirect methods (self-reports, electronic 
drug monitoring, refill verification) have disadvantages ranging from the accuracy of 
the data to cost and practicality issues.19 Our data support the use of interactive 
self-report as an efficient tool in assessing adherence in paediatric patients, despite 
a well-recognised potential for overreporting.19,20 We must acknowledge that the 
study was conducted within a well-established paediatric HIV program with vigorous 
adherence interventions, and adherence reports were collected through interactive 
interview with the caregivers and older children by familiar clinic personnel in a 
non-biased nonjudgmental style that has the potential to decrease the 
overestimation of adherence. The study also used repeated adherence assessments, 
with an average number of reports of 4.5 per study period instead of a single 
report, which increased the reliability of self-reports.  
 
In accordance with previously published studies, the higher level of adherence was 
significantly associated with the likelihood of reaching virological suppression when 
compared with a lower level of adherence. Rarely adherent (25 - 49%) and never 
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adherent (< 25%) patients were equally unlikely to achieve a viral load of less than 
400 copies/ml. 
 
The finding that adolescents were significantly less likely to reach an undetectable 
viral load than younger children in our study correlates with previously published 
data on the lower rates of ART adherence among HIV-infected youth.3,10 Although 
we acknowledge that the adolescents in the study had perinatally acquired HIV, 
were highly treatment experienced, and therefore had higher chances of HIV 
resistance and virological failure, we must recognise many additional obstacles to 
ART adherence emerging during puberty. Transition to adolescence by children with 
perinatally acquired infection leads to changes in lifestyle involving growing 
independence, separation from parental involvement, increased peer pressure and 
fear of stigmatisation, increased risk-taking behaviour, psychiatric problems and 
substance abuse.6,19-22 For providers and caregivers loss of adherence during 
puberty in adolescents with perinatally acquired HIV represents a difficult and 
emotional challenge that requires a team approach and close collaboration. While 
several strategies (directly observed therapy, regimen-related, education and 
counselling interventions) have been suggested to maximise ART adherence during 
this transition period,6,19-22 clinicians frequently seek guidance from research and 
practice in other paediatric chronic illnesses such as asthma, juvenile rheumatoid 
arthritis and type I diabetes mellitus. Given the lack of a well-defined adherence 
intervention model in adolescents with HIV, more research on adherence among 
HIV-infected youth with interdisciplinary collaboration is warranted. 
 
We recognise limitations of our study such as the retrospective study design, small 
sample size and lack of direct patient/caregiver interviews. In addition, all of the 
pharmacy information gathered from self-reports was not confirmed by the 
verification of refill histories. Other factors, such as drug resistance and treatment 
history, could account for the differences in reaching an undetectable viral load. In 
summary, self-reported adherence and age were the only significant predictors of 
ever reaching an undetectable HIV viral load during the 52 weeks of follow-up.  
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ABSTRACT 
Human immunodeficiency virus (HIV)-infected children are at risk of developing 
several types of renal diseases, including HIV-associated nephropathy (HIVAN), 
which is usually seen during late stages of infection in children with a high viral 
load. This disease is defined by the presence of proteinuria associated with 
mesangial hyperplasia and/or global-focal segmental glomerulosclerosis combined 
with microcystic transformation of the renal tubules. Because HIVAN can have an 
insidious clinical onset, renal biopsy is the only definitive way of establishing a 
diagnosis. Given the risk of performing this procedure in HIV-infected children with 
other AIDS-defining illness, we sought to identify informative biomarkers such as 
growth factors in the urine of 55 HIV-infected children that might be predictive of 
the extent and activity of the renal lesions characteristic of HIVAN. We found that 
the levels of epidermal growth factor were lower in the urine of children with renal 
disease, whereas levels of fibroblast growth factor-2 and metalloproteinase-2 were 
higher as compared with those levels in infected children without renal disease. 
Similar changes were observed in HIV-Tg26 mice correlating with the progression of 
renal disease in this model of HIVAN. Our findings suggest that this urinary growth 
factor profile may be useful in facilitating the diagnosis of HIV-infected children at 
risk of developing HIVAN when interpreted in the appropriate clinical setting.  
A Urinary Biomarker Profile for Children with HIV-Associated Renal Diseases  
 
147 
INTRODUCTION 
Childhood human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) is 
a renal disease (RD) defined by the presence of persistent proteinuria associated 
with mesangial hyperplasia and/or global-focal segmental glomerulosclerosis in 
combination with microcystic transformation of renal tubules and rapid progression 
to chronic renal failure.1-3 It is usually seen during the late stages of HIV infection in 
children with a high viral load. Black children show a unique susceptibility to 
develop this RD, and if the US data from the pre-HAART (highly active antiretroviral 
therapy) era were extrapolated to Africa,4 we speculate that approximately 300,000 
children without access to antiretroviral therapy could develop HIVAN. In addition, 
HIV-infected children can develop other RD or tubular toxicity secondary to HAART 
and other drugs.1-3 Thus, to prevent the severe complications associated with these 
RD, it is necessary to perform an early diagnosis, and the only way of establishing a 
definitive diagnosis of HIVAN is to make a renal biopsy. Given the risk of performing 
this procedure in HIV-infected children, it is necessary to find new biomarkers to 
identify children at high risk of developing HIVAN.  
 
In a recent study using a proteomic approach, we were unable to identify a single 
urine protein biomarker to identify children with biopsy-proven HIVAN.5 Here, we 
sought to determine whether growth factors released into the urine of children with 
HIV-RD reflect the extent and activity of the renal lesions characteristic of this 
disease. This approach is based on earlier studies showing a progressive 
accumulation of heparin-binding growth factors in correlation with the development 
of the renal microcystic tubular lesions that are a characteristic feature of childhood 
HIVAN.6-9 We found elevated urine levels of fibroblast growth factor-2 (FGF-2) and 
matrix metalloproteinase-2 (MMP-2), in association with reduced urine levels of 
epidermal growth factor (EGF) in children with HIV-RD. As these growth factors are 
involved in the processes of renal tubular regeneration and cyst formation,10-20 our 
findings suggest that this urine profile might be useful in identifying children 
undergoing the tubular interstitial and microcystic lesions characteristic of HIVAN.  
 
 
MATERIALS AND METHODS 
Patients 
Urine samples were collected from HIV-negative children (n = 28) and HIV-infected 
children (n = 56) who received regular clinical care at the Children's National 
Medical Center (CNMC) during the period between January 1995 and December 
2008. The study protocol and consenting documents were approved by the CNMC's 
IRB. All HIV-infected patients acquired HIV-1 from their mothers through vertical 
transmission, with the exception of one child who was infected through a blood 
transfusion in the perinatal period. Children ranged in age from 3 months to 19 
years with an approximately equal rate between male and females. Approximately 
94% of all children were African Americans, whereas the remaining patients were 
Caucasians, Asians, and Hispanics. The diagnosis of HIV-infection and AIDS was 
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based on the criteria established by the Center for Disease Control (CDC). The HIV-
infected patients were in the following CDC clinical categories: asymptomatic-A 
(~ 4%); mildly symptomatic-B (~ 52%), and severely symptomatic-C (~ 44%). All 
children received standard pediatric doses of antiretroviral therapy under the 
supervision of attending physicians with expertise in the treatment of HIV-infected 
children. The viral load (HIV-1 RNA PCR) was measured using standard laboratory 
assays at least every 6 months as part of routine clinical care.  
 
In seven patients (one child < 2 years, and six children > 2 years of age), the 
diagnosis of HIVAN was confirmed by renal biopsy. In two additional patients, the 
diagnosis of HIVAN was based on the following clinical findings: (1) presence of 
protein creatinine ratios > 0.2 mg/mg for more than 6 months; (2) enlarged 
echogenic kidneys with a typical clinical history of HIVAN; and (3) development of 
chronic renal failure during the longitudinal follow-up period. With the exception of 
one child, all urine samples harvested from children with HIVAN were collected when 
the blood urea nitrogen and serum creatinine levels were within the normal range. 
All samples were stored immediately at -70 °C, and processed whenever indicated.  
 
Urinary markers of renal injury  
The urinary protein and creatinine levels were confirmed using colorimetric assays 
from Wako Diagnostics (Richmond, VA) and R&D Systems (Minneapolis, MN), 
respectively. Cystatin C was measured using an enzyme-linked immunoabsorbent 
assay according to the manufacturer's instructions (R&D Systems). γ-Glutamyl 
transpeptidase and alkaline phosphatase were assayed following the procedures 
described by Chung et al.21 and adapted to microtiter plates. Lysozyme was 
measured as described by Shugar.22 Units of lysozyme/ml were determined 
following the Sigma quality control test for lysozyme.  
 
Urinary growth factors and metalloproteinases  
Urinary levels of EGF, FGF-2, MMP-2 and -9 were measured by enzyme-linked 
immunoabsorbent assay kits following the instructions of the manufacturer (R&D 
Systems). Gelatin zymography was performed with 10% SDS-polyacrylamide gels 
containing 1 mg/ml gelatine as described earlier.23 Urine samples were diluted 3:1 
with substrate gel buffer (10% SDS, 4% sucrose, 0.25M Tris-HCl, pH 6.8, and 0.1% 
bromophenol blue) and loaded immediately onto the gel without boiling.23 After 
staining the gels with Commassie Blue R-250, the gelatinolytic activity appeared as 
white bands of the corresponding molecular weight. Additional urine samples were 
incubated with an MMPs inhibitor 20 mM 1, 10-phenanthroline to inhibit the activity 
of MMPs.24 The zymography gels were then scanned with an Epson EP1670 scanner, 
Long Beach, CA, USA, using Adobe Photo Shop and results were expressed in 
arbitrary optical density (OD) units as OD/urinary creatinine ratios.  
 
Growth of cultured CV-1 cells 
CV-1 cells (American Type Culture Collection, Manassas, VA)25 were seeded at a 
density of 2.0 x 102 on 96-well plates, and exposed to urine samples harvested 
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from HIV-infected children with and without RD (10% urine diluted in Dulbecco's 
modified Eagle's medium supplemented with 1% fetal bovine serum and antibiotics 
(penicillin G, streptomycin sulfate, and amphotericin B) (Invitrogen, Grand Island, 
NY). To neutralize the activity of EGF in the urine, selected urine samples were 
preincubated with 30 µg/ml of EGF antibody for 1 h at 37 °C (R&D Systems). After 
96 h, cell growth was measured colorimetrically by absorbance at 490 nm using the 
Cell Titer 96 reagent (Promega; Madison, WI).  
 
HIV-Tg26 mice  
Human immunodeficiency virus-Tg26 mice carrying a defective HIV-1 proviral DNA26 
were used to confirm our findings. Urine and kidney samples were harvested in a 
sequential manner at 10, 25, and 60 days of life (n = 4 in each group) from WT 
littermate and HIV-Tg26 mice with and without RD. Urinary EGF-like activity was 
determined by doing binding displacement assays in cultured A431 cells exposed to 
125I-EGF (0.1 µCi/ng, DuPont-New England Nuclear, Wilmington, DE, USA) as 
described by Mesri et al.27 
 
Northern blots EGF analysis  
Total RNA was harvested from the renal medulla of mice at specific time points using 
guanidine-thiocyanate as described by Chirgwin et al.28 Total RNA (10 µg) was 
electrophoresed through formaldehyde-agarose gels and transferred to nitrocellulose 
filters. The filters were hybridized with the 754 bp (SmaI-PvuII fragment (bases 
2886–3639)) or preproEGF cDNA clone (pmeg10)17 as described by Horikoshi et al.14 
Blots were normalized by probing for the small ribosomal protein S14 (American 
Type Culture Collection, plasmid no. 59247) as described earlier.29 The collagenolytic 
activity of urine samples harvested from mice of 10, 25, and 60 days of age was 
assessed by gelatin zymography and quantified as described above.  
 
Statistical analysis 
Comparison between two groups was done with the Student t-test. P-values less 
than 0.05 were considered significant. When more than two means were compared, 
significance was determined by one way analysis of variance followed by multiple 
comparisons using the Student-Neuman-Keul's post hoc test. Non-normal data were 
either logtransformed before analysis or analyzed by the Kruskal-Wallis analysis of 
variance followed by Dunn's multiple comparisons post-test.  
 
 
RESULTS 
Renal tubular injury in HIV-RD  
As shown in Figure 1, we found elevated levels of cystatin C, γ-glutamyl 
transpeptidase (γ-GT), and lysozyme in a group of children with established HIV-RD. 
The urinary lysozyme levels were also significantly elevated in HIV-infected children 
with trace proteinuria (P < 0.05) (Figure 1a), suggesting that the brush border of 
renal proximal tubular cells was injured in these patients. On the basis of these 
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findings, we hypothesized that the urinary excretion of EGF, which is synthesized 
mainly by renal epithelial cells, would be reduced in children with HIVAN.  
 
Decreased urinary levels of EGF in children with HIV-RD 
To determine the urinary levels of EGF in HIV-positive and -negative children of 
different ages without RD, EGF was measured in the following groups of control 
children: (1) < 2 years of age, with functionally immature kidneys with respect to 
glomerular function; (2) 2 - 12 years of age, with functionally mature pre-
pubescent kidneys; and (3) > 12 years, with mature pubescent kidneys. No 
significant differences in urinary EGF levels were found between HIV-positive or 
-negative children of similar age without RD (data not shown). However, children 
< 2 years showed the highest urinary EGF levels when compared with all other age 
control groups (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Increased levels of urinary biomarkers of renal tubular injury in HIV-infected children 
with renal disease. Panels a-d show mean ± SEM values for cystatin C (a), γ-glutamyl-
transpeptidase (γ -GT) (b), lysozyme (c), and alkaline phosphatase (AP) (d) in urine samples 
harvested simultaneously from HIV-infected children without proteinuria (HIV-C; n = 10); trace 
proteinuria (HIV-T; n = 8); and established renal disease (HIV-RD; n = 9. Urine values were 
expressed as a urinary creatinine (UCR) ratio. P-values less than 0.05 were considered 
statistically significant. (* and # indicates a P < 0.05; **  indicates a P < 0.001 when compared 
to the HIV-C, and HIV-T groups, respectively).  
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Table 1 Average urinary levels of EGF, FGF-2 and MMP-2 in children without renal disease 
Control group age (years)* Biomarker 
< 2 2 - 12 > 12 
EGF/UCR (pg/mg) 96,045 ± 7751 *  40,238 ± 2,967 29,485 ± 6,468  
FGF-2/UCR (pg/mg) 5.86 ± 1.32 4.9 ± 1.14  2.33 ± 0.39  
MMP-2 (ng/mg) 2.93 ± 0.86  0.93 ± 0.23  1.10 ± 0.22  
EGF – epidermal growth factor; FGF-2 – fibroblast growth factor-2; MMP-2 – matrix metalloproteinase-2; 
UCR – urinary creatinine ratio.  
All values are expressed as the mean ± s.e. of the mean, and expressed as a ratio of the urinary 
creatinine value. (n = 8 - 24 children per group). Non-parametric analysis of variance * P < 0.05 
and 0.001 when compared with the EGF groups of children of 2 - 12 years and > 12 years of age, 
respectively. No statistically significant differences were found between the groups of children > 2 
years of age for EGF, FGF-2, and MMP-2 (P = 0.0648; 0.1716; and 0.5668, respectively). 
 
The urinary EGF concentration was significantly lower in children > 2 years with 
biopsy-proven HIVAN (n = 6), when compared with their corresponding age-
matched HIV controls and trace proteinuria groups (Figure 2a, P < 0.0001 and 
Figure 2b, P < 0.05). Moreover, two children < 2 years with HIVAN also showed a 
reduction in their urinary EGF levels of approximately 32 and 45%, relative to the 
mean values of age-matched controls. These changes were similar to the low values 
reported in children of similar age with congenital obstructive nephropathy.10 In 
summary, only one child within six children > 2 years with biopsy-proven HIVAN 
showed normal urinary EGF levels.  
 
Growth-promoting activity of EGF in urine samples harvested from HIV-
infected children  
As shown in Figure 2c, urine samples harvested from HIV-infected children with and 
without RD stimulated the growth of cultured renal tubular epithelial CV-1 cells by 
an average 88 and 145% (P < 0.001), respectively, when compared with the cells 
exposed to control media containing 1% fetal bovine serum. Moreover, urine 
samples harvested from children with HIVAN increased the growth of CV-1 cells by 
an average of 57.6% when compared with the control samples (P < 0.05) (Figure 
2c). EGF-neutralizing antibodies were able to suppress the growth-promoting 
activity of urine samples harvested from the HIV-infected controls (HIV-C; 
P < 0.001) and trace proteinuria (HIV-T; P < 0.01) groups, respectively (Figure 2d 
and e). In contrast, EGF antibodies failed to exert a complete growth inhibition of 
CV-1 cells exposed to urine supernatants harvested from children with HIVAN 
(P > 0.05) (Figure 2f). These data suggest that other growth factors that are 
present in the urine of children with HIVAN (that is, FGF-2), may act in synergy 
with EGF to enhance the proliferation of tubular epithelial cells in these patients.6-9 
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Figure 2 Decrease EGF levels in the urine of HIV-infected children > 2 years of age with HIVAN. 
Panel a shows the urinary EGF levels in controls (HIV-negative children without renal disease; 
n = 8); HIV-infected children without renal disease and low viral load (< 5000 copies/ml; HIV-LVC, 
n = 15); HIV-infected children without renal disease and high viral load (> 10,000 copies/ml; HIV-
HVC, n = 26); and children with biopsy-proven HIVAN (n = 6). Urine values are expressed as % 
change relative to the control group. Panel b shows changes in urinary EGF levels in HIV-infected 
children > 2 years of age without proteinuria (HIV-C; n = 10); trace proteinuria (HIV-T; n = 8); and 
biopsy-proven HIVAN (n = 6). Panels c - f show the urinary EGF-induced growth promoting activity 
in cultured CV-1 renal tubular epithelial cells. CV-1 cells were exposed for 96 h to urine samples 
harvested from HIV-infected children without proteinuria (HIV-C), trace proteinuria (HIV-T), and 
HIVAN as described in the Materials and Methods section. CV-1 cells exposed to 1% FBS media 
were used as controls. These experiments were made in the presence or absence of an anti-EGF-
neutralizing antibodies. Bars represent the mean ± s.e.m. P-values less than 0.05 were considered 
statistically significant. (* and # indicate a P < 0.05; ** and ## indicate a P < 0.001; *** indicates 
P < 0.0001 when compared to all other groups. when compared with the control alone and cells 
exposed to urine, respectively). All the experiments were performed in triplicate. 
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Increased urinary FGF-2 in children with HIVAN  
Children < 2 years show the highest urinary levels of FGF-2, but these changes 
were not statistically significant when compared with all other age control groups 
(Table 1). All children > 2 years with biopsy-proven HIVAN (n = 6) showed high 
abnormal urinary FGF-2 levels, when compared with their corresponding age-
matched HIV controls and trace proteinuria groups (Figure 3a and b). Similarly, in 
both children < 2 years with HIVAN, the urinary FGF-2 levels increased by an 
average of 2.5- to 11-fold over their age-matched controls, and above the normal 
values reported for children of similar age.18 
 
Increase urinary MMP-2 in children with HIVAN  
Children < 2 years showed the highest urinary levels of MMP-2, when compared 
with all other age control groups (Table 1). MMP-2 was elevated in the urine of 
children > 2 years with biopsy-proven HIVAN (n = 6) in comparison with their 
respective age-matched control (P < 0.001) and trace proteinuria (P < 0.05) groups 
(Figure 3c and d). In a similar way, urinary MMP-2 increased in both children < 2 
years with HIVAN by an average of 0.5- to 68-fold over their age-matched controls 
and above the normal values reported by others.13 Finally, no significant differences 
in the urinary levels of MMP-9 were detected between HIV-infected children in the 
control, trace proteinuria, and HIVAN groups, respectively (> 0.05) (Figure 3e). In 
summary, all children with biopsy-proven HIVAN showed abnormally elevated 
urinary levels of both MMP-2 and FGF-2 relative to their corresponding age-matched 
control groups.  
 
Gelatin zymographic analysis  
Figure 4a shows a representative gelatin zymographic analysis of urine samples 
harvested from HIV-infected children with and without RD, including seven children 
with HIVAN. The collagenolytic activity in these urine samples was inhibited in the 
presence of 20 mM 1, 10-phenanthroline, confirming the presence of 
metalloproteinases activity (Figure 4a). MMP-2 was detected as 72 and 64 kDa 
collagenolytic bands corresponding to the latent and active forms of this 
metalloproteinase.13 The activity of MMP-2 was increased in the urine of children 
with established RD relative to the control group (Figure 4b). MMP-9 was detected 
as 92 and 82 kDa collagenolytic bands corresponding to the latent and active forms 
of this metalloproteinase (Figure 4c). HIV-infected children with trace proteinuria 
and established RD showed an increased urinary MMP-9 activity; however, these 
changes were not statistically significant (Figure 4c).  
 
Progressive changes in urinary EGF, FGF-2, and MMP-2 levels in a child 
with biopsy-proven HIVAN  
As shown in Figure 5, the urinary levels of EGF in a child with HIVAN increased in 
correlation with the recovery of renal function in response to antiretroviral therapy 
(Figure 5a and b). In contrast, the urinary concentration of FGF-2 and MMP-2 
decreased in correlation with the recovery of renal function. However, the urinary 
levels of EGF, FGF-2, and MMP-2 remained within abnormal values throughout the 
follow-up period (Figure 5c and d).  
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Figure 3 Increase FGF-2 and metalloproteinase 2 (MMP-2) levels in the urine of HIV-infected 
children > 2 years of age with HIVAN. Panels a and c show changes in FGF-2 and MMP-2 urine 
values corresponding to controls (HIV-negative children without renal disease; n = 8); HIV-
infected children without renal disease and low viral load (< 5000 copies/ml; HIV-LVC, n = 15); 
HIV-infected children without renal disease and high viral load (> 10,000 copies/ml; (HIV-HVC, 
n = 26); and children > 2 years of age with biopsy-proven HIVAN (n = 6). Urine values are 
expressed as a % change relative to the control group. Panels b and d show changes in FGF-2 (b) 
and MMP-2 (d) urine values in HIV-infected children > 2 years of age without proteinuria (HIV-C; 
n = 10); HIV-infected children with trace proteinuria (HIV-T; n = 8); and HIV-infected children 
> 2 years of age with biopsy-proven HIVAN (n = 6). Panel e shows urinary levels of MMP-9 (e) in 
HIV-infected children of all ages without proteinuria (HIV-C; n = 10); trace proteinuria (HIV-T; 
n = 8); or established renal disease (HIV-RD; n = 9). This last group included seven children of 
all ages with biopsy-proven HIVAN. P-values less than 0.05 were considered statistically 
significant. (* and # indicate a P < 0.05 when compared with HIV-C, and HIV-T groups, 
respectively; ** and *** indicate P < 0.001 and P < 0.0001, respectively, when compared to all 
the other groups). 
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Figure 4 Representative zymographic analysis of urine samples harvested from HIV-infected 
children without proteinuria (HIV-C), trace proteinuria (HIV-T), and established renal disease 
(HIV-RD). Duplicate gels were subjected to incubation in the presence of 20 mM 1, 
10-phenanthroline, an MMP inhibitor. Panel a shows urinary zymograms of HIV-infected children 
with and without RD. Panels b and c show the mean ± s.e.m. collagenolytic activity values 
corresponding to MMP-2 (b) and MMP-9 (c). The results are expressed in arbitrary optical density 
units (OD) as a urinary creatinine (UCR) ratio (OD/UCR). HIV-C, n = 10; HIV-T, n = 8; and HIV-
RD, n = 9 (* and ** indicate P < 0.05 and 0.001 when compared with the HIV-C, respectively). 
 
Changes in EGF and MMPs expression in correlation with the development 
of RD in HIV-Tg26 mice  
As shown in Figure 6, representative urine samples harvested from wild-type (WT) 
littermate control mice showed an increased EGF-binding activity when compared 
with the samples corresponding HIV-Tg mice with severe RD (Figure 6a). When 
adjusted for the urinary creatinine concentration, EGF activity was approximately 
fivefold greater in the urine of WT mice relative to the urine of HIV-Tg mice with 
RD. In support of these findings, northern blots analysis showed a significant 
reduction of EGF mRNA expression of approximately one- to twofold in the renal 
medulla of HIV-Tg26 mice with early and late RD when compared with WT control 
littermate mice (Figure 6b). In a similar manner, the collagenolytic activity of MMP-
9 and MMP-2 was increased in the urine of HIV-Tg26 mice with RD by an average of 
10- to 50-fold, relative to WT and HIV-Tg26 mice without RD (Figure 6c). Finally, in 
an earlier study, we found a significant accumulation of FGF-2 in the kidney of HIV-
Tg26 mice with RD in association with the presence of the tubular microcystic lesions 
characteristic of HIVAN.9 Taken together, all these findings strongly suggest that 
the urinary profile of EGF, MMP-2, and FGF-2 changes in correlation to the 
progression of the renal tubulointerstitial and microcystic lesions characteristic of 
HIVAN.  
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Figure 5 Progressive changes in the urinary biomarker profile in a child with biopsy-proven 
HIVAN. Progressive changes in serum creatinine (SCr) and blood urea nitrogen (BUN) (a), EGF 
(b), FGF-2, (c) and MMP-2 (d) in urine samples collected from a child with biopsy-proven HIVAN 
treated successfully with antiretroviral therapy. Dotted lines indicate the expected average normal 
values for each measurement. 
 
DISCUSSION 
Childhood HIV-associated nephropathy is characterized by the presence of 
mesangial hyperplasia and/or focal segmental glomerulosclerosis in association with 
the microcystic transformation of renal tubules and rapid progression of the RD.1-3 
Earlier studies have shown that cytokines play a role in the development of these 
renal lesions.30-33 In the present study, we found a reduced excretion of EGF in the 
urine of children with HIV-RD in association with increased urinary levels of FGF-2 
and MMP-2, when compared with HIV-positive or -negative children without RD. 
Overall, six out of seven children of all ages with biopsy-proven HIVAN showed 
abnormal urinary values of all three candidate biomarkers in samples collected 
when their blood urea nitrogen and serum creatinine levels were still within the 
normal range. In contrast, none of the HIV-positive or -negative control children 
without RD or trace proteinuria showed abnormal urinary levels for all three 
candidate biomarkers. These findings suggest that the urinary profile of EGF, FGF-2, 
and MMP-2 may allow the identification of children at high risk of developing HIVAN. 
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Both EGF and FGF-2 are powerful mitogenic growth factors for renal tubular 
epithelial cells.14-20 They play important roles during renal development and in the 
pathogenesis of renal cystic disorders. EGF is predominately synthesized by renal 
tubular epithelial cells,14-17 and in the presence of renal tubular injury, its synthesis 
and release into the tubular lumen is expected to decrease. This notion is supported 
by the findings in HIV-Tg26 mice with RD, which showed a significant reduction in 
EGF mRNA expression in correlation with the presence of renal tubular injury and 
progression of the RD. A similar global reduction of mRNA and protein EGF 
expression was found by Horikoshi et al.14 in mice with polycystic kidney disease 
(cpk). EGF is needed for the normal growth and regeneration of renal epithelial 
cells,14-17 and we have confirmed that EGF present in the urine of HIV-infected 
children can stimulate the growth of cultured human renal tubular epithelial cells. 
However, as antibodies against EGF were unable to suppress the complete 
mitogenic activity of the urine samples harvested from children with HIVAN, other 
growth factors present in these urine samples (that is, FGF-2) might play a 
synergistic role with EGF in this process.6-9 In summary, taken in consideration all 
these findings, we propose that the progressive reduction in the urinary levels of 
EGF in HIV-infected children with RD reflect the presence of diffuse renal tubular 
injury characteristic of childhood HIVAN. In support of this notion, we have found 
that at least three markers of tubular injury, cystatin C, γ-glutamyl transpeptidase, 
and lysozyme, were elevated in the urine of patients with RD in correlation with the 
decreased EGF levels.  
 
Fibroblast growth factor-2 is a heparin-binding growth factor that lacks a classic 
signal peptide for secretion, but is released into the circulation by non-conventional 
pathways and injured endothelial cells.3,6-9,34 In an earlier study, we found elevated 
levels of FGF-2 in the plasma of children with HIVAN.6 In addition, we found an 
upregulation of heparan sulfate proteoglycans in the kidney of HIV-infected children 
and HIV-Tg26 mice with RD.6-9 Thus, renal heparan sulfate proteoglycans may act as 
a sink trapping FGF-2 and other heparin-binding growth factors from the circulation. 
In addition, renal tubular epithelial cells harvested from the urine of children with 
HIVAN produce and release high levels of FGF-2, as well as an FGF-binding protein, 
that facilitates the release of several members of the FGF's family, including 
FGF-2.7,8 These findings may explain the elevated levels of urinary FGF-2 in children 
with HIVAN. In support of this notion, HIV-Tg26 kidneys with RD show a significant 
accumulation of FGF-2 and FGF binding protein-1 in parallel binding protein1 in 
parallel with the decreased renal production of EGF mRNA and development of renal 
microcysts.8,9 We have earlier found that FGF-2 induces the proliferation of human 
renal epithelial and mesangial cells harvested from HIV-infected children,6 and 
systemic infusions of FGF-2 into rodents and monkeys induce mesangial 
hyperplasia, FGFS and/or microcystic transformation of renal tubules.35-40 In 
summary, these findings suggest that the accumulation of FGF-2 in the kidney of 
HIV-infected children may constitute a risk factor for the development of HIVAN. 
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Matrix metalloproteinases are metal-dependent enzymes that participate in the 
remodeling of extracellular matrix.12,13 In the kidney, the migration and 
transdifferentiation of renal tubular epithelial cells and fibroblasts is at least partially 
mediated by the proteolytic activity of MMPs, which degrade the renal basement 
membranes allowing the release of FGF-2 and the activation of growth factors 
bound to the extracellular matrix.11,12,39,40 The activity and excretion of MMP-2 is 
increased in a murine model of infantile-type polycystic kidney disease.12 Moreover, 
the expression of MMP-2 in cells harvested from patients with AIDS–Kaposi's 
sarcoma is induced by FGF-2,34 and increased levels of MMP-2 and FGF-2 are found 
in the urine of patients with AIDS-Kaposi's sarcoma or polycystic kidney 
diseases.40-42 Given the extent of renal tissue remodeling and microcystic changes 
in children with HIVAN, we speculate that FGF-2 and MMPs may play a similar role 
in the pathogenesis of HIV-RD. In support of this notion, we have found a 
consistent elevation of MMP-2 protein and activity in the urine of HIV-infected 
children with HIVAN and HIV-Tg26 mice in correlation with the accumulation of FGF-
2 and progression of the RD. Taken together, these findings may explain the 
synergistic increase in urinary FGF-2 and MMP-2 in children with HIVAN.  
 
We also found elevated levels of MMP-2 and/or MMP-9 in a few HIV-infected 
children without proteinuria. These findings are consistent with the results of other 
studies showing that both MMP-2 and MMP-9 can be detected in the urine of healthy 
children, probably in connection to the process of normal tissue growth and 
remodeling.43 However, the changes in MMP-2 activity seen in children with HIVAN 
can be clearly differentiated from all the other seen in HIV-infected patients. Of 
interest, earlier studies have shown that protease inhibitors can inhibit the activity 
of MMP-2 by blocking the conversion from its latent to the active form.44-46 On the 
basis of these data, we speculate that these drugs could have a potential beneficial 
effect in children with HIV-RD by blocking the activation of MMP-2.  
 
In conclusion, urinary levels of EGF, FGF-2, and MMP-2 might be useful to identify 
HIV-infected children undergoing the renal tubular interstitial and microcystic 
lesions characteristic of childhood HIVAN. It remains to be determined whether this 
urinary growth factor profile is specific for childhood HIVAN, or could be also found 
in HIV-infected children with other RD. A large multicenter clinical study will be 
needed to answer this question. Nevertheless, urinary biomarkers acquire their 
clinical value when interpreted in the appropriate clinical context. African-American 
children with HIVAN typically show enlarged echogenic kidneys and isolated 
proteinuria, which is responsive to HAART, in the absence of early-onset 
hypertension, hematuria, generalized edema, or acute renal failure.1-3 We have 
presented evidence that the urinary levels of EGF, FGF-2, and MMP-2 can also 
change in response to HAART. In contrast, other RD seen in HIV-infected children 
are less responsive to HAART and can be suspected by their clinical history and 
symptoms, the urinalysis, ultrasound findings, and their response to 
antihypertensive drugs or steroids.2 In summary, we propose that if the urinary 
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EGF, FGF-2, and MMP-2 profile is interpreted in the appropriate clinical context, it 
will facilitate the early identification of children at high risk of developing HIVAN. 
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EVOLUTION OF ANTIRETROVIRAL THERAPY IN PEDIATRIC HIV INFECTION 
Following the development of the first antiretroviral (ARV) drugs in the late 1980s, 
the treatment of pediatric HIV infection has evolved from monotherapy with 
zidovudine (ZDV), to dual therapy with nucleoside reverse transcriptase inhibitors 
(NRTIs) and subsequently to multi-drug therapy involving a combination of three or 
more ARV agents.1,2 This therapeutic evolution has allowed to decrease significantly 
the incidence of opportunistic infections and HIV-associated complications, prevent 
the detrimental effect of the HIV disease on growth and development, and achieve 
highly functional survival and improved quality of life in HIV-infected children and 
adolescents.3-5 The success of pediatric antiretroviral therapy (ART), however, 
comes with the price of managing chronic multi-drug therapy throughout the period 
of transition from infancy through early school and teenage years into young 
adulthood. With increased ART exposure among pediatric patients worldwide, the 
concerns for long-term ART adherence, ARV drug resistance and long-term ART 
associated toxicities, some of which are only now beginning to be investigated in 
children, have arisen. The choice of the most efficient and least toxic ART and 
optimal ARV drugs dosing at different stages of growth and maturation in children 
of diverse ethnic and racial background is challenging and requires ongoing efforts 
in producing high quality pharmacological pediatric data. 
 
Approval of pediatric ARV drugs 
Out of 22 ARV medications currently marketed for therapy of HIV infection, 16 are 
licensed in the United States for use in children younger than 16 years of age.2 The 
approval of ARV drugs in children by the FDA requires the submission of 24 week 
safety and tolerability data and the antiviral activity is accessed from non-
comparative data. A significantly smaller number of ARV drugs is approved for use 
in resource limited settings, primarily due to cost and availability considerations.6 As 
with any new therapeutic modality, the data guiding the dosing, efficacy and safety 
of ARV drugs for children have lagged behind the information for adults. With the 
lag of approval of new medications for children, off-label prescribing of ART in 
pediatric HIV-infected patients became a necessary and accepted practice. Off-label 
use of ARV medications for unapproved age groups at unapproved dosages and 
frequencies of administration has the potential to expose children to treatment 
failure and ARV associated toxicity. Fortunately, the era of ARV drug development 
coincided with significant changes in the legislative and regulatory initiatives for the 
pediatric drug approval process. While the majority of the NRTIs and first non-
nucleoside reverse transcriptase inhibitor (NNRTI) were evaluated prior to the Food 
and Drug Modernization and Administration Act (FDAMA) from 1997, the evaluation 
of the majority of the protease inhibitors (PIs) took place following the enacting of 
the Best Pharmaceutical for Children Act (BPCA) in 2002 and the Pediatric Research 
Equity Act (PREA) in 2003. The approval of pediatric dosing of the newer PIs, entry 
and fusion inhibitors, integrase inhibitors and C-C chemokine receptor type-5 
(CCR5) inhibitors is happening in the era after the Food and Drug Administration 
Amendments Act (FDAAA) of 2007 and EU Pediatric Regulation of 2007. In addition, 
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strong international advocacy efforts driven by the universal nature of the HIV 
epidemic, support by large international organizations such as the World Health 
Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS), 
quick availability of extensive federal and private funding, and industry interest in 
world size marketing, have contributed to early incorporation of pediatric trials into 
the development of ARV drugs.7 As a result, the evaluation and approval of age-
appropriate doses and regimens of ARV drugs in children made a relatively fast 
progress unlike many other therapeutic modalities such as pediatric tuberculosis 
drug development.8  
 
Principles of the development of pediatric ART 
The pediatric ARV dose development is aimed primarily to meet the HIV therapeutic 
exposure targets from adults while adjusting to the developmental changes in drug 
metabolism and disposition in children. A different dose strategy to match adult 
peak (Cmax), trough (Cmin) and area under the curve (AUC) exposure is required in 
pediatric populations.9 Acceptable mean/median differences and size of extreme 
values for the pharmacokinetic (PK) parameters need to be defined and optimized 
based on PK and pharmacodynamic (PD) knowledge. Most importantly, the 
differences in pediatric HIV infection need to be taken into consideration. Children 
are prone to rapid progression of failure to thrive and gastrointestinal illness with 
dehydration, both scenarios having the potential to affect the absorption and 
distribution of ARV drugs. The high impact of HIV viremia on neurocognitive 
development in young children makes central nervous system (CNS) penetration of 
ARV drugs more relevant in pediatric patients than in adults. Moreover, the HIV 
disease progression is more rapid in younger children and has different criteria for 
the initiation of ART.  
 
Developmental and disease specific parameters determine the design and 
development of pediatric ARV clinical trials.9 The most important considerations for 
pediatric ART study design are reflected in Figure 1. In very young infants, the 
difference in the HIV diagnostic tests (virologic vs antibody tests) between young 
infants and older children needs to be considered. PK evaluations through sparse 
blood sampling and limited blood volumes are particularly important in small 
children, especially in resource limited settings where co-morbidity and malnutrition 
are frequent causes of anemia. The exposure to maternal ART during the time of 
breastfeeding and its effect on drug metabolism and development of viral resistance 
in resource limited settings needs to be addressed. Finally, the inclusion of the 
pediatric expertise in the development of ARV clinical trials in children is crucial and 
can contribute significantly to the success of the study.  
 
Clinical trials of ART in children 
A significant number of clinical trials in HIV-infected children have been conducted 
by the pediatric HIV research networks and pharmaceutical industry since the late 
1980s. In the early era of the HIV epidemic and ARV development, when the 
treatment options were extremely limited, the design of ARV drug trials in adult and 
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pediatric patients was driven by the model of oncology studies with the concept of 
the maximally tolerated dosing. Single agent studies were conducted for the first 
NRTIs such as ZDV, didanosine (ddI) and lamivudine (3TC) in the late 1980s and 
early 1990s.9 (Table 1) NRTIs are subject to intracellular phosphorylation and have 
linear PK without cytochrome P450 (CYP450) associated induction or inhibition. The 
drugs from this class have a short plasma half-life and high inter- and intra-subject 
variability. Single dose PK usually serves as a good predictor of steady-state 
concentrations, however due to the intracellular metabolic pathway and relatively 
weak antiviral activity, the plasma concentrations serve as a poor biomarker of the 
clinical outcome. During the first stage investigations of ZDV monotherapy the 
limited understanding of the PD of HIV infection has led to high and frequent (5 
times a day) dosing which resulted in significant toxicity. The high rates of NRTI 
dose associated clinical and laboratory toxicities pushed the clinical trials toward the 
consideration of significantly lower doses which resulted in subtherapeutic exposure 
and increased HIV resistance. As a consequence, the pediatric trials of NRTIs have 
conducted most of the PK evaluation after a single dose and had a more than 10 
times dose range within the dose escalation module. As a result of those trials, the 
"effective doses" of NRTIs entered pediatric practice by mid 1990s, and only a 
handful of studies have re-evaluated those doses and dosing schedules since then. 
Among those is our study of the developmental changes in 3TC PK in a cohort of 51 
children with a median age of 8.4 years (1.7 to 18 years) receiving a standard 
recommended dose of 3TC.10 The age of 6 years appeared to be a cut-off for a 
change in PK of 3TC in this study, with children < 6 years of age having a median 
AUC 43% lower and a median Cmax 47% lower than older children. In line with these 
observations, clearance (CL/kg) and volume of distribution (Vd/kg) were 79% and 
89% higher in children aged 6 years or less when compared to children aged 7 
years and older. The mean Cmax and AUC in children ≥ 7 years were almost similar 
to the adult PK values. Moreover, the decreased 3TC exposure in younger children 
is potentially related to the development of M184V HIV mutation and resistance to 
3TC, and deserves further investigation. 
 
The majority of highly potent second generation classes of ARV drugs (NNRTIs and 
PIs) have been evaluated using concentration controlled clinical trials (PACTG P1039 
for lopinavir (LPV), P382 for efavirenz (EFV), and P1020 for atazanavir (ATV)).9 
(Table 1) Drugs from both classes of the medications are 
substrates/inducers/suppressors of the CYP450 enzymes and have complex drug 
interaction profiles. The relationship between plasma concentrations and viral 
efficacy is strong, and for some drugs (EFV) the relationship between plasma 
exposure and drug associated toxicity has been reported. The pediatric NNRTIs and 
PIs studies have used 1 - 2 dose levels and assessed the PK at steady state. These 
trials were the first to use combination ART with NRTI backbone and to address the 
optimization of the backbone regimen in patients with NRTI resistance. Therapeutic 
drug monitoring (TDM) was included in the majority of these studies. In recent 
years, the clinical trials have been evaluating the new classes of highly potent ARV 
drugs such as second generation PIs and NNRTIs, fusion inhibitors, integrase 
inhibitors and CCR5 inhibitors.9 (Table 1) These drugs are  equally 
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substrates/inducers/suppressors of CYP450 and uridine-glucuronosyltransferase 
(UGT) enzymes and are prone to multi-drug interactions. The plasma concentration-
effect relationship of these drugs is associated with a flat portion of the 
concentration-effect curve. Since ART is started in all infants and at earlier stages of 
HIV disease in children > 12 months of age, the patient population in clinical trials 
is more heterogenic than ever before in terms of previous ART exposure and HIV 
resistances. As a result, the newest pediatric ARV clinical trials are designed to 
evaluate single dose concentrations in mini cohorts of highly treatment experienced 
children. TDM is included in some of the newer ARV drug trials. Early rapid 
assessment of PK generated from "mini-cohort" ensures limiting the number of 
subjects exposed to potentially inadequate ART. 
 
Figure 1 Considerations for pediatric ARV drugs study design. 
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Throughout the course of the evolution of clinical trials of ARV drugs in children, 
new elements of ART study design have emerged. With a larger number of more 
potent agents in practice our definition of "optimal background" has changed, it has 
become more difficult to define the control arm and the concept of "functional 
mono-therapy" has emerged in patients with multi-drug ARV resistance. Moreover, 
the proper tools of measuring the adherence component has become of crucial 
importance in the evaluation of short and long term efficacy and toxicity of ART in 
children. Although many pediatric PK studies describe variability in ARV 
concentrations or PK parameters such as clearance, typically derived from non-
compartmental analytic techniques, variability within and between individuals is not 
distinguished.11 In contrast, population PK techniques estimate distributions of PK 
parameter values globally across the entire study population as well as for the 
individual subjects within the population, and more accurately partition sources of 
variability such as age and/or developmental stage. There are several other 
advantages to population analyses that are relevant to ART studies in children. 
Homogeneous data is not a pre-requisite; therefore, strict adherence to a sampling 
schedule is not required.11 Population and individual parameter values may be 
estimated with sparse data, although accuracy, precision, and predictive power of 
population PK models will suffer with increasingly sparse data. Most importantly, 
population analysis offers a formal method to incorporate what is known about the 
PK of a drug, e.g. in adults, so that estimation of pediatric PK does not begin from a 
zero-knowledge state. Most importantly, because population models are 
distributions of parameter estimates, they may be used to predict PK parameter 
values, with measures of statistical confidence, and thus ARV concentrations in 
children who were not part of the study population.  
 
In recent years, the population PK/PD modeling approach to the development of 
dosing strategy of pediatric ART became highly supported by the US and European 
regulatory authorities. Pediatric Model Based Drug Development (MBDD) often have 
existing information on drug and disease processes and can be focused to fill 
knowledge gaps. Since pediatric labeling is based on a limited number of studies the 
use of modeling and simulation (M&S) might allow the development of age 
appropriate dosing and maximize the information gained from a successful trial. The 
M&S part of the FDA Conceptual Framework for the Pediatric Initiative has also the 
potential to fill in the gaps in communication between pharmacologists, statisticians 
and clinicians. 
 
In this thesis we present several of our studies of pediatric HIV therapy that 
contributed to the evolution of pediatric ART. These studies addressed the 
developmental changes in PK and PD of ARV drugs, ontogeny of ARV metabolizing 
enzymes and drug transporters, the application of TDM, and sustainability and 
complications of pediatric ART in children with perinatally acquired HIV infection. 
(Table 2) The descriptions of these studies and their results are included in the 
discussion.  
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Table 2 Summary of the studies from this thesis 
Developmental changes in PK and PD of ARV drugs  
• Age-dependent pharmacokinetics of lamivudine in HIV-infected children  
• Population pharmacokinetics of lopinavir in children 
Ontogeny of ARV drug metabolizing and transporter enzymes 
• Association between CYP3A5, MDR1 and OATP1B1 polymorphisms with the PK/PD of lopinavir 
in children 
Therapeutic drug monitoring of pediatric ART  
• The use of nevirapine concentration in non-stimulated saliva as an alternative for plasma 
sampling in children  
• The role of therapeutic drug monitoring in the pharmacotherapy of HIV infection in 
adolescents 
Sustainability and complications of ART in children 
• Evaluation of adherence to medication in children and adolescents with HIV infection 
• Urinary biomarker growth factor profile for children with HIV-associated nephropathy 
PK – pharmacokinetics; PD – pharmacodynamics; ARV – antiretroviral; ART – antiretroviral 
therapy; CYP3A5 – cytochrome 3A5; MDR1 – multidrug resistant transporter 1; OATP1B1 – 
organic anion transporting polypeptide 1B1. 
  
THERAPEUTIC TARGETS OF ANTIRETROVIRAL DRUGS FROM INFANCY TO ADOLESCENCE 
The primary outcomes of ARV studies are typically surrogate markers that include 
the virologic response (e.g. undetectable HIV RNA or > 1 log10 drop in HIV RNA 
viral load) and/or immunologic response (e.g. change in CD4+ lymphocyte count or 
percentage), all measured at baseline and after a defined duration of therapy. The 
immunologic surrogates are associated with the occurrence of opportunistic 
infections and survival,12-14 and virologic surrogates define treatment success or 
failure.6 Since in the majority of ART trials these virologic and immunologic 
surrogates are not measured typically until after 12, 24 or 48 weeks of therapy, 
several strategies have been proposed to predict outcomes of ART even before the 
first dose, including target therapeutic concentrations and inhibitory quotients (IQ). 
The IQ incorporates both patient-specific drug exposure and ARV susceptibility of 
the dominant strain as a ratio of Cmin to IC50, with IC50 being equal to the 
concentration of drug required for 50% inhibition of viral replication in vitro. This is 
more specifically termed the phenotypic IQ, or pIQ. Alternatives to the pIQ include 
the virtual IQ (vIQ), normalized IQ (nIQ) and genotypic IQ (gIQ). The vIQ uses the 
fold-change in virtual IC50 (derived from the genotype),12 multiplied by a reference 
wild-type protein-adjusted IC50 as the measure of viral susceptibility. The nIQ is 
the patient-specific IQ divided by a reference IQ calculated as the ratio of typical 
Cmin for a given dose and wild type viral IC50, which normalizes the IQ target across 
ARVs to a ratio of > 1. The gIQ is the ratio of Cmin to the number of resistance-
associated mutations (RAMs) as defined in one of several large databases (e.g. 
Stanford, International AIDS Society [IAS], or Agence Nationale de Recherche sur le 
Sida [ANRS]). When applying any form of IQ, it is important to recognize that the 
resistance to the first-generation NNRTIs, NVP and EFV, can be high-level with a 
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single mutation, and it is not considered possible to overcome such resistance by 
increasing the dose. In contrast, for all PIs resistance develops cumulatively with 
successive mutations, and therefore can, at least theoretically, be overcome by 
higher doses if they can be tolerated. For adults, various IQ targets have been 
proposed for the majority of the PIs. Although the second generation NNRTI ETV is 
similar to PIs in this regard, there is currently no data on the significance of ETV IQ.  
 
Because all ARV drugs except CCR5 inhibitors have viral rather than human 
molecular targets, a major assumption for pediatric therapy has been that ARV 
PK/PD targets should be the same in children as in adults. Indeed, all ARV PK 
studies in children have been designed to find the dose which is associated with 
exposures (e.g., Cmax, AUC, and Cmin) similar to those already known to be safe and 
effective in adults. This section describes what is known of the relationships 
between ARV drug concentrations and antiviral efficacy and toxicity in pediatric 
patients with HIV.  
 
Therapeutic targets of NRTIs 
The relationship between plasma NRTIs concentrations and virologic and 
immunological outcomes are not well correlated. Nonetheless, improved virologic 
suppression has been demonstrated in adults dosed with NRTIs to achieve specific 
plasma targets vs standard dosing.13 The relationship between ZDV and ddI 
exposure and virologic outcome was also reported in infants and children.14,15 Low 
tenofovir dixoproxil fumarate (TDF) exposure (single-dose and steady-state 
tenofovir (TFV) AUC) in younger pediatric patients has also been associated with 
virologic outcome.16 The relationship between the intracellular NRTI concentrations 
and virologic and immunologic outcome has been studied in adult population only. 
Intracellular concentrations of ZDV and 3TC were both strongly and significantly 
related to virologic replication and immunologic recovery, while neither outcome 
was related to plasma concentrations of either drug.17 Correlation between plasma 
and intracellular drug concentrations was also weak. Moreover, the intracellular 
concentrations of NRTIs are unlikely to become therapeutic targets for ART, since 
the measurement of active intracellular triphosphate metabolites is extremely 
expensive and labor-intensive, and is limited to highly specialized centers. In 
addition, the methodology requires larger blood volumes than typical plasma 
samples which make it unsuitable for the pediatric populations. Overall, due to the 
limited exposure–efficacy data for NRTIs no therapeutic targets for NRTIs have been 
defined to date in adult or pediatric populations except those used in specific ARV 
clinical trials. The relationship of the NRTI exposure and toxicity is not well defined. 
Chronic anemia has been associated with the degree of ZDV exposure where the 
decrease in hemoglobin was associated with elevated mean ZDV plasma 
concentrations.18 The ddI induced pancreatitis appears to be dose related, but no 
relationship with plasma exposure has been found.19 Increased frequency of TDF 
associated nephrotoxicity and osteoporosis in patients with concomitant 
administration of the boosted PIs has been reported, however, no significant 
relationship with TFV plasma concentrations has been demonstrated.20  
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Therapeutic targets of NNRTIs 
For the NNRTIs, the relationship between plasma drug concentrations and efficacy 
and toxicity has been well established in adult studies.21 Long-term virologic 
suppression of HIV has been associated with maintenance of trough plasma 
concentrations above 3000 ng/ml for NVP, in and above 1000 ng/ml for EFV in adult 
patients with HIV infection.22 Higher NVP plasma trough concentrations (> 4300 
ng/ml) have been associated with reduced emergence of resistance mutations 
relative to lower troughs (3000 - 4300 ng/ml) in adults.23 However, no similar 
pediatric NVP PD data have been published. In children earlier HIV RNA suppression 
has been associated with higher EFV concentrations with significant differences in 
virologic suppression rates between plasma trough concentrations of 1.9 mcg/ml vs 
1.3 mcg/ml, respectively (P = 0.01).24 Recent studies report a correlation between 
suboptimal EFV plasma concentrations and suboptimal virologic suppression and 
fast development of NNRTI resistance in pediatric patients in West Africa.25 
Suboptimal exposure in this study occurred in 19% of children (44% of children 
weighing less than 15 kg) with the use of FDA-approved pediatric dosing. Most 
importantly, similar findings of subtherapeutic EFV exposure in pediatric populations 
from the different regions using the standard EFV dose have been reported.26,27 As 
a result of these findings, consideration is being given to a potential increase in the 
recommended dose of EFV in pediatric patients. Current pediatric ART guidelines 
recommend EFV dose adjustment with TDM in selected clinical situations, such as 
virologic rebound or lack of response in an adherent patient.2 EFV is the only NNRTI 
with a well established relationship between EFV induced CNS toxicity associated 
with the Cmin plasma concentrations > 4 mcg/ml in both adults and children.24,28,29 
Finally, for the second generation NNRTI ETV adult data have not shown a 
relationship between ETV plasma concentrations and 48-week efficacy.30 No 
pediatric data on therapeutic targets of ETV are available, but the Phase II study of 
efficacy and tolerability is in progress. 
 
Therapeutic targets of PIs 
For the PIs, efficacy plasma trough concentrations have been established for 
atazanavir (ATV), fosamprenavir (f-APV), indinavir (IDV), lopinavir (LPV), nelfinavir 
(NFV), ritonavir (RTV), saquinavir (SQV) and tipranavir (TPV) in treatment-naïve 
adults.22 The expected trough concentrations for all PIs are reported in combination 
with low-dose, boosting RTV, except for ATV, where the Cmin for both unboosted and 
RTV-boosted ATV have been reported. Pediatric ATV PD data were derived from an 
ongoing PACTG 1020A study with TDM component, which used a PK target of AUC 
> 45 mcg*h/ml.31 Dosing without RTV required higher ATV doses which resulted in 
a very high ATV Cmax, particularly in younger children, and as a result is generally 
not recommended for children.2 If dosing unboosted ATV in pediatric patients, TDM 
is recommended to achieve adequate exposure. Similar to adult data, a minimum 
target plasma trough concentration of ATV in children (150 ng/ml) is currently 
recommended and higher target trough concentrations may be required in PI-
experienced pediatric patients.32 ATV does not have a well identified window of 
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toxicity, although ATV induced hyperbilirubinemia has been associated with 
increased ATV plasma trough concentrations in adult patients.33,34  
 
IDV is one of very few ARV drugs that has been studied in HIV-infected children 
both as monotherapy and in combination with other ARV drugs. Decreased IDV 
exposure (AUC0-8 of < 15 mg*h/l and Cmin < 100 ng/ml) was associated with 
virologic failure.35 The administration of IDV in combination with RTV booster has 
generated AUC and Cmin concentrations similar to those observed with standard 
IDV/RTV doses in adults (with the Cmax slightly decreased), and resulted in good 
virologic efficacy.36,37 The data on the efficacy concentrations of IDV in children is 
limited due to the low usage of this drug in pediatric practice associated with high 
rates of drug associated nephrotoxicity in children.38 IDV is the only PI with a well 
defined therapeutic window with a high frequency of nephrolithiasis associated with 
an IDV Cmax > 10000 ng/ml39 and Cmin > 500 ng/ml40 in adults. For LPV the 
association of plasma trough concentration with the degree of susceptibility of HIV 
(half maximal effective concentration = EC50) has been shown to be significant in 
children. We prospectively developed a population PK model of LPV PI-experienced 
children and showed that, based on simulations from the model, approximately 
more than two-thirds of children with standard FDA approved dose of LPV/RTV 
would be unlikely to achieve a pIQ ≥ 15 for the wild type virus,41 a target which has 
been recommended in adults.42 However, for even moderately resistant viral 
strains, well within the partially sensitive range of commercially available tests, 
fewer than 10% of children will achieve therapeutic target concentrations. This 
conclusion was supported by our results from another prospective study in a cohort 
of PI-experienced children treated with high-dose LPV.43 Subsequently, we showed 
that at a pIQ of > 25, 69% of PI-experienced pediatric patients 4 - 18 years of age 
had undetectable HIV RNA vs only 20% of those with a pIQ < 25 (P = 0.01).44 In a 
multivariate logistic regression that included duration of LPV therapy, self-reported 
adherence, age, and gender, only pIQ was a significant predictor of virologic 
suppression in our cohort of treatment experienced pediatric patients.44 A recent 
study of reduced-dose LPV/RTV (70% of the standard recommended) in PI-naïve 
Thai children demonstrated adequate LPV/RTV exposure and virologic suppression 
in 83% of children, compared with 50% of children on the standard dose.45 These 
findings reinforce the conclusions from our LPV population PK study that the 
majority of PI-naïve children are more likely to achieve adequate LPV exposure, but 
up to 10% may not do so. Moreover, low-dose LPV/RTV would not be appropriate 
for PI-experienced children, who, on the contrary, may benefit from augmentation 
of the LPV exposure near the maximal end of the observed safe range. 
 
Among other PIs, NFV has been extensively studied in HIV-infected children in 
combination with other ARV drugs. Although NFV has a major metabolite, M8, with 
virologic activity, the contribution of M8 to overall activity of NFV is unclear; target 
troughs have largely been proposed for NFV.46,47 An increased risk of virologic 
failure was associated with low NFV drug exposure, particularly with a NFV Cmin 
< 1000 ng/ml, in adults.48 In a study of children treated with NFV, NFV Cmin plasma 
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concentration > 800 ng/ml was significantly associated with virologic outcome.47 
Significant differences in virologic responses between the two age groups (3.8 and 
8.3 years of age) were observed, which reinforces the fact that drug clearance and 
therefore dosing does not generally vary linearly with weight. For SQV a significant 
correlation between average trough plasma concentration and viral suppression was 
reported in pediatric patients, with an apparent threshold mean trough SQV 
concentration > 200 ng/ml correlating with sustained HIV RNA suppression.49 SQV-
based ART has been reported to produce higher SQV and LPV exposure and 
stronger virologic response in treatment-experienced children when used in 
combination with RTV.50-52 Although both SQV/RTV and SQV/LPV/RTV regimens 
appeared to be promising, the appropriate dosing in children and adolescents for 
the different possible PI combinations is not known, and the strategy of "double-
boosted" PIs has been deemed by the development of new ARV therapeutic agents. 
TPV efficacy and PK in HIV-infected children was evaluated in an open-label, 
multicenter, randomized trial, PACTG 1051/BI-1182.14, among treatment-
experienced children (2 - 18 years of age) comparing two dose regimens with an 
optimized backbone ART.53 For TPV virologic outcome was strongly predicted by gIQ 
in the high dose group. Finally, the efficacy data for DRV has not been published to 
date.  
 
Therapeutic targets of entry and fusion inhibitors and CCR5 inhibitors 
For the entry inhibitor enfuvirtide (T-20) no statistical relationship between T-20 
drug exposure and virologic benefit was observed in pediatric studies.54-56 A 
minimally effective plasma concentration relative to in vitro viral susceptibility has 
not been established for the integrase inhibitor raltegravir (RAL). In early dose 
ranging studies in treatment-naïve patients, identical 48-week virologic and 
immunologic efficacy was seen with doses ranging from 100 to 600 mg 
administered twice daily.57 In triple-class experienced patients, 24 week virologic 
efficacy was the same in the 200 mg twice daily group as in the 600 mg twice daily 
group.58 RAL is currently being evaluated in IMPAACT 1066, a Phase I/II study in 
HIV-infected children. To date, there are no reports of the PD of CCR5 antagonist 
maraviroc (MVC) in children or adolescents < 16 years of age.  
 
 
THERAPEUTIC DRUG MONITORING OF ANTIRETROVIRAL DRUGS IN CHILDREN 
The main goal of TDM is to individualize the dose/regimen of the therapeutic 
agent(s) in order to achieve maximal benefit and avoid or minimize drug associated 
toxicity. In order to apply TDM into practice a number of important components 
need to be present. (Figure 2) Among ARV drugs, NRTIs do not meet the majority 
of the described TDM requirements, while NNRTIs and PIs have been identified as 
most suitable candidates for TDM in HIV therapy. Given the physiologic and 
maturational differences between children and adults, numerous reviews, position 
papers and guidelines suggest children as a target population for ARV TDM, while 
routine ARV TDM in adults is considered of questionable benefit.59-63  
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Figure 2 Components of therapeutic drug monitoring. 
 
Despite the almost universal recognition of the potential benefits of ART TDM in 
children, substantial barriers exist that limit its routine use in clinical practice.63 The 
expertise in pediatric PK samples collection and data transfer (accurate 
dose/time/demographic/adherence information) is limited to a few clinical centers 
with experience in pediatric clinical trials. The current matrices for TDM of ARV 
drugs in children include plasma/serum, saliva, urine, cerebrospinal fluid (CSF) and 
peripheral blood mononuclear cells (PBMC). The collection of blood samples is the 
most precise and common way to assess ARV exposure, but it is invasive, requires 
separation via centrifugation and cryopreservation. If transformed into the dried 
spot heat resistant methodology, it has the potential to become an attractive choice 
for future use, particularly in resource-limited settings. Dried blood and plasma spot 
ARV TDM studies are underway in several TDM laboratories with preliminary data 
showing limited processing issues with recovery.[personal communications] The 
collection of saliva represents an attractive, affordable and, most importantly, non-
invasive alternative for the potential replacement of blood sampling in children.64,65 
The proper sample collection, however, is challenging and the saliva samples have 
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the potential for a large discordance with blood matrices due to protein binding and 
pH effects. Clearly, CSF and PBMC sampling are limited to research or rare clinical 
scenario settings due to the highly invasive nature of the first one and labor and 
resource involvement of the second one, respectively.  
 
In addition to matrix consideration, the selection of TDM sampling strategy requires 
thorough evaluation in pediatric patients. The trough or pre-dose plasma 
concentrations (Cmin) have a higher parental and child's acceptance, smaller blood 
volumes, are easier to collect, and can be linked to PD evaluation through of 
genotypic and phenotypic IQ. The interpretation of plasma Cmin concentrations, 
however, is quite sensitive to dose/sample time variations and is therefore subject 
to a greater degree of intra- and inter-patient variability. In contrast, a full AUC 
evaluation is much more reliable in predicting the average drug exposure-response 
relationship and is less dependent on the dose/sample time and patient adherence. 
The clear disadvantages of conducting a full PK study in children involve a higher 
degree of parental and patient inconvenience, higher volumes of blood samples and 
higher cost and time commitment involved. Several adult studies have evaluated 
limited sampling (LS) strategies to provide reasonable estimates of AUC for ARV 
drugs, but they have not been validated in children.66-69 Among pediatric patients, 
LS strategies have been reported for ZDV, ddI, 3TC, d4T and NVP.70-72  
 
LS approaches in children can be best used in PK/PD models, which have the 
potential to reduce the number of study subjects for the drug/dose/schedule 
approval and evaluation. While, LS data suffer from the same problem as traditional 
TDM of pre-defined sampling times, the full individual Bayesian adaptive control or 
forecasting allows for prediction of plasma drug concentrations at any time after a 
dose, given all information known about a patient, such as dose amount, frequency, 
estimated times of drug administration and known time(s) of blood sampling, 
regardless of the elapsed time.63,73 Information not specific to the patient, but 
nonetheless relevant, such as PK behavior in other children or in adults, may also 
be included in the model to improve the quality of the predictions. The PK modeling 
techniques have been applied to a limited number of pediatric ARV PK studies to 
date.63,74-76  
 
To date, the concentration controlled ARV dosing strategy has been confirmed to be 
efficient for EFV, NFV, and LPV/RTV/SQV in a series of pediatric clinical trials and 
case reports.2,24,41,63,77 The inclusion of TDM in the pediatric study design has been 
limited by guaranteed access to validated ARV assays, extensive PK laboratory with 
real time capabilities, and analysis experience. Inability to rapidly adjust ARV dose 
based on early clinical response has become one of the barriers to include TDM into 
new drugs study design. In addition, the lack of healthy volunteer information to 
guide dosing, high inter-subject variability of many ARV drugs, formulation and food 
interactions constraints, limit the application of TDM in research and clinical 
practice. 
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The current practice of TDM in pediatric ART is limited to clinical trials and special 
indications such as adherence, ART failure in the presence of adherence, and drug-
drug interactions. While smaller, well-conducted trials and case reports (including 
our data) have shown the benefit of TDM in the pediatric population,2,24,41,63,77,78 
data on clinical utility of pediatric ART TDM are lacking. The available pediatric data 
support the use of TDM in infants or adolescents that may "outgrow" ARV doses. It 
may also help determine the route of discordance between expected response and 
viral genotype/phenotype and identify drug-drug interactions in untested drug 
combinations. New, more potent ARV drugs with well defined PK data have the 
potential to limit the justification of TDM in treatment-naïve patient populations. 
However, the development of HIV resistance will most likely outpace the ability to 
design drugs for resistant virus making TDM more relevant for consideration among 
fusion and integrase inhibitors, and CCR5 inhibitors. Larger trials of TDM in children 
are needed to evaluate the cost-benefit analysis of TDM in pediatric populations, 
particularly in infants and adolescents. In order to conduct larger trials of TDM in 
children, newer, cheaper and patient friendly TDM matrices and LS sampling 
strategies need to be developed. Finally, the development and incorporation of 
modeling and simulation in pediatric clinical trials is critical in evaluating the 
exposure-response relationship of ARV drugs in children.79 
 
 
GLOBALIZATION AND INDIVIDUALIZATION OF THERAPY OF PEDIATRIC HIV INFECTION 
Treatment of HIV infection in infants, children, and adolescents is rapidly evolving 
and becoming increasingly complex. On the global scale of the HIV epidemic, 
individualization of pediatric ART is restricted by the drug development process 
geared towards an economically sustainable and standardized weight band based 
doses suitable for resource-limited settings. Nevertheless, we must not forget that 
HIV-infected pediatric patients represent a highly heterogeneous group of infants, 
young and school age children, and adolescents with vertically and horizontally 
transmitted HIV infection. The maturational process does not proceed at a regular 
and predictable pace in all children, and PK and PD variability throughout different 
stages of growth and development needs to be addressed in pediatric patients on 
ART. 
 
Valuable data on the PK and PD of ARV drugs in children have been generated and 
many lessons have been learned, yet many questions remain unanswered. To date 
very limited data have been collected on individualizing ARV exposure in HIV-
infected children. Within the pediatric ART studies the concentration/efficacy/ 
toxicity dose adjustment has been difficult to implement due to many constraints 
including:  
 
• sample and dose time variability 
• study and expert dependent data interpretation  
• non-adherence confounder  
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• difficulties in defining target concentrations  
• limited time window for benefit  
• timely integration of viral phenotype/genotype information  
• additional resources and cost considerations  
 
Few data are available on the dosing of ARV drugs in very young infants and the 
data are lacking on the efficacy and toxicity of PI and NNRTI based regimens in 
early infancy. Little attention has been paid to the effects of developmental 
processes of puberty on the PK/PD targets in the adolescent population. The ARV 
dose selection remains challenging during puberty, where the continued use of 
higher (weight- or surface-based) pediatric doses can result in potentially toxic drug 
exposure and early introduction of lower adult doses can lead to the development of 
drug resistance and virologic failure.77  
 
Pharmacogenetics of ART in children  
The impact of pharmacogenetics (PG) on the PK and PD parameters in children is 
poorly understood, as little knowledge is available on the ontogeny of drug 
metabolizing enzymes and transporters in children. Similar to the data from 
adults,80,81 CYP2B6 G516T polymorphisms and age were shown to significantly 
change the clearance of EFV in children and have been associated with increased 
CNS toxicity, but failed to show significant association between virologic and 
immunologic responses to date.82 This polymorphism is highly prevalent in patients 
of African descent who currently represent the majority of the HIV-infected 
population worldwide.83,84 In this thesis we describe successful EFV dose reduction 
in two African American adolescent patients with extremely high EFV exposure due 
to the CYP2B6 G516T polymorphism.78 Interestingly, although both patients and 
their families recalled that the children experienced transient sleep problems shortly 
after the initiation of EFV therapy, their high EFV exposure did not prompt 
treatment discontinuation. Similar studies of EFV dose reduction in patients with 
CYP2B6 genotype have recently emerged in the adult and pediatric literature.63,85 
While low EFV exposure has been reported to be associated with virologic failure,28 
no studies have evaluated the long term consequences of high EFV exposure to 
date, and no cost analysis of EFV dose adjustment has been conducted. We believe 
that selective genotyping of populations with high prevalence of CYP2B6 
polymorphism deserves strong consideration and future studies need to be 
conducted to evaluate the validity of CYP2B6 genotyping as a guide to EFV dose 
adjustment. Another drug metabolizing CYP2C19 G681A polymorphism was found 
to be strongly associated with metabolism of NFV in pediatric HIV-infected 
patients.86 In addition to the CYP2C19, the drug transporter MDR1 C3435T 
polymorphism has also been shown to affect plasma NFV concentrations and 
clearance, and was associated with virologic outcome in pediatric patients.87 Finally, 
the impact of growth and development on the activity of other UGT isoforms is well 
recognized and has been reported in the relationship to many drugs, including 
ZDV.88 Collectively, these data suggest that developmental changes in drug 
metabolizing enzymes and drug transporter activity have the potential to affect 
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disposition and clearance of NNRTIs, PIs entry and fusion inhibitors, integrase 
inhibitors and CCR5 inhibitors.  
 
Malnutrition and pediatric ART  
In addition to the developmental changes in drug absorption and disposition, the 
potential effects of malnutrition and concomitant infections on the PK/PD of ARV 
drugs in pediatric patients complicate the dosing of ART in resource-limited settings 
where decreased weight and delayed growth among HIV-infected children are 
common.5,89,90 The high prevalence of co-morbidity with gastrointestinal illnesses, 
hepatitis, malaria and tuberculosis creates additional challenges in delivering 
efficient ART to pediatric HIV-infected patients. The presence of emesis, diarrhea, 
malabsorption, concomitant infections or malignancy may lead to altered absorption 
of ARV drugs. The loss of fat and lean body mass, and associated metabolic and 
endocrine abnormalities have the potential to influence the volume of distribution 
and the total body clearance of ARV agents, particularly of lipophilic drugs, such as 
PIs.91,92 The changes in plasma albumin and α1-acid glycoprotein concentrations 
have been associated with the potential to alter the plasma exposure to total and 
free concentrations of the PIs.93,94 Moreover, severe malnourishment during puberty 
when the transition to an adult dosing regimen is based on the sexual maturation 
might compromise ARV dosing in adolescents, whose body weight and development 
lags significantly behind the average growth parameters of a similarly aged cohort 
in developed countries. The data on the PK and PD of ARV drugs in children have 
been mostly generated in developed countries, though more data on regional, racial 
and ethnic pediatric PK and PD diversity have started emerging in the literature 
during recent years.95,96 Limited pediatric data suggest that underlying malnutrition 
does not adversely affect immunologic and virologic response to ART.97,98 While 
these PK immunologic and virologic outcome data in malnourished children is 
encouraging, more studies are necessary to evaluate the full effect of nutritional 
status and co-morbidities on the PK and PD of ART in pediatric patients.  
 
Drug-drug interactions with ARV drugs  
The presence of co-morbidities such as malaria and tuberculosis (TB), which are 
most commonly associated with HIV infection,99 further complicates pediatric ART in 
the resource-limited setting.100-102 Co-administration of anti-TB and ART is common 
and results in potent drug-drug interactions affecting PK of ARV drugs caused by 
the induction of the CYP450 system. Significant reduction of NVP and EFV 
concentrations with concomitant rifampicin has been reported, particularly during 
the lead-in dose period when subtherapeutic concentrations occur in the majority of 
patients. Even more significant are the drug-drug interactions between rifampicin 
and RTV-boosted PIs, when the therapeutic concentrations can only be achieved 
with adjusted doses of LPV/RTV or with SQV/RTV. However, such dose adjustment 
has been reported to produce high rates of hepatotoxicity in healthy volunteers.103 A 
few studies have evaluated the ARV and anti-TB drug interactions in pediatric HIV- 
and TB-co-infected patients.104,105 In the studies of South African pediatric HIV-
infected patients, attempts were made to compensate for the rifampicin generated 
Chapter 12 
 
182 
induction of LPV/RTV metabolism by increasing LPV/RTV ratio from 4:1 to 1:1.104,105 
Despite this change in boosting, the median Cmax and AUC0-12 were lowered by 26% 
and 31%, respectively,104 and LPV oral clearance (CL/F) was decreased by 30%, 
and plasma Cmin greater than 1000 ng/ml were observed in most children in both 
studies. These data highlight the need to define optimal combination dosing 
regimens both for ARV and anti-TB drugs, and is particularly relevant today when 
several large international trials evaluating the new treatment modalities for 
pediatric TB in HIV-infected children are under way.  
 
Another potential factor that can influence PK/PD of ARV drugs in children is the use 
of traditional herbal medicines (THM), which frequently represent primary 
treatment for HIV/AIDS and HIV-related problems.106,107 Several drug interactions 
between herbal remedies and ART have been shown to affect the serum 
concentrations of ARV drugs resulting in clinical symptoms of toxicity in adults, and 
no studies are published in children.108 Herbal remedies have the capacity to affect 
the metabolism of ARV drugs, especially NNRTI, PIs, CCR5 inhibitors and integrase 
inhibitors through the induction/suppression of CYP450 enzymes. It is equally 
important to consider the potential of herbal remedies to have an effect on ARV 
drug efficacy, as well as the potential for ARV drugs to increase the toxicity of THM. 
To date, no pediatric studies on ARV and THM interactions have been published.  
 
Complications of pediatric ART 
Recent greater awareness and understanding of metabolic and cardiovascular ART 
complications in adults have generated renewed attention to long term 
consequences of HIV disease and ART exposure in children.109,110 The data on the 
prevalence of pediatric ART associated metabolic complications in children start 
emerging from the studies conducted in developed countries, while in resource-
limited settings, where the majority of HIV-infected children live, the prevalence 
and risk factors of metabolic complications are largely unknown. The significance of 
childhood ART associated lipodystrophy, dyslipidemia, insulin resistance, 
hyperlactatemia, renal insufficiency and osteopenia in the development of the 
cardiovascular, renal and bone disease of adulthood is not known and the 
management of these complications during childhood is under investigation.111 Very 
few studies (including ours) have evaluated the impact of ARV drug exposure on the 
development of those complications.112-115 A recent study in adolescents and young 
adults with HIV acquired perinatally or early in life reported a high rate of coronary 
artery abnormalities on cardiac magnetic resonance imaging (MRI), suggesting 
possible early atherosclerosis in this population.116 Although not associated with 
coronary artery disease in adults, coronary irregularities were seen in youth with 
increased cumulative exposure to TDF and emtricitabine.116 Given the potential risk 
of such condition and delayed onset of their clinical presentations, it is necessary to 
find new biomarkers to facilitate early identification of children at high risk of 
developing ARV associated toxicities.  
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Long-term sustainability of ART in children 
A limited number of studies has investigated the long-term sustainability of ART 
regimens in children. The ability to retain the first and second line ART regimens is 
highly dependent on the degree of patient's adherence. It is well recognized that 
HIV-infected children face multiple adherence challenges such as dependence on a 
caregiver for obtaining medications, palatability of liquid preparations, daily pill 
burden, food-drug and drug-drug interactions and interference with lifestyle of both 
the child and caregiver. As the child continues to grow, many additional obstacles 
related to the psychosocial changes during puberty emerge. Among these are 
changes in lifestyle involving growing independence and rebellion against parental 
involvement, increased peer pressure and fear of stigmatization, increased risk-
taking behavior, denial and fear of HIV infection (particularly in recently diagnosed 
youth), long history of poor adherence and nondisclosure issues in perinatally 
infected adolescents, psychiatric problems (depression), and alcohol and substance 
abuse.117,118 In our study of adherence in a cohort of 127 perinatally HIV-infected 
children complete adherence (100%) was reported in only 24% of the patients.118 
Self-reported adherence and age were significant predictors of reaching 
undetectable viral load. Most importantly, our data showed that adolescents 
(13 - 18 yrs old) were significantly less likely to reach undetectable viral load than 
younger children (< 13 yrs old).118 For every year increase in age, the odds of 
reaching undetectable viral load decreased by 10% after controlling for self-
reported adherence and refill mechanism.118 A few pediatric studies have conducted 
a comprehensive assessment of adherence through different methods (self-report, 
pill count, pharmacy refills, and therapeutic drug monitoring) in children.119,120 
Although strategies to promote long-term adherence to ART have not been 
rigorously evaluated in adolescents to date, preliminary data suggest that 
interventions based on intensive follow-up, involvement of family and peers, use of 
reminder systems, alternative dosing schedules, and modified directly observed 
therapy may facilitate adherence to the dosing regimen in this vulnerable 
population.121,122 Moreover, developmental and psychosocial factors affecting ART 
adherence in children and adolescents from different cultural and ethnic regions of 
the world are not well described and need to be evaluated. Culturally sensitive and 
acceptable adherence evaluation tools and interventions need to be developed.  
 
Challenges in formulations of ARV drugs  
Due to the global need for pediatric ART, the ARV drugs face significant challenges 
in formulations of heat resistant small size solid preparations suitable for children. 
Following international efforts in ART delivery, it became quickly evident that the 
availability of liquid pediatric ARV formulations, which met the need of pediatric ART 
in developed countries, could not assure the delivery of ART in a large majority of 
resource limited settings with the highest prevalence of pediatric HIV disease. 
Alternative medication delivery systems, such as skin patches, have been 
investigated and are considered to be problematic in children due to the high inter- 
and intra-patient variability in absorption and metabolism and developmental 
changes in PK. As a result, in recent years a substantial effort has been made to 
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manufacture sustainable small size tablets and fixed dose co-formulations (FDC) of 
first line ARV drugs for pediatric patients in resource limited settings. To date, 
generic suppliers have developed a number of inexpensive, generic pediatric FDC 
formulations for reconstitution of once- or twice-daily dosing (i.e. combinations of 
ZDV, ABC, d4T, 3TC and NVP) in a variety of different ratios in formulations of 
regular and dispersible tablets, and suspension for reconstitution. The development 
of these formulations requires a ratio of active drugs to be in balance to allow dosing 
across a wide range of ages and body sizes. The bioequivalence and exposure-
response for all FDC components needs to be considered and evaluated in Phase III 
trials in pediatric cohorts.123 A few recent studies have addressed the PK and PD of 
FDC in children and raised concern for underdosing of NVP in pediatric patients.123,124 
It is clear that the availability of ARV FDC will generate more randomized, controlled 
studies to evaluate their therapeutic potential in pediatric patients. 
      
 
CONCLUSION 
Multiple factors, including drug (formulations, PK, PD, drug-drug interactions), 
patient (developmental stage, PG, co-morbidities, malnutrition, adherence), and 
viral (genotypic/phenotypic profile, exposure targets) characteristics need to be 
combined in order to achieve sustained ART success at the minimal price of short 
and long-term complications in pediatric HIV-infected patients. Many excellent 
research and clinical data have been generated to address the optimization of 
pediatric ART, while ongoing ARV drug developments in the era of more complex 
therapies continue to generate new questions to be answered. In our center and 
through multiple collaborations, we will continue ongoing pediatric studies aimed to 
investigate: 1) the application of the gIQ and pIQ in LPV/rtv based ART in children; 
2) the effect of puberty on the metabolism of EFV and ontogeny of CYP2B6 and 
UGT; 3) the development of pediatric population PK/PD models for TDF and EFV; 4) 
the relationship between childhood PI and NNRTI exposure and metabolic and 
hematologic complications of ART; and 5) the impact of incentive awards on 
pediatric ART adherence.  
 
Modern pediatric combination ART faces a difficult challenge of preserving the focus 
on an individual child while addressing the globalization of ARV exposure. Future 
trials of ARV drugs in children will need to address the individualization of ART in 
the pediatric HIV-infected patient. Current pediatric ART research priority focuses 
on the most important areas with the least knowledge such as developmental 
changes in drug metabolizing enzymes and drug transporter activity (with particular 
emphasis on puberty), long term metabolic complications of ART in children, and 
the impact of pharmacogenetics on ARV drug disposition and response to ART in 
children of diverse racial/ethnic background. Finally, better adherence interventions 
and assessment tools need to be studied in large international trials. I hope that my 
thesis and future research in this field can contribute to the quest for optimization 
of the outcome of pediatric HIV infection in children worldwide.  
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SUMMARY 
Despite the significant progress of the prevention of mother-to-child transmission of 
HIV, nearly 1,200 new infections in children younger than 15 years of age continue 
to occur daily. With an estimated > 3 million children and adolescents living with 
HIV infection, the delivery of efficient antiretroviral therapy (ART) to the world's 
pediatric population is of crucial importance. Given the growing number of HIV-
infected children and adolescents with access to treatment, a better understanding 
of the therapeutic targets of antiretroviral (ARV) drugs in pediatric HIV infection is 
urgently needed. 
 
The important etiological, physiological, psychological and social differences 
between children and adults create a unique consideration for HIV-infected pediatric 
patients, and require a population specific approach to ART. The global picture of 
pediatric HIV infections and pediatric ARV drug development is presented in the 
Introduction (Chapter 1). While acknowledging the important work of many 
international investigators, the chapter outlines the most significant gaps of 
knowledge in pediatric ART.  
 
PART I focuses on the developmental changes from infancy to adolescence and its 
impact on ARV drug disposition and efficacy. The data guiding the dosing, efficacy 
and safety of medicines for children have lagged substantially behind as compared 
to the information available for adults. As a consequence, pediatricians who are 
faced with the prospect of confining their practice to medicines with adequate 
information have frequently resorted to prescribing medicines for unapproved uses 
(different dose, frequency, age group, route, indication or formulation). Chapter 2 
reviews the history and current progress in pediatric pharmacological research and 
pediatric drug development. The basic principles of drug absorption, distribution, 
metabolism and elimination from neonates to adolescents are summarized. 
Subsequently, Chapter 3 focuses on the developmental changes in drug disposition 
during puberty. The study reviews physiological and psychological changes 
associated with physical and sexual maturation, and analyzes the potential impact 
of these changes on the pharmacokinetics (PK) and pharmacodynamics (PD) of ARV 
drugs in adolescent HIV-infected patients. The chapter reveals the paucity of data 
on the pharmacology of ARV drugs in puberty and provides a comprehensive 
summary of current adolescent ART guidelines. The lack of clear understanding of 
the PK and PD of ARV drugs during puberty leads to the continued use of higher 
(weight- or surface-based) pediatric doses with potential toxic drug exposure or 
early introduction of lower adult doses with the subsequent development of drug 
resistance and virologic failure.  
 
HIV-infected children represent an incredibly diverse group of patients, ranging 
from neonates to young adults. With the change in age and maturity, pediatric ART 
evolves from the meticulous twice-daily dosing of milliliters of liquid preparations to 
a choice of once-daily dosing of a single fixed dose co-formulated tablet. The use of 
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simplified pediatric regimens may enhance the ability to achieve successful 
implementation of ART in HIV-infected children. PK/PD studies of ARV drugs and 
their combinations need to be conducted in infants, children, and adolescents to 
develop appropriate dosing in each of these specific groups. The current challenges 
in the availability, formulations and regimens of the pediatric ART are discussed in 
Chapter 4. 
 
PART II of the thesis is dedicated to the analysis of developmental changes in the 
PK and PD of specific ARV drugs in children and adolescents. Chapter 5 reports the 
data of a study conducted in collaboration with the University of Nijmegen, the 
Netherlands on the PK of lamivudine (3TC) in HIV-infected pediatric patients. 3TC is 
frequently used as NRTI backbone of treatment for HIV infection in children. 
Previous studies have indicated a higher oral clearance of 3TC in children than in 
adults. Therefore, the recommended dose of 3TC in children is approximately two 
times higher when compared to adults. In our study, the PK data were collected 
from 51 HIV-1 infected children (median age of 8.4 years) using a standard 
pediatric dose of 3TC and were compared with adult PK parameters. AUC, Cmax, 
Cmin, CL/kg and Vd/kg were significantly related to age with younger children having 
lower exposure to 3TC. The age of 6 years appeared to be a cut-off for a change in 
3TC PK parameters, with children ≤ 6 years of age having a median AUC 43% lower 
and a median Cmax 47% lower than older children. In line with these observations, 
CL/kg and Vd/kg were 79% and 89% higher in children ≤ 6 years of age when 
compared to older children. The mean Cmax and AUC in children ≥ 7 years of age 
were almost similar to adult PK parameters. Most importantly, the decreased 3TC 
exposure in younger children is potentially related to the development of M184V 
HIV mutation and resistance to 3TC, and deserves further investigation. 
 
The development of a population PK model for the most widely used inhibitor (PI) 
lopinavir (LPV) in pediatric practice is presented in Chapter 6. The data were 
obtained from HIV-infected, PI-experienced children receiving LPV through intensive 
PK sampling and were fitted to candidate PK models (using MM-USCPACK software). 
The final model was used to simulate 1,000 children to determine the probability of 
achieving an LPV phenotypic inhibitory quotient (PIQ) of > 15, which has been 
associated with a higher likelihood of viral suppression in adult studies. The 
probability of achieving an LPV PIQ of > 15 was > 90% for wild-type virus but 
< 10% for even moderately resistant virus. The currently recommended dose of 
lopinavir/ritonavir appears to be adequate for children infected with wild-type virus 
but is unlikely to provide adequate inhibitory concentrations for even moderately 
resistant HIV. PI-experienced HIV-infected children will likely benefit from 
longitudinal, repeated LPV measurement in plasma to ensure that drug exposure is 
most often near the maximal end of the observed safe range. 
 
The ontogeny of ARV metabolizing enzymes and drug transporters is investigated in 
the study of the association between the CYP3A5, MDR1 (ABCB1) and OATP1 
(SLCO1B1) polymorphisms on the PK and PD of LPV/RTV therapy in children 
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(Chapter 7). CYP3A5, MDR1 and SLCO1B1 polymorphisms have been associated 
with variability in the PK of PIs. In this study we investigated the influence of 
CYP3A5 A6986G, MDR1 (C3435T and G2677T), and SLCO1B1 (T521C and A388AG) 
polymorphisms on the PK/PD of LPV/RTV in a prospective cohort of 50 HIV-infected 
children (median age 11.2 yrs). The results showed no statistically significant 
association between LPV or RTV AUC or CL, and CYP3A5, MDR1 or SLCO1B1 A388G 
polymorphisms. There was a significant association between SLCO1B1 T521C and 
LPV AUC (P = 0.042) and a nearly significant association with LPV CL (P = 0.063). 
Studied polymorphisms, however, were not associated with virologic outcome within 
the study period. Larger pediatric studies of the developmental changes in drug 
distribution and metabolism are needed to better understand the role of 
pharmacogenetic factors in the response to ART in children of diverse racial/ethnic 
background. 
 
PART III consists of two studies focusing on the role of the therapeutic drug 
monitoring (TDM) in the management of ART of pediatric HIV infection. Chapter 8 
investigates the non-invasive matrix of salivary concentrations of non-nucleoside 
reverse transcriptase inhibitor nevirapine (NVP) as an alternative to the plasma 
sampling in pediatric HIV-infected children. Adequate trough concentrations of NVP 
predict successful therapy while subtherapeutic levels are correlated with virologic 
failure and development of resistance. Our study examined the extent of agreement 
between total and free plasma NVP concentrations and non-stimulated saliva NVP 
concentrations and evaluated the feasibility of saliva sampling as an alternative tool 
for TDM of NVP in children. NVP concentrations were obtained in paired plasma and 
saliva samples of pediatric patients receiving ART including NVP. The saliva NVP 
concentrations reflected the free concentrations very closely, but were on average 
34% higher. The Bland-Altman plots indicated that the discrepancy between saliva 
and plasma measures is consistent across the range of average NVP concentrations. 
Our study results strongly indicate the agreement between saliva and plasma NVP 
concentrations in pediatric patients with HIV infection. Non-stimulated NVP saliva 
concentrations can be used as an interchangeable non-invasive, reliable, cost-
effective method for the application of TDM of NVP therapy.  
 
Currently, TDM of ART is recommended to rule out subtherapeutic drug 
concentrations and to differentiate among malabsorption, drug interactions, poor 
adherence, or increased drug metabolism or clearance as possible causes of 
decreased drug exposure. The use of TDM is also considered to assist in finding the 
optimal dose of a drug in patients whose virus has shown reduced susceptibility to 
that drug. As outlined in Chapter 3, the dosing of ARV drugs in adolescent patients 
shows the transition of a dosing regimen from higher pediatric (weight and surface-
based) to adult (fixed) range but this is not well defined. Developmental PK 
differences contribute to high variability in pediatric and adolescent patients and an 
increased frequency of suboptimal ARV exposure as compared to in adults. 
Individualized, concentration-targeted optimal dosing of ARV medications can be 
beneficial to patients for whom only limited dosing guidelines are available. The role 
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of TDM in the optimization of pharmacotherapy of HIV infection in adolescent 
patients is discussed in Chapter 9. In this chapter we describe two scenarios of the 
application of TDM in treatment-experienced adolescent patients whose ART was 
optimized using ARV TDM. In the first scenario TDM served as an efficient tool in 
the evaluation of the treatment failure in light of self-reported excellent medical 
adherence. The second scenario represents the first report of successful reduction 
of the efavirenz (EFV) dose in adolescent patients based on the CYP2B6 genotype in 
combination with PK evaluation. TDM of ARV drugs is useful in managing the 
pharmacotherapy of HIV in adolescent patients and is well received by the 
adolescent patients with HIV and their families. Among others, TDM in adolescents 
provides valuable information about the clinical pharmacology of ART during 
puberty. 
 
PART IV addressed the issues associated with long-term sustainability and 
complications of ART in children and adolescents. Chapter 10 investigates the 
relationship between self-reported adherence to ART and the virologic and 
immunologic outcomes of HIV infection in 127 perinatally infected adolescents 
(mean age 9.9 yrs). In addition the relationship between the pharmacy supply of 
ARV drugs and self-reported adherence and HIV viral load (VL) in HIV-infected 
children was evaluated. The complete adherence (100%) was reported in only 24% 
of the patients. With 40% of the patients being rarely or never completely 
adherent, 64% of children achieved undetectable VL during the study period. In our 
study, we did not find an association between pharmacy supply and self-reported 
adherence. Self-reported adherence (P = 0.0328) and age (P = 0.025) were the 
significant predictors of reaching undetectable VL. Most importantly, adolescents 
(> 13yrs) were significantly less likely to reach undetectable VL than children < 13 
yrs (OR = 0.38; 95% CI: 0.16, 0.89). For every year increase in age, the odds of 
reaching undetectable VL decreased by 10% after controlling for self-reported 
adherence and refill mechanism. While we acknowledge that the adolescents in the 
study had perinatally acquired HIV, were highly treatment experienced, and 
therefore had higher chances for HIV resistance and virologic failure, we must 
recognize many additional obstacles to ART adherence emerging during puberty. For 
the providers and caregivers loss of adherence during puberty in adolescents with 
perinatally acquired HIV represents a difficult and emotional challenge that requires 
team approach and close collaboration. Given the lack of a well defined adherence 
intervention model in adolescents with HIV, more research on adherence among 
HIV-infected youth with interdisciplinary collaboration is warranted.  
 
The development and application of biomarkers for the early identification of HIV-
associated nephropathy are presented in Chapter 11. HIV-infected children are at 
risk of developing several types of renal diseases, including HIV-associated 
nephropathy (HIVAN). Childhood HIVAN is defined by the presence of proteinuria 
associated with mesangial hyperplasia and/or global-focal segmental 
glomerulosclerosis (FSGS), in combination with microcystic transformation of renal 
tubules. HIVAN can have an insidious clinical onset and the only way of establishing 
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a definitive diagnosis is to perform a renal biopsy. Given the risk of performing this 
procedure in HIV-infected children with other AIDS-defining illness, it is necessary 
to find new biomarkers to identify children at high risk of developing HIVAN. In this 
study, we sought to determine whether growth factors released into the urine of 
HIV-infected children with renal disease parallel the extent and activity of the renal 
lesions characteristic of HIVAN in fifty five HIV-infected children. We found reduced 
levels of Epidermal Growth Factor (EGF) in the urine of children with HIVAN in 
association with increased levels of Fibroblast Growth Factor- 2 (FGF-2) and 
metalloproteinase-2 (MMP-2), when compared to HIV-infected children without 
renal disease. Similar changes were found in HIV-Tg26 mice in correlation with the 
progression of the renal disease. These findings suggest that the urinary growth 
factor profile of EGF, FGF-2 and MMP-2 may be a useful candidate biomarker to 
identify HIV-infected children at risk of developing HIVAN. Of interest, previous 
studies have shown that PIs can inhibit the activity of MMP-2 by blocking the 
conversion from its latent to the active form. Based on these data, we speculate 
that PIs could have a potential beneficial effect in children with HIVAN by blocking 
the activation of MMP-2.  
 
Finally, the general discussion in Chapter 12 focuses on the thorough review of the 
development and approval of ARV drugs in pediatric HIV disease. The paper 
summarizes the available data on the developmental PK and PD of ART and 
identifies current gaps in the knowledge of ART in children. This final chapter 
reviews the need for the globalization and individualization of pediatric ART and 
outlines the roadmap of future studies to optimize ART in HIV-infected infants, 
children and adolescents worldwide. 
 
Current pediatric ART research priority focuses on the most important areas with 
the least knowledge such as developmental changes in drug metabolizing enzymes 
and drug transporter activity (with particular emphasis on puberty), long term 
metabolic complications of ART in children, the impact of pharmacogenetics on ARV 
drug disposition and response to ART in children of diverse racial/ethnic 
background. Moreover, better adherence assessment tools and interventions need 
to be studied in large international trials. This thesis represents collaborations of 
several academic and clinical programs in the Netherlands and USA. The global 
nature of the pediatric HIV infection requires global research efforts in developing 
better treatment modalities for pediatric HIV disease. 
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SAMENVATTING 
Het voorkomen van de overdracht van HIV van moeder naar kind is de laatste jaren 
aanzienlijk verbeterd. Desondanks openbaren zich dagelijks nog bijna 1200 nieuwe 
infecties bij kinderen jonger dan 15 jaar. Met een geschat aantal van meer dan 3 
miljoen kinderen en adolescenten die met een HIV-infectie leven, is het van 
doorslaggevend belang om kinderen, waar ook ter wereld, efficiënte antiretrovirale 
therapie (ART) te geven. Het feit dat een groeiend aantal HIV-geïnfecteerde 
kinderen en adolescenten toegang hebben tot een behandeling maakt het beter 
begrijpen van de therapeutische doelen van antiretrovirale geneesmiddelen bij de 
behandeling van HIV bij kinderen dringend noodzakelijk. 
 
De belangrijke etiologische, fysiologische, psychologische en sociale verschillen 
tussen kinderen en volwassenen vereisen een unieke overweging voor HIV-
geïnfecteerde kinderen en vragen om een populatiespecifieke aanpak van ART. Het 
wereldbeeld van HIV-infecties en antiretrovirale geneesmiddelontwikkeling bij 
kinderen wordt besproken in de introductie (Hoofdstuk 1). Dit hoofdstuk geeft, 
naast erkenning van het belangrijke werk van vele internationale onderzoekers, de 
meest belangrijke tekorten in kennis van ART bij kinderen aan.  
 
Deel 1 richt zich op de veranderingen die plaatsvinden tijdens de ontwikkeling van 
kind tot adolescent en de invloed van deze veranderingen op het verwerken en de 
effectiviteit van antiretrovirale geneesmiddelen. De gegevens die als richtlijn dienen 
bij het doseren van het geneesmiddel, evenals de gegevens betreffende effectiviteit 
en veiligheid van geneesmiddelen bij kinderen, zijn duidelijk van een lagere 
kwaliteit in vergelijking met die voor volwassenen. Kinderartsen worden daardoor 
geconfronteerd met het feit dat er nauwelijks geneesmiddelen voorhanden zijn 
wanneer ze zich zouden beperken tot het voorschrijven van geneesmiddelen 
waarvan voldoende bekend is. Hierdoor zijn deze artsen genoodzaakt tot het 
voorschrijven van geneesmiddelen waarvoor geen toestemming voorhanden is, 
zoals het gebruik van een andere dosis, frequentie, leeftijdsgroep, wijze van 
toediening, indicatie of toedieningsvorm. Hoofdstuk 2 geeft een overzicht van de 
geschiedenis en huidige vooruitgang van kinderfarmacologisch onderzoek en 
geneesmiddelontwikkeling. De basisprincipes van geneesmiddelabsorptie, 
distributie, metabolisme en eliminatie bij pasgeborenen tot aan adolescenten 
worden hier samengevat. Hoofdstuk 3 richt zich vervolgens op het veranderende 
effect van geneesmiddelen tijdens de puberteit. Dit deel geeft een overzicht van de 
fysiologische en psychologische veranderingen die geassocieerd zijn met de 
lichamelijke en sexuele rijping. Verder wordt ingegaan op de mogelijke invloed van 
deze veranderingen op de farmacokinetiek en farmacodynamiek van antiretrovirale 
geneesmiddelen bij HIV-geïnfecteerde adolescenten. Dit hoofdstuk laat het gebrek 
aan gegevens betreffende de farmacologie van antiretrovirale geneesmiddelen 
tijdens de puberteit zien en geeft een uitgebreide samenvatting van de huidige 
richtlijnen voor het gebruik van antiretrovirale middelen bij adolescenten. Het 
gebrek aan kennis van de farmacokinetiek en farmacodynamiek van antiretrovirale 
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middelen tijdens de puberteit heeft enerzijds geresulteerd in het gebruik van hoge 
(gebaseerd op gewicht of lichaamsoppervlakte) kinderdoseringen met het risico op 
overdosering. Anderzijds heeft het toedienen van lagere volwassen doseringen 
geresulteerd in geneesmiddelresistentie en daardoor virologisch falen. 
 
HIV-geïnfecteerde kinderen vertegenwoordigen een ongelofelijk diverse groep van 
patiënten, variërend van pasgeborenen tot jonge volwassenen. Gedurende de groei 
en ontwikkeling verandert ART op de kinderleeftijd van het preciese doseren van 
tweemaal daags een drankje, naar eenmaaldaags een tablet met een vaste dosis. 
Het gebruik van vereenvoudigde kindergeneeskundige doseringsschema's verbetert 
mogelijk het succesvol implementeren van ART bij HIV-geïnfecteerde kinderen. 
PK/PD studies van antiretrovirale geneesmiddelen en combinaties van deze 
geneesmiddelen moeten plaatsvinden bij zuigelingen, kinderen en adolescenten om 
de juiste doseringen voor elke leeftijdsgroep te bepalen. De beschikbaarheid, de 
toedieningsvormen en de doseringschema's van antiretrovirale middelen bij 
kinderen worden besproken in hoofdstuk 4. 
 
Deel 2 van dit proefschrift is gewijd aan de analyse van de ontwikkelings-
afhankelijke veranderingen in de PK en PD van specifieke antiretrovirale 
geneesmiddelen bij kinderen en adolescenten. Hoofdstuk 5 beschrijft de 
uitkomsten van een studie naar de PK van lamivudine (3TC) bij HIV-geïnfecteerde 
kinderen, welke is verricht in samenwerking met de Universiteit van Nijmegen. 3TC 
wordt vaak gebruikt als onderdeel van de nucleoside reverse transcriptase remmers 
(NRTI) component bij de behandeling van HIV-geïnfecteerde kinderen. Eerdere 
studies laten een hogere orale klaring zien van 3TC bij kinderen in vergelijking met 
de klaring bij volwassenen. Derhalve is de geadviseerde dosering van 3TC voor 
kinderen twee keer zo hoog als de dosering bij volwassenen. In onze studie werden 
PK-gegevens verzameld bij 51 HIV-1-geïnfecteerde kinderen (mediane leeftijd 8,4 
jaar), gebruikmakend van een standaard kindergeneeskundige dosering van 3TC. 
Deze PK-gegevens werden vergeleken met PK-gegevens bij volwassenen. AUC, 
Cmax, Cmin, CL/kg en Vd/kg toonden een significante relatie met leeftijd, waarbij 
jongere kinderen een lagere blootstelling aan 3TC hadden. De leeftijd van 6 jaar 
lijkt een duidelijke grens te zijn voor een verandering in 3TC PK-waarden, waarbij 
kinderen jonger dan 6 jaar een 43% lagere mediane waarde voor AUC en een 47% 
lagere mediane waarde voor Cmax laten zien vergeleken met oudere kinderen. In 
overeenstemming met deze observaties zijn CL/kg en Vd/kg 79% en 89% hoger bij 
kinderen van 6 jaar of jonger vergeleken met oudere kinderen. De gemiddelde Cmax 
en AUC bij kinderen van 7 jaar en ouder waren bijna identiek aan de PK-waarden bij 
volwassenen. Het belangrijkste is echter dat verlaagde 3TC-blootstelling bij jongere 
kinderen mogelijk gerelateerd is aan het ontwikkelen van de M184V HIV-mutatie en 
resistentie tegen 3TC. Dit verdient nader onderzoek. 
 
De ontwikkeling van een populatie PK-model voor de meest gebruikte 
proteaseremmer lopinavir (LPV) voor de kindergeneeskundige praktijk wordt 
beschreven in hoofdstuk 6. De gegevens werden verkregen door een intensieve 
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PK-studie van HIV-geïnfecteerde kinderen die al behandeld werden met 
proteaseremmers en LPV kregen. Deze gegevens werden getoetst aan verschillende 
kandidaat PK-modellen, gebruikmakend van MM-USCPACK programmatuur. Het 
uiteindelijke model werd gebruikt om voor 1000 fictieve kinderen de kans te 
berekenen op het bereiken van een LPV-fenotypisch remmingsquotiënt van meer 
dan 15. Want een dergelijk quotiënt is bij volwassenen geassocieerd met een grote 
kans op virusonderdrukking. De kans op het bereiken van een LPV PIQ van meer 
dan 15 was groter dan 90% voor het wild-type virus maar minder dan 10% voor 
zelfs een matig resistent virus. De huidige geadviseerde dosis van 
lopinavir/ritonavir lijkt voldoende voor kinderen geïnfecteerd met het wild-type 
virus, maar het is onwaarschijnlijk dat het voldoende remming geeft van zelfs een 
matig resistent virus. HIV-geïnfecteerde kinderen die al blootgesteld zijn aan 
proteaseremmers, zullen waarschijnlijk profiteren van herhaalde bepalingen van 
LPV-spiegels om te garanderen dat de blootstelling aan LPV resulteert in spiegels 
die hoog en toch nog veilig zijn. 
 
De ontogenie van enzymen en transporters betrokken bij het metabolisme en 
transport van antiretrovirale geneesmiddelen werd onderzocht in een studie waarin 
gekeken werd naar de associatie tussen CYP3A5, MDR1 (ABCB1) en OATP1 
(SLCO1B1) polymorfismen en de PK en PD van LPV/RTV therapie bij kinderen 
(hoofdstuk 7). CYP3A5, MDR1 en SLCO1B1 polymorfismen zijn geassocieerd met 
variatie in de PK van proteaseremmers. In dit onderzoek hebben we het effect van 
CYP3A5 A6986G, MDR1 (C3435T and G2677T), en SLCO1B1 (T521C and A388AG) 
polymorfismen op de PK/PD van LPV/RTV in een prospectieve cohortstudie van 50 
HIV-geïnfecteerde kinderen (mediane leeftijd 11,2 jaar) nagegaan. De resultaten 
lieten geen statistisch significante associatie zien tussen LPV of RTV AUC of CL, en 
CYP3A5, MDR1 of SLCO1B1 A388G polymorfismen. Er was een significante 
associatie tussen SLCO1B1 T521C en LPV AUC (P = 0.042) en een bijna significante 
associatie met de klaring van LPV (P = 0.063). De onderzochte polymorfismen 
waren echter niet geassocieerd met de virologische uitkomst tijdens de 
studieperiode. Grotere studies bij kinderen naar de veranderingen in 
geneesmiddeldistributie en metabolisme tijdens groei en ontwikkeling zijn 
noodzakelijk om de rol van farmacogenetica op het effect van ART bij kinderen met 
verschillende raciale/etnische achtergronden beter te begrijpen. 
 
Deel 3 bestaat uit twee studies die zich richten op de rol van therapeutische 
geneesmiddelbewaking (TDM) bij de behandeling van HIV-infectie bij kinderen met 
ART. Hoofdstuk 8 beschrijft het onderzoek naar de rol van het meten van de non-
nucleoside reverse transcriptaseremmer nevirapine (NVP) in speeksel als een niet-
belastend alternatief voor het meten van NVP in plasma bij HIV-geïnfecteerde 
kinderen. Adequate dalspiegels van NVP voorspellen een goede uitkomst van de 
behandeling, terwijl subtherapeutische spiegels gecorreleerd zijn met virologisch 
falen en resistentie tot gevolg heeft. Onze studie onderzocht de verhouding tussen 
totaal en vrij (niet eiwitgebonden) plasma NVP spiegels versus NVP spiegels in niet-
gestimuleerd speeksel en onderzocht tevens of speeksel bruikbaar is als een 
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alternatief voor TDM bij kinderen. NVP-spiegels werden bepaald in gepaarde 
plasma- en speekselmonsters van kinderen die met ART èn NVP werden behandeld. 
De NVP-spiegels gemeten in het speeksel kwamen sterk overeen met de vrije NVP-
spiegels in plasma, maar waren gemiddeld 34% hoger. De Bland-Altman figuren 
lieten zien dat de verschillen tussen speeksel- en plasmawaarden consistent zijn 
over de het gehele gebied van de gemeten spiegels. Onze resultaten tonen derhalve 
een sterke overeenkomst tussen speeksel- en plasma-NVP-spiegels bij HIV-
geïnfecteerde kinderen. NVP speekselspiegels zonder speekselstimulatie kunnen dus 
gebruikt worden als een uitwisselbare, niet-belastende, betrouwbare en 
kosteneffectieve methode voor de toepassing van TDM van NVP-therapie. 
 
Op dit moment wordt TDM van ART geadviseerd om subtherapeutische 
geneesmiddelconcentraties uit te sluiten en om onderscheid te maken tussen 
malabsorptie, geneesmiddelinteracties, lage therapietrouw, of verhoogd 
metabolisme en/of klaring van het geneesmiddel als mogelijke oorzaken van 
verlaagde geneesmiddelblootstelling. Het gebruik van TDM wordt ook overwogen 
om te helpen bij het vinden van een optimale dosering van een geneesmiddel bij 
patiënten waarbij het virus minder gevoelig blijkt jegens het geneesmiddel. Zoals 
beschreven in hoofdstuk 3 laat het doseren van antiretrovirale geneesmiddelen bij 
adolescenten de overgang zien van een doseringsregime met hoge 
kinderdoseringen (op gewicht en lichaamsoppervlakte gebaseerd) tot een relatief 
lage volwassendosering (vaste dosis). Dit is echter niet duidelijk gedefinieerd. PK-
verschillen gebaseerd op de ontwikkeling van het individu dragen bij tot de sterke 
variabiliteit bij kinderen en adolescenten en een toegenomen frequentie van 
suboptimale blootstelling aan antiretrovirale geneesmiddelen vergeleken met 
volwassenen. Geïndividualiseerde, concentratie-gericht optimaal doseren van 
antiretrovirale geneesmiddelen kan gunstig voor patiënten zijn voor wie alleen 
beperkte doseringsrichtlijnen voorhanden zijn. De rol van TDM voor het 
optimaliseren van de farmacotherapie van HIV-infectie bij adolescente patiënten 
wordt in hoofdstuk 9 bediscussieerd. In dit hoofdstuk beschreven we twee 
scenario's van het toepassen van TDM bij adolescente patiënten die al behandeld 
zijn met antiretrovirale geneesmiddelen waarbij ART verbeterd werd door TDM van 
deze middelen. TDM bleek een goede methode om, in het eerste scenario waarbij 
de patiënt zelf beweerde therapietrouw te zijn, het falen van de behandeling te 
evalueren. Het tweede scenario geeft een eerste verslag van een succesvolle 
verlaging van de dosering van efavirenz (EFV) bij adolescente patiënten gebaseerd 
op CYP2B6 genotype in combinatie met PK-evaluatie. TDM van antiretrovirale 
geneesmiddelen is bruikbaar bij het regelen van de farmacotherapie van HIV bij 
adolescente patiënten en wordt door adolescente patiënten met HIV en hun families 
als waardevol ervaren. TDM geeft ook bij adolescenten waardevolle informatie over 
de klinische farmacologie van ART tijdens de puberteit. 
 
Deel 4 beschrijft kwesties geassocieerd met langetermijn houdbaarheid en 
complicaties van ART bij kinderen en adolescenten. Hoofdstuk 10 beschrijft de 
relatie tussen zelfgerapporteerde therapietrouw met ART en de virologische en 
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immunologische resultaten van HIV-infectie bij 127 perinataal geïnfecteerde 
adolescenten (gemiddelde leeftijd 9,9 jaar). Tevens werd de relatie tussen de 
manier van antiretrovirale geneesmiddelvoorziening door de apotheek, 
zelfgerapporteerde therapietrouw en HIV-virale belasting bij HIV-geïnfecteerde 
kinderen geëvalueerd. Complete therapietrouw (100%) werd slechts door 24% van 
de patiënten gerapporteerd. Bij de 40% van de patiënten die zelden of nooit 
helemaal therapietrouw waren, werd bij 64% daarvan een niet-detecteerbare virale 
belasting gevonden tijdens de duur van de studie. In onze studie vonden we geen 
associatie tussen de manier van geneesmiddelvoorziening door de apotheek en de 
zelfgerapporteerde therapietrouw. Zelfgerapporteerde therapietrouw (P = 0.0328) 
en leeftijd (P = 0.025) waren de belangrijke voorspellers voor het bereiken van een 
niet detecteerbare virale belasting. Het meest belangrijk was dat adolescenten 
(> 13 jaar) veel minder in staat waren niet-detecteerbare virale belasting te 
bereiken dan kinderen jonger dan 13 jaar (OR = 0.38; 95% CI: 0.16, 0.89). Voor 
elk jaar ouder verminderde de kans op het bereiken van niet-detecteerbare virale 
belasting met 10% rekeninghoudend met zelfgerapporteerde therapietrouw en de 
wijze van geneesmiddelvoorziening door de apotheek. Hoewel we toegeven dat de 
adolescenten in deze studie HIV perinataal hadden gekregen en vele behandelingen 
hadden ondergaan, waardoor ze een verhoogde kans op HIV-resistentie en 
virologisch falen hadden, zagen we toch extra belemmeringen voor optimale 
therapietrouw tijdens de puberteit. Voor zowel artsen als verzorgers betekent 
afname van therapietrouw tijdens de puberteit bij adolescenten met perinataal 
verworven HIV, een grote en emotionele uitdaging, dat goed teamwerk vereist. 
Aangezien een goed gedefinieerd model voor interventies gericht op therapietrouw 
voor adolescenten met HIV ontbreekt, is meer onderzoek naar therapietrouw bij 
HIV-geïnfecteerde jongeren met een interdisciplinaire samenwerking noodzakelijk. 
 
De ontwikkeling en toepassing van biomarkers voor vroege detectie van HIV-
geassocieerde nefropathie wordt besproken in hoofdstuk 11. HIV-geïnfecteerde 
kinderen lopen het risico allerlei nierziekten te krijgen, onder andere HIV-
geassocieerde nefropathie (HIVAN). HIVAN tijdens de kinderleeftijd wordt 
gedefinieerd door de aanwezigheid van proteïnurie-geassocieerd met mesangiale 
hyperplasie en/of globale-focale segmentale glomerulosclerose (FSGS), in 
combinatie met microcysttransformatie van de niertubuli. HIVAN kan een 
verraderlijk klinisch beloop hebben. Een nierbiopsie is de enige manier om de 
diagnose te stellen. Het risico van een dergelijke ingreep bij HIV-geïnfecteerde 
kinderen met andere HIV-gerelateerde aandoeningen, maakt het vinden nieuwe 
biomarkers noodzakelijk. Kinderen die risico lopen op het ontwikkelen van HIVAN 
zijn dan gemakkelijker op te sporen. In deze studie keken we bij 55 HIV-
geïnfecteerde kinderen of groeifactoren die HIV-geïnfecteerde kinderen met 
nierziekte in de urine uitscheiden, overeenkomen met de uitgebreidheid en activiteit 
van de karakteristieke lesies van HIVAN. We vonden verminderde concentraties van 
epidermale groeifactor (EGF) in de urine van kinderen met HIVAN in associatie met 
verhoogde concentraties van fibroblast groeifactor-2 (FGF-2) en metalloproteinase-
2 (MMP-2) vergeleken met HIV-geïnfecteerde kinderen zonder nierziekte. 
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Overeenkomstige veranderingen werden gevonden in HIV-Tg26-muizen, 
gecorreleerd aan de progressie van hun nierziekte. Deze bevindingen suggereren 
dat het groeifactorprofiel van EGF, FGF-2 and MMP-2 in urine mogelijk een nieuwe 
biomarker is om HIV-geïnfecteerde kinderen met een kans om HIVAN te 
ontwikkelen te identificeren. Eerdere studies hebben al laten zien dat 
proteaseremmers de activiteit van MMP-2 kunnen remmen door het blokkeren van 
de omzetting van MMP-2 van de latente naar de actieve vorm. Gebaseerd op deze 
gegevens speculeren we dat proteaseremmers een positief effect bij kinderen met 
HIVAN kunnen hebben door het blokkeren van de activatie van MMP-2. 
 
Tot slot richt de algemene discussie in hoofdstuk 12 zich op een grondig overzicht 
van de ontwikkeling en goedkeuring van antiretrovirale geneesmiddelen voor HIV-
ziekte bij kinderen. Het vat de beschikbare gegevens samen van 
ontwikkelingsfarmacologie (PK en PD) van ART en wijst op de leemtes in de kennis 
van ART bij kinderen. Dit laatste hoofdstuk pleit voor een wereldwijde 
samenwerking voor toekomstige studies om ART te optimaliseren, zodat HIV-
geïnfecteerde zuigelingen, kinderen en adolescenten waar ook ter wereld een 
individuele aanpak kunnen krijgen. 
 
De prioriteiten voor ART-onderzoek liggen bij gebieden waarvan nauwelijks iets 
bekend is zoals:  
 
• de veranderingen door groei en ontwikkeling van geneesmiddelmetaboliserende 
enzymen en geneesmiddeltransportactiviteit (met speciale aandacht voor de 
puberteit),  
• langetermijn metabole complicaties van ART bij kinderen,  
• de rol van farmacogenetica bij kinderen met verschillende raciale en etnische 
achtergrond wat betreft het verwerken van antiretrovirale geneesmiddelen en de 
reactie op ART,  
• grote internationale studies voor het verbeteren van methoden om therapie-
trouw vast te stellen en te vergroten.  
 
Dit proefschrift is tot stand gekomen dankzij samenwerking tussen verscheidene 
academische en klinische programma's in Nederland en de Verenigde Staten. Het 
mondiale karakter van HIV-infectie bij kinderen vereist mondiaal onderzoek om de 
behandelingsmogelijkheden voor kinderen met HIV te verbeteren.  
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3TC   Lamivudine 
 
ABC   Abacavir 
AIDS    Acquired immunodeficiency syndrome 
AMP    Amprenavir 
ART    Antiretroviral therapy 
ARV    Antiretroviral 
ATV    Atazanavir 
AUC    Area under the (concentration-time) curve 
AZT    Zidovudine 
 
BSA   Body surface area 
 
CCR5    C-C chemokine receptor 5 
CDC    Centers for Disease Control 
CL    Clearance 
Cmax    Maximum (peak) concentration 
Cmin    Minimum (trough) concentration 
CV    Coefficient of variation 
CYP450   Cytochrome P450 
 
d4T   Stavudine 
ddI    Didanosine 
DME(s)  Drug metabolizing enzyme(s) 
DOT    Directly observed therapy 
DRV    Darunavir 
 
EFV    Efavirenz 
EGF    Epidermal growth factor 
ETR   Etravirine 
ETV    Etravirine 
 
f-AMP   Fosamprenavir 
FDA    Food and Drug Administration 
FDC    Fixed dose combination 
FGF    Fibroblast growth factor 
FTC    Emtricitabine 
 
GFR    Glomerular filtration rate 
GH    Growth hormone 
GIQ    Genotypic inhibitory quotient 
 
HAART  Highly active antiretroviral therapy 
HD    Home delivery 
HIV    Human immunodeficiency virus 
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HIVAN   HIV-associated nephropathy 
 
IC     Inhibitory concentration 
ICC   Interclass correlation coefficient 
IDV    Indinavir 
IGF-1   Insulin-like growth hormone 
IMPAACT  International Maternal Pediatric Adolescent AIDS Clinical Trials Group 
IPP    In pharmacy pick up 
IQ    Inhibitory quotient 
IRB    Institutional Review Board 
 
LPV    Lopinavir 
LPV/RTV   Lopinavir/ritonavir (Kaletra®) 
 
MCTC   Mother-to-child transmission 
MDR1   Multidrug resistance gene 
MEC   Minimal effective concentration 
MMP    Matrix metalloproteinase 
MVC    Maraviroc 
 
NAT    N-acetyltransferase  
NCRR   National Center for Research Resources 
NICHD   Eunice Kennedy Shriver National Institute of Child Health & Development 
NIH    National Institutes of Health 
NIQ    Normalized inhibitory quotient 
NMEs    New molecular entities  
NNRTI(s)  Non-nucleoside reverse transcriptase inhibitor(s) 
NRTI(s)  Nucleoside reverse transcriptase inhibitor(s) 
NVP    Nevirapine 
 
OATP    Organic anion transporting polypeptide 
 
PACTG   Pediatric AIDS Clinical Trials Group 
PD    Pharmacodynamic(s) 
PEPFAR   The United States President's Emergency Plan for AIDS Relief 
PG    Pharmacogenetic(s) 
P-gp   P-glycoprotein 
PI(s)   Protease inhibitor(s) 
PIQ   Phenotypic inhibitory quotient 
PK    Pharmacokinetic (s) 
PMTCT   Prevention of mother-to-child transmission 
 
RAL    Raltegravir 
RD    Renal disease 
RTV    Ritonavir 
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SD    Standard deviation 
SLC    Solute carrier 
SQV    Saquinavir 
 
TB    Tuberculosis 
TDF   Tenofovir diproxil fumarate  
TDM    Therapeutic drug monitoring  
TFV    Tenofovir 
THM    Traditional herbal medicines 
TPV    Tipranavir 
 
UDP    Uridine diphosphate 
UGT    Uridine 5'-diphospho-glucuronosyltransferase  
 
Vd    Volume of distribution 
VL    Viral load 
 
WHO    World Health Organization 
WT    Wild type 
 
y-GT    y-glutamyl transpeptidase 
 
ZDV    Zidovudine 
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John and me. Both of you have made remarkable achievements in your fields and I 
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to thank you for everything you have done for me. Your love for me and your family 
is one of the rare kind of self sacrifice that only a few people can achieve and can 
understand. Your bright and inquisitory mind, noble and honest heart and deep 
loving soul shine the light on me throughout my life. You protected every minute of 
my childhood in the difficult years of our life in a couple of rooms of the old house 
shared with 5 other families. You inspired me and created the best possible learning 
environment for me during my school and university years. You followed me and 
supported me throughout the most difficult years of accreditation of my diploma in 
the US. You embraced my husband and followed me to the Netherlands and then 
back to the US. You were there for us when our son was born to whom you give the 
same love you have given me. You are indeed the best mother and the best 
grandmother in the world. What is even more – you have always been and remain 
мой дружок. 
 
Dear husband John van den Anker, lieverd, the love of my life, from the day we 
saw each other for first time you have been my strength and protection, my caring 
and tender friend, my devoted loving husband. Your stubborn Dutch character, your 
incredible determination and self discipline have brought you a great success in 
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your career. You taught me and continue teaching me many secrets of professional 
and academic success. You are proud for every successful step I make and you are 
standing by me in every failure and difficulty to support me. You will make me 
laugh, you will dry my tears. You will talk to me and I will always listen, even if I try 
to deny it in my own stubbornness. You have shared your love for Deborah, Nico 
and Thea with me, and through you I love them too. Your love for me and our son 
have made me the happiest woman in the world and I only hope that my love 
brings you the same happiness as you have given me. 
 
Dear son John van den Anker, родной Ванечка, here comes the time to say the 
most important word to the most important man in my life. You have given me the 
joy and happiness every mother wishes to have in life. You have made me many 
times proud of you even though you are still a young man. When one stops to look 
at the scope of work one has done or evaluates the new step in their life, the 
important things become very straightforward. This thesis is the stop before moving 
on and I use this time to tell you a few simple things that I believe matter in life the 
most. Be good and truthful, live your life with dignity and strong sense of who you 
are. Work hard, respect and help others. Read good books. Be wise, have good 
friends and a good wife.  Mamma.  

  
  
 
